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ASSfRACT 
fublio OBtorprijMs ooeupy ^oowiaadiag higbts* of iMdiaii 
•conoiiy. m»A timy eovtr o wldo spoetrmi of laAuttriol » political 
and acowMitc activity la tha eoumtry* In viaw of political aad 
ao€io»acoao«ic sigitlflcaace of titt public aactoi* i» Imdia^  i t la 
wmctaMBTy that tha public aactor mkaa aidi)atatttial ooBtrlbutioa 
to national wealth, at ^la saaa tiaa fulfilling largar aoeial 
aani natiooal ob^actlvaa* 
tlia social aad acoaoaie ob^ctivas of tha public aactor 
i s India ara { to iielp in attaining pipid a^»no«ic grawtli in tha 
country} to craata tha naeaaaary infmatruetura for aeoaonie 
growthi to attain aalf-ralianea in atratagie aaetors of tha 
aconovyi to raduea iaaq^talitiaa in tha <Ustribatioii of ineoiia 
and vaalthi to «!isura a balanead grm^m of tha diffarant ragiont 
of tha couatiy and to pravant coneantrntion of aeoaottic powar.lo 
achioYa thasa ob^tivaa, tha rola of naricetii^ nanaganest is 
»ost crucial in tht ^n^m of pftsduetiofiy dlstributlo»t pro^otlea 
aiKi priclag. 
tilt pul>Ilc s«etor i» t&Aim also covtrs tlio ^nigs as4 
pfo@rs®C€ t^ieal tat^stry, Sb* l»di«a pbsm»c«utieal Imdujitry IWB 
Investaiist la the tills Indliiiitry ii«t rlft«ii froci &^  24 emr«s In 
195^ to si07« tfe«n 700 cmrts at pivseAt. Itodla la mm i^oduclag 
a larg* quaatltjr of verl©d phaneacmitlcal |^^<}acts, Howover tbo 
<l»velopaeitt of l i^ian drttgie ^ad piisraeceatlcftl £3i^«ti7 la goii«r»l 
d»el tbe rol« play«d |>y t l» p;^Xlc soctar drag i»Bits 1» partleularp 
is Bot eocpseafiir«to vith the size of t l ^ coitatr^ and ttm grwtimg 
jiotds of I ts popiletloa* Vtteroas tbt li^reasiu^ costrlliutlofi of 
IHtbllc jsoctor irug yalts of the co«»tiy Is ^im r«eosalso<l la t«r«9 
of r«sesreh aad 4mf9XQpmut activity, in aootii^l ^ « rtqulr«ft#at8 
of hi^lk drugs Gild fiao cta«slc»Is SISES In g«Mr«tl»g dlroct aa^ 
iadiract oaployitsiit. I t is geatraXly fa i t tbat aaritatliig aspacts 
of public saetor drug uBits heim ifi<»t bean glvaa 4tta ^BSlSaratiois* 
la sotttt casaSf i t is tba lack of affaetlira ntrkatlag stratagies 
tbat l»a advarsaly affected tne parfomaaca of ptibXlc saetor • 
drag co«ptal«s« A cXaarar parspactlva oa the aerketlag actlvitlas 
of public saetor lirug aalts i s , tbarafora, caXlad for. fha pras^st 
stiKly Is aa attaispt i» this diraetloi%« 
gra^at Stuivt 
Tba prasaat stady Is eoaearatd vlth aaHkatl^ strataglas 
of ttm drugs aad pbamacaatleal ualts la tb9 public saetor la ladia. 
tft* aArk«tliig pra«^le*s of public svetor drug uaits, |»n»bI«M 
ft-cvd by th«a in ta9»l«ii«AtiBg tht Mrk«tiiig «tr«t«iy »w& «Miaur«s 
atAdttf to solv* ttMii# pr«bl«i»» eowt irndtr the jMurvl«v of this 
study* Tim •«!« Miphasis in s tu^ It se a ^*dti««l ftintluatloii of 
tho fuACtioiial polieios of ttio publie Mct«r drug ooapAsifts l» tho 
areas of productio]%» distributioR» froftotiott sadi prieiAji, 
1 ^ dnigs sad pharasestitlesls iadustrf lios boea etios«» 
CIS am sree of this ressaixb work for • aumber of ressoas } f irst , 
this ladustry plays »Ji iaportaat aoelal rolty for i t is diraetXy 
eonceraed with the health of the people, ivhieh is a basic aaad 
of every eitiaea* Secoadly, the eoatributioa of the drug ooapeaiM 
ia the spherea of iHroduetioa, earaiag af f oreiga axehaag* aad 
ianreataeat ia the ladiaa eooaoay has beea quite aigaifioaat, 
thirdly, the Hathi Coaalttee la ita report aasipMd a laaderahtp 
role to thf public sector drug eafterpriaea. Beemtae thia aector 
has beea playiag a vital role ia the proaotioa of drug iadustry 
ia the eountfy, ia the aupply of basic bulk drugs to the saall 
aad aediiM sectors aad offers techaleal assistaaoe to ^ e i^ivate 
aad 4oiat aectors. l«aatly, drug iadustry is a raseareh based oaa» 
Haseareh aaiS developaeat activity ig oae of the basic aaeda of 
the ia<kistry« 
fha miia objectives of the present study are as follows i 
1^  to fiad out the existlag aarltatiag policies of the public 
sector drug uaits ia the coatext ot the pravailiag busiaeas 
ecviroi^ Reat ia the eouolry. 
2. to •amXye the attitudes asd "vimm ot tfe» it«aai«r« 0!^  tine 
public stetor druB «t»i«Ptsl£iB£,8 regarding tbt Miri^tiiig pmetieAs 
of th«ir ^iiiitt, 
3, ^o as^ass th* Ispaet «f taaHi^ tiag optrationa MI tl^ perfon^ac* 
oi puMic sector drtag undtrtakiiigs. 
4* fo astets tbe #ff«etivme«s of polieias ptsrsued lij public ctctor 
drug units ia th@ ar9mB ot proaictioii» 4istriiMiti^Ay M^ j^ proasoti^ ai 
tm^ pricing of their products, 
5. 9^ suggeet scasures for improviifig the existing ssrketlng 
praeticas of public sector drug usits in tt» light of ^it anilyfis 
of fiadif^s aiMl conclusions draws irtm tbe stu^iy. 
Apart froa tim rmin objecti¥e8 diseussed above, tbere 
were certsia sec^sry ob^ctives of '^is studsr, vbieii are gives 
belov s 
to study tiMi p'oitt^ putterm of tbe isdias pberRaceutlCBl 
industry and to make a conpiratiTe study of different sectors of the 
eeonony and their net contributions torirsrds tbe growth of the 
industry. To study the developsent of the drug industry in India» 
i t s structural set up end the role ployed by foreign drug ooinpenies 
operating in India mwA i» «xa»ine» brie^y^ the r^e of nultinetisnel 
dfug oonpwBiies in the context of Xs i^an econonic mirirMHieat. 
Hm present s^idy is confined to the nsrlietl^ policies 
in the foUowini centrally owMd public sector <^ ug imlts 1 
1) IDPL 
2) HAL 
3) ICHL 
4) BIL 
5) SSPL 
th« study aise eovtrt the follovlng br»aehts of thtst 
public stetor 4nig tt»di«rtAkiiigs i 
DIDK, (Itodrai)^ (2) 1I»»L ( Hfd«r«b«d / 
3)OPi3i»L (UlClaiw ) ' (#) M«>L ( Jaipor ) ^ 
$)HJkL( li«ir OtlHi ) ^ (6) HAL (iif(l«raba<l ) 
7) l£APL(Btfi«Iore ) (8) BePL( iif<ltr»)Mi<t ) . 
9) BXL {Xmhrm Dm) . 
3lie rt««iali« l»7«nch«s of the ebove-MOiittoiiccI eoKtrally 
owned public sector drug eo«|>aiiles haire sot been lAdiKied beesuse 
of the l laitstloi is of resources si»i t lae. However tiie ssHple Is 
sigiiifIceMt though i t ineljudes oiay fo«rteen out of More thsm si.»e 
thousaid phsrsseeutiesl eoBceras in the eoui^ry beesuse of the 
ttsgaitu4e of isnrestneiKt in the public sector drug eoBpsaies, which 
aocouats for above 30 per cost of the total iwves^Mat in the 
drug industry i» the country, end im view of the fact that the 
drug conpenies in the public stetor are the chief suppliers of bulk 
drugs asd basic chenieals ia the country. 
The present study s e ^ s to ex«sine the ^nceting 
strategies of public sector drug units on the basis of folloving 
assisRptionsi 
( • i l l ) 
t.CbvcrMBitst coatroXs on th@ pri<»B of drugs h^vm »&mr»mly 
af f«eteil tiit ^odhiction ttaa ]»rofitaMXi% pBrtortmmm of public 
sector dmg tiiiits« 
2. ttie lic@]iBiaig policy &i th@ goveraaeiit hindors th* fNroctss of 
growth and d«9«lqpsent of Ii^iea drug ludustrjr, 
5. BsLmBBivn £over£nr»t Int^rftroi^e in tho Amf to d&y ®ffairs of 
t ^ public sector drc units ims sdwri^Zf effect#^ aaafigerial 
motlvatioi} $tnii orgBmimti^fml tffoetivciiess of tbo p«ri»lic «tetor 
dmg uBits, 
For coXisetlQg dstt tt«e prtsoitt Mtvkdy lias »sd« ys« of e 
e^abisBtiott of mtl^te siicit as colioctioa of primnTf as veil «s 
sscoadsrjr d@tt lacluctiag SMUisl rsp^fts^ doc^neats SIKI rsi^rds 
of co«|>8aieSt aailii^ of ^•stieiBM»lr« to tlse oo^ ;NMiiiis and 
ooaductiog personal i»t«#ri»w8 with ssaior «%nt#tiii^  sad 
distribution a8iiai.ters of tl^ fmblie ssctor drug coMpsai^s. 
Tkid prtsoist stuffy IB bassd oa iafomstioii fron 
sscoadary sources aveiXslklft i s difforsat ^mimsls^ psriodi^Xs 
and dftiXias* thoughilis studf hss aade a Xfnited usa of the 
primary data gatt^rad wltb tfe® }»lp of a Qt^stiosRaira ai^ 
discuasioiis vitli coiipai^ i^fieiaXs* tl^ idsss sad oplalens of 
saaior saitcetisf axacutlvas oa fiarketing poXicias and stnit^^ias 
of pubXic sactor d i ^ iaditstry, hava baas ascartaiaad t i tb ttie 
b«lp of iatarviews* 
i'actual data posa m fomidabla prol>ftitt i» etioosinf 
the research area of aay kind in India. l^maeeutioaX in&istrjr 
l a tue publie a«etor sutfers tttm tb£ aas* eosstrsiet «s 8 i ^ 
other Industry i a tb# pikl»llc ssetor irhtrtt iieay aee^ss to the 
date 1ft a d i f f le t i l t ^ b * 
Publie saetar ia la^ie aeectplaft a plaea o£ is^rtanca 
in tlia acaiioBie l i f e a f the «oamtrr« Siiaca a v i t a l rala has 
iHiea asaigntd to this aaetor , i t 1MK;O««8 imc%mtrf tbat i t 
sakes a ftignitie^nt co^ribiit iaB tow^rda the eeoa^sie progress 
of the aotiatiy « 
the publie sector drug Industry has Miffered a set 
back §m productiOB and t a r ^ t s set i s this |^  respect have net 
bee» achieved. 
ttm study reveals that the proMOtion as well as 
distribution policies aitopted 1^ p ib l ie sector drug coapaaiea 
ere i l l conceived aad they have not yielded the desirable 
results* Ho specific pl^)» for cateriii^ to rura l requiretteats 
of Midem Bedieixtes have beea dratm up so far by these compuftiea. 
th pric» laeehesias adopted bf the Ckivenneat , which is 
supposed to be based oa «>clal reasoBii^« is »»t eeo»a«ieally 
feasible for t^e dmg industry ia geaeral aad the public sector 
drug units i s p 8 r t i ^ l r r » 
fbe facus of this study is oa the aai%eti i^ strftegi&s 
of drugs aad pharaaeeutical coopaaies ia '^e public sector. 
(x) 
the «tudy eoBtaias aiat el}ftpt«rs* fi«si^i tli* first, 
introductory eheptor, th« followiag «iglit eli«pt«rs b«v« b*«n 
Chapter 2 4*3erib«s tti« eoaetptiiftl fmacwork 
of thff study. Coaeopta rwlatiag to iiait*tii^ atrotogy and 
puUlc oftttf^rlsos la Zadia and tlia ralatloiithlp bati^ OR a 
eoapanyU* aarfcatlag atrstagf and its aavlroaBtart: baira b«t» 
axaaiiiitd, 
Chaptar 3 giwa a raviaw of litaraturt ralatad to 
tha araa of tha praatat ttady* Xt aias to attrvay th» attidias 
carriad out coa^i^iag aarkatiag practieat of pyblic aaetor 
drug uaits« Kasasroh work doat ia tha arta* of ^odactioa, 
distrilnitiOB, pri«ias, pr«aotioa aad HAD activity of public 
factor eoapaaiaa baaa y#ria««d. Xaportaat fiadiags of aixeb 
atudiaa, tiMrir Ma|>la aiza« atthodolf^* ol»4activ®8 ate, 
iiava boan briafly aaatlaaed ia this ehi^ar. 
Chaptar k givas a prafiXa of tha public aactor 
dn^ iadaatzy ia ladia« it covers aapaets aueh as tiia 
atruetura of the dfug iaduatry, worliiag and it»X« of public 
aoetor drug ooi^iiaies, and ttiair raaaarch ai^ davalopntat 
actlvitiai. 
Oiaptar f foouaats oa produetioa stratagy* It 
dadi with the daaead for dmga, divaraifioatiaa polioiaa 
of tha ccBpaaiaSt brtadi^, as moll as import aad asqport 
policiaa of the eoapaaies and eontribatioa of t£» public 
sector drug eoapeaias to tht total drug produetioa ia the 
iadustry. 
Cbapttr 6 9tUx* •« tiMilfSis of th* promotioMl pollc|r 
of pul>lic meter conpaiilcs moA <ils6tiA«ts the aetliods of proaotion 
audi tools used for product profNitioo. It ftvos oowpuratlvo figuroo 
of progiotloaKl oxpcadituro locitrrod by difforoot toetoro of tlio 
iaduotry, Xt ol«o oxaaiaes tho <llstributioB policl^a^ in^udliig 
th« ehaiHii«Xs of distribution ••Xocti<Hk of <to«l#rs, eroilit policy 
mA tho cost of distribution* 
Cbsptor 7 gives mm aislysis of tbe priciag policy of 
pt^lic sector drug units. It foettss«s on issues iwlating to prioo 
dotentiiuttioiit pricing priaeiples la public eaterprises ead i t 
criticslly exsMlnes the iDrug l^ice Control Orders (OPCOs) enforced 
in Iadia« 
Chapter 8 contaias a detailed analysis of the infomation 
obtained with the help of a questloimaire* Xaforaatioa gathered with 
the help of iaterviews has also beea analysed. 
Chapter 9 eontaias a suaaary and the eoaclasioas of 
tha stiidy .^ 
MARKETING STRATEGIES OF DRUGS 
AND PHARMACEUTICAL INDUSTRV 
IN THE PUBilC SECTOlt 
THESIS SUBMITTED FOR THE DEGREE 
Bottor of ^Iiilo^opI)? 
IN 
COMMERCE 
BY 
KHAblQ AHMAD 
Under the supervision of 
Dr. A. FAROOQ KHAN 
M. Com., D. B. A., MBA (Aston. Birmingham). Ph.D. 
DEPARTMENT OF COMMERCE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH (INDIA) 
1 9 8 7 
<v}« 
v^ M Sj 
11 
^ W88 
CH;r r:. ;;::-9» 
x^r, eyi, Mrooa limn 
D.BA , M.B.A. (Birmingham) 
Ph.D. Reader 
DEPARTMENT OF COMMERCE 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH-202001-INDIA 
TEL. : 5761 
C E R T I F I C A T E 
This i s to cer t i fy tha t the Ph.D. t h e s i s e a t i t l e d 
"MARKETINS STRATEGIES OF DRUGS AMD PHARMACEUTICAL 
INDUSTRY IN THE PUBLIC SECTOR", submitted by 
Mr. Khaliq Ahmad, has been conpleted usder ny 
supervisioB« This woiic i& By.opimion i s su i t ab le 
for sulxiission for the award of Ph.D, degree i> 
Commerce, 
j ^ ' ^ 
( DR. A. Farooq iQiam ) 
Supervisor 
Residence : 9 TEACHERS QUARTER (Near M.M. HALL) A.M.U. ALIGARH-202001 
C O N T E N T S 
PREFACE 
LIST OF TABLES 
LIST OF FIGURES 
LIST OF ABBREVIATIONS USED 
1- INTRODUCTION 
1.1 The Problem 
1.2 Objectives of the Study 
1.3 Importance of the Study 
1.4 Hypothesis 
1.5 Methodology 
1.6 Scope of the Study 
1.7 Limitations of the Study 
1.8 Presentation of the Study 
1.9 Growth of Public Enterprises in India 
2- CONCEPTUAL FRAMEWORK 
2,1 Introduction 
Concept of Public Enterprises (P.Es, 
Concept of Marketing Strategy 
2,2 
2,3 
2A A Company's Marketing Strategy 
and i t s Environment 
2.4.1 Economic Factors 
2.4.2 Sociological -Cultural Factors 
2.4.3 Political-Legal Factors 
2.5 A Framework of the Study 
2.6 Summary 
• • • • 
•. • • • 
• • • « 
• • • < 
• • • « 
• • • < 
• • • < 
• • • < 
• • • < 
• • • ) 
• • • 4 
• • • < 
• • • 
lE 
• • • 
• t • 
sJ 
• • • 
t • • 
• • • 
• • • 
• • • 
• t • 
• • • 
PAGE NO. 
i 
v i 
ix 
X 
1 
6 
6 
9 
16 
16 
18 
20 
21 
1 • • • • 2H 
31 
32 
— 33 
37 
39 
^5 
49 
51 
5A 
58 
PAGE NO, 
3- LITERATURE REVIEW ,,,. 62 
4- DRUG AND PHARMACEUTICAL COMPANIES IN PUBLIC SECTOR 84 
4.1 Introduction ,,,. 86 
4.2 Importance of Public Sector Drug Industry ... 87 
4.3 Structure of Drug Industry ,,,, 98 
4.4 Indian Drugs & Phannaceutlcals Ltd.(lDPL) 104 
4.4.1 Brief History ,,.. 105 
4.4.2 Organisttion and Management ••., 105 
4.4.3 Production Capacity ,,., 109 
4.4.4 Working of IDPL .,., 114 
4.4.5 Research & Development ,,,, II9 
4.5 Hindustan Antibiotics Ltd. ( HAL ) ,.,, 121 
4.5.2 Brief History .... 122 
4.5.2 Production Capacity ,,,, 123 
4.5.3 Woricing of HAL .... 127 
4.6 Bengal Chemicals & Pharmaceuticals Ltd.(BCPL) 128 
4.6.1 Brief History .... 129 
4.6.2 Organisation and >Sanagement ,.,, 129 
4.6.3 Production Capacity ,,., 133 
4.6.4 Working of BCPL 1... 140 
4.7 Smith Stanistreet Pharmaceuticals Ltd,(SSPL) 143 
4,7.1 Brief History .... 144 
4.7».2 Performance .... 147 
4.7.3 Production Capacity ..,. 151 
4.7.4 Research & Development ,,•... 152 
4.8 Bengal Immunity Ltd,( BIL ) ..... 153 
4.8.1 Brief History .... 154 
4.8.2 Production Capacity ,,,. 158 
4.8.3 Working of BIL 
PACSS NO. 
4,9 Summary •••• '^^^ 
5- PRODUCT AND MARKET DIVERSIFICATION .... 'J67 
5.1 Product Planning and Development •••. "ISS 
5.2 The Demand for Drugs •••. 171 
5.3 Product Line Extension Strategy .... 176. 
5.4 Diversification Strategy .... 177 
5.4.1 Product Diversification Strategy .... 178 
5.4.2 Market Diversification Strategy •... 179 
5.^.2,1 Import Strategy .... 1B3 
5.4,2,2 Sectorwise Production and Import .... 185 
of Bulk Drugs 
5.4.2^3 Import Dependence in Drug Industry ••.. 187 
5.4.2.4 Export Strategy .... 1^2 
5.4.2.5 Sectorwise Production of Formulations .... 497 
5.5 Branding Strategy ••«. 199 
5.5.1 Criteria of Good Brand Name .... 202 
5.5.2 Bases for Selecting a Good Brand Name •••. 206 
5.6 Summary •••• 207 
6- PROMOTION AND DISTRIBUTION POLICIES .... 212 
6.1 Introduction •••• 214 
6.2 Promotional Policy •••* 217 
6.2.1 Promotion in Phannaceuticals •••. 217 
6.2.2 Promotional Strategy for Ethical Products*.•. 218 
6.2.3 Promotional Strategy for Non-Ethical Products 219 
6.3 Methods of Promotion •••* 220 
6.3.1 Visits of Medical Representatives •••• 220 
6.3.2 Mailing Literature Directly to Doctors ...• 223 
6.3.3 Advertising in Professional Journals •••• 223 
7-
6.3 .4 Arranging M«dl|Dal Film Shows and 
Bxhlbltbns 
6.3.5 Presenting Ko^Hles 
6.4 Promotional Ebjpendlture 
6.5 U & D Actlvltf for Product Positioning 
6.5.1 Research & Dfe4elopment Expenditure 
6 .5 .2 fleasons for t f e Poor Growth Rate In R&D 
Expenditure 
6,d.3 Areas of Reseferch & Development 
6.6 Distribution policy 
6.7 Government Regulations Regarding Distribution 
6.8 Distribution ^nannel8 
6.8.1 Main ConsIdtdatIons 
6 .8 .1 .1 Selling Dljfectly to Hospitals 
6 .8 .1 .2 Selling Dlifectly to Doctors 
6 .8 .1 .3 Combined Q^annel of Distribution 
6.8.2 Dealer's SeUctlon 
6 .8 .3 Credit Policir 
6.9 Distrlbutionl tKJsts 
6.10 Sunmary 
PRICING POLICIES 
7.1 Introductloii 
7.2 Pricing Str^xegy 
7*3 Pricinf of iDrucs in India 
7.4 Drug Price <fontrol 0rdtr8-1970 and 1979 : 
An Assessment 
PAGE NO, 
223 
224 
226 
230 
23b 
243 
247 
250 
252 
255 . 
258 
259 
959 
?60 
.262 
.263 
264 
2D6 
271 
272 
273 
275 
277 
PAGE NO. 
7 .5 Impact of Unjg Pr ice Control Ofders-
1970 and 197^ •••• '^ '^ 
7.6 Pricing Prinliples in Public Sector,,, 288 
Drug Companies 
7.7 Determinants!of Pricing Policy ,... 291 
304 
• • • • 
• • • • 
APPENDICi'S 
SELECTED BIBLI0GR4PHY 
• • • • 
• •. • 
***** 
309 
7^8 Summary 
8 . ANALYSIS OF FINDINpS 
9 . SUW4AHY AND COKCLuKJiONS . . . » ^52 
376 
390 
(-'J 
P R E F A C E 
The growth ot public sector in India has been one of 
the most signiticant developments In the post-independence 
period. The role played by the public undertakings has had 
far«reaching consequences extending beyond the realm of the 
business, and affecting social, cultural and political values 
of the country. But at the same time, several instances of their 
slacknesses in terms of declining profitability and productivity, 
ineffective management , ind ill-conceived isarketing activities, 
have also been observed. 
Realising the important role public sector can play in 
transforming the econonic developnent of the country and making 
available the best technological competence, on the one hand, 
and the potential threat it poses to the public funds, on the 
other, the govemmenti attitudes towards these undertaking has 
now been ambivalent. In many thrust areas of the economy govern-
ment has motivated the private capital investment in order to 
give up the sectoral reservations awi activate the operations of 
these public undertakings. 
The public sector also covers drugs and phaximaceutical 
industry in the country. The role played by the public sector 
(-i) 
drug enterprises in India can not be overamphasised. 
These units have made a significant contribution 
towards total drug production in the country and offered 
technological assistance to other sectors particularly the 
small sector of the industry. However, the development 
of Indian drug industry in general and the public sector 
units in particular reaains questionable and the chief 
reasbn for this is attributed to poor oarketing planning 
and management. Most of the undertakings are still 
production-oriented or at the best sales-oriented. The 
activities of public-sector drug units lack •arfeetii:^  
orientation. There has been an absence of integrated 
approach involving customer satisfaction and distribution 
efficiency. Besides the marketing practices concerning 
production and market diversification, pricing, distrib-
ution and promotion differ to a gre* extent among various 
public sector drug undertakings. Although complete uniformity 
in the marketing practices of public sector drug units 
is neither feasible nor desirable yet a coordinated and 
balanced approach is necessary. A clearer perspective 
on the marketing strategies of drugs and pharmaceutical 
enterprises is therefore, called for. The present research 
work is an endeavour in this direction. 
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C H A P T E R -1 
Public sector occupies a prominent place 
in the Indian econony. Public enterprises cover a 
wide spectrum of industrial and economic activity in 
the country and they occupy 'commanding hights» of 
the Indian economy. The basic objectives of the public 
sector in India aire j to help in attaining rapid 
econcanic growth in the country; to cr«ate the neceasaiTr 
infrastructure for economic growth; to attain self -
reliance in strategic sectors of the economy; to reduce 
inequilities in the distribution of income and wealthj 
to prevent concentration of economic power and to ensure 
a balanced growth of different regions in the country. 
It is expected that the attainment of these objectives 
by public enterprises will bring about a marked change 
in the pace of industrialisation In the country. Public 
enterprises have a great potential for infusing dynamism 
for achieving balanced growth in the country. 
In view of the political and socio- economic 
significance of the public sector in India, it is nece-
ssary that these enterprises are run on highest possible 
3 
standards of efficiency. Their operation deaands that 
the public sector makes substantial contribution to 
national w«alth at the same time fulfilling larger 
social and national ob;)ectives. To achieve these obje» 
ctives the role of narketing manageaent is rather of 
crucial significance. Efficiency in marketing operations 
in the areas of production, distributionf proaotion and 
pricing is essential for the success of these enter • 
prises. 
The econcBic development of India is signifi-
cantly linked with the success of public undertakings. 
This sector of the economy is not only much larger than 
the organised private sector, but also much more signi-
ficant than it. 
In the central sector alone the number of 
public enterprises has increased from 5 as on 31st March, 
1951 to 221 by Fferch end 1985. 3be investment has incre-
ased from %• 29 crores to te, 39,324 crores during ttiis 
period. If the enterprises of state and local self gover-
nments are also included, the public sector seems to touch 
almost every part of our life. In the production sector it 
covers steel, coal, petroleum, chemicals, heavy and light 
engineering, consumer goods, agro-based industries etc, , 
4 
In the service sector the public sector covers tradit-
ional transportation ( air^ water, land), financial 
Institutions, insurance, tourism etc. in addition to 
public utilities services like electricity, water,road, 
transport etc» Thus public enterprises have reached the 
»consBanding bights' of our econooy and they do occupy 
the position of centrality. 
In view of the gigantic size of public sector 
in terms of investment, diversity of operations and 
involvement in public life, it is imperative that the 
performance of these enterprises is of high standard. 
Unfortunately in most of the cases the actual perfor-
mance of these enterprises has fallen far short of the 
expectations. Although performance can be measured on 
the basis of several criteria, the most common yard 
stick is the net profit earned on capital employed. The 
net profit of public enterprises of the central govern-
ment in 1981-82 was te« 485 crores or an investment of 
fe, 24,761 crores , that is ;just 2 per cent. Thus there 
is apparently something basically wrong in the working 
of public undertakings. 
In the performance of every organisation the 
importance of efficient marketing operations can not 
be overemphasised. Thus if public enterprises are to play 
5 
more productive role In the socio-economic transformation 
of the country, then these organisations have to lay a 
greater emphasis on increased efficiency in marketing opa-
rations whidi hold the key to greater productivity and 
economic prosperity. 
The public sector also covers drugs and pharmaceutical 
industry in the country. The Indian pharmaceutical industry 
has emerged as one of the country's leading industries,The 
capital investment in the pharmaceutical industry has risen 
from 8s, 24 crores in 1952 to more than 700 crores now, 
India is now producing a lar^r quantity of varied pharrna-
ceutical products. However the development of Indian drugs 
& pharmaceutical industry in general and the role played by 
public sector drug units in particular is not commensurating 
with the size of the country and growing needs of our popu-
lation, Whereas the increasing contribution of public 
sector drug units of the country is being recognised in 
strengthening Research & Development activities in the 
industry, in meeting the requirements of bulk dnig produc-
tion and in generating direct and indirect employment, it 
is generally felt that marketing aspects of public sector 
drug units have not been given due attention. In some cases, 
it is the lack of effective marketing strategy that has 
adversely affected the perfonaance of public sector drug 
companies, A clearer perspective on the marketing practices 
6 
of public sector drug units is therefore, called for. 
The present study is an attempt in this direction. 
The Problem i 
The present study is concerned with marketing s t r a t -
egies of the drugs and phannaceutical units in the public 
sector in India. The marketing practices of public sector 
drug uni ts , problems faced by them in implementing the 
marketing strategy and measures needed to solve these 
problems, come under the purview of this study. The main 
emphasis in the study is on a c r i t i ca l evaluation of the 
functional policies of public sector drug companies in 
the areas of production, promotion, distr ibution and 
pricing. 
The drug industry has been chosen for many reasons • 
Fi i^ t , this industry plays an^jmBortant^social ro le , for 
i t is directly concerned with the health of the people, 
which is a basic ased of every ci t izen. The drug industry 
operates in a highly complex enviroraaent, Indian pharma-
cutical companies have been operating in a rapidly chan-
ging environment particularly since mid-sixties. I t i s 
therefore necessary to examine what changes have been 
Introduced by the companies in their marketing strategies 
to cope with environment, 
/ 
The second reason for choosing the pharmaceutical 
industry, as the subject of this study, is that the cont* 
ributinn of the drug companies in the spheres of produc-
tion, earning of foreign exchange and investmentTn the 
Indian econoay has been quite significant. 
Third, the financial performance of the pharmaceutical 
companies operating in the public sector deserves a spelcal 
consideration. The profitability trends, working of public 
sector drug units and the dependence of drug industry on 
imports are some of the areas which have also been touched 
upon in this study. 
The fourth reason for choosing this area of research is 
the leadership role of the public sector in India. The 
Hathl Committee appointed by the central Government submitted 
its report in 1975, In Its report a leadership role was 
assigned to the public sector drug enterprises, because this 
sector, has been playing a vital role in the promotion of 
dj?ug industry in the country. The public sector units supply 
basic bulk drugs to the small and medium sectors of the 
Industry and offer technical assistance to the private as 
well as ;joint sectors. They have undertaken a number of big 
pro;}ect8 needing huge capital Investment which could not 
have come from any other agency. 
g 
LastZy, drug industzy Is a research based one. 
Research & development activity Is one of the basic 
needs of the industry. In the past Billions of dollars 
were spent on R & D by the technologically advanced 
countries of the world for evolving basic chealcals 
for new drugs. Due to this peculiar nature of the 
Industryt It is argued by many that the public sector 
enterprises alone are capable of undertaking new researw 
ches in the critical sectors of Indian econoay* 
Ob.iectlves of the Studyt 
The main objectives of the present study are as 
follows I 
1, To find out the existing oarketing policies of the 
public sector drug units in the context of the prev-
ailing business environment in the country, 
2, To analyse the attitudes and views of the public 
sector managers towards the marketing practices of 
Public Sector drug units^ 
3, To assess the impact of marketing operations on the 
performance of public sector drug units, 
4, To assess the effectiveness of marketing policies 
i) 
pursued by public sector drug units in the areas of 
production, distribution, R&D, promotion and 
pricing of their products, 
f^'^o suggest measures for improving the existing aark-
eting practices of public sector drug units in the 
light of the analysis of findings and conclusions 
drawn from. 
Apart from the main ob;}ectives discussed above 
there were cer*tain secondary objectives of this study, 
which are given below j-
To study the growth pattern of Indian Pharma-
ceutical Industry and to make a comparative study of 
different sectors of the economy aai their net contributions 
towards the growth of the industry, 
'To study the development of the drug industry 
in India, its structural set up, the role played by foreign 
drug companies operating in India and to examine, briefly, 
the role of miltinational drug companies in the context cf 
Indian economic environsent. 
Importance of the Study t 
The study on marketing strategics of the drug 
Ifl 
and pbaraaceutlcel industrjr in the public sector is 
important on aany grounds. First, public sector 
occupies a crucial place in the developing countries 
like India where about sixty per cent of all invest-
ment is made out of public funds. The importance of 
the drug industry can not be over-emphasised because 
of the significant contribution its products make in 
curing people suffering from various ailmaits. So, 
both in view of the role of public sector in Indian 
economy in general and that of the drug industry in 
particular a study of the drug and pharmaceutical 
industry is important. 
The present study is also important on the 
ground that while other agencies viz, private sector 
and the MNCs operating in Indian drug industry are 
motivated by profit making, the public sector drug 
enterprises exist t) meet the basic needs of the people 
in the rural as %rell as urban areas by producing drugs 
which are required in the country. Profit making is not 
their primary concern. Thus a study concerning the 
public sector drug industry, assumes a special signi-
ficance. 
The present study is also important for this 
is one of the least researched areas. There have been 
11 
some research concerning the problems of Indian drug Industry 
In general, and the role and working of drug multinationals 
1 2 
in particular for example Joshi (1977)^ Johri (1983)^ Singh 
(1985)^ and Lall and Streeten (1977) . But these studies have 
focussed mainly on problems concerning the multinational drug 
companies and they have not looked into the marketing areas 
of public sector drug units. There are a few papers which have 
examined the working of public sector drug enterprises. The 
objective of the present study is different from earlier stu-
dies and its scope is confined to marketing policies of public 
sector drug units. 
This study is relevant because it also focusses on 
of 
the effectiveness .marketing policies of public sector drug 
units in terms of growth and profitability. The declining 
profits of public sector drug companies is matter of serious 
concern and some of these units are incurring losses. What 
are the causes of the poor performance of these units? Is it 
due to lack of efficient marketing operations or inefficient 
management or due to the wrong financial policies pursued by 
the public sector drug companies ? 
These aspects need to be explored at some length-
Marketing is the key factor on which the success of a busin-
ess depends, lliis is because marketing aanagement is conce-
rned with the end purpose of business enterprises i.e. profi-
table creation, and sale of products and services which 
12 
satisfy the needs of the customers. In public undertakings 
this is more relevant because their worth is evaluated in 
terms of social good. Scientific marketing management helps 
identifying profitable customers and taking corrective 
measures for satisfying them. This leads them towards achiev-
ing their objectives of serving customers and to the society 
at large. Thus a study of the marketing practices such as 
marketing strategy and planning, product development, distri-
bution and price strategy, promotion planning and marketing 
research of selected public sector drug undertakings for 
obvious reasons is Important, 
Tables 1,1 and 1,2 show the poor financial perfor-
mance of two public sector giants viz, the Hindustan Antibio-
tics Limited ( H A L ) and the Indian Drugs and Pharmaceuticals 
Limited ( IDPL ) during the years 1973-7^ to 1977-78, and 
1970-71 to 1973-7^ respectively. 
Table 1,1 shows that although HAL earned a meagre 
profits of Rs,20 lakhs, Rs, 26 lakhs, and Rs.27 lakhs before the 
payment of all the taxes and liabilities in 1970-71,1971-72 
and 1972-73, the company suffered net losses to the extent 
of Rs, 148 lakhs, Rs. 326 lakhs, Rs, 292 lakhs, te,5A lakhs and 
Rs, 211 lakhs during the years 1973-74, 1974-75, 1975-76, 
1976-77 and 1977-78 respectively. Similarly fable 1,2 
showsthat IDPL has suffered net losses of te, 764 lak]\s, 
Rs, 470 lakhs , fc. 370 lakhs, and Rs,182 lakhs in 1970-71 
13 
1971-72, 1972-73 and 1973-74 respectively. It can be 
seen from this table that these losses were incurred 
despite the huge public investments made in IDPL i.e. 
Rs. 2,595 lakhs, fe. 2,750 lakhs, Hs. 3370 lakhs and 
fis.3,420 lakhs , during this period. However,the company 
did show a net profit of Rs. 797 lakhs in the year 1977-78, 
Hence the possible causes of the poor financial 
performance of public sector drug companies need to be 
explored. It is therefore, important to examine critically 
the marketing policies of the public sector drug units to 
identify the problem areas so that corrective measures for 
revamping the marketing management in public undertakings 
could be suggested. 
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Hypothesis t 
Tbe present study seeks to examine the marketing 
strategies of public sector drug units on the basis of 
following hypothesis : 
1- Goverranent controls on the prices of drugs have 
adversely affected the production and profitability 
performance of public sector drug units, 
2, The licensing policy of the government hinders the 
process of growth and development of Indian drug 
industry, 
3. The excessive government interference in the day to 
day affairs of the public sector drug units has 
adversely affected managerial motivation and organi-
sational effectiveness of public sector drug units. 
Methodology j 
For collecting data the present study has made use 
of a combination of methods such as collection of the 
secondary data including annual reports, documents and records 
of companies^mailing of questionnaire to the companies and 
conducting of personal interviews with senior marketing and 
distribution managers of the public sector drug companies. 
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Factual data pose a JTormidable problem in 
choosing the research area oX" any kind in India, 
Pharmaceutical industry in India suffers from the 
same constraint and as any other industry in the 
public sector where easy access to the data is a 
difficult Job. 
The present study is mainly based on inform-
ation from secondary sources available in different 
Journals, periodicals and dailies^ Among the various 
journals and periodicals used in obtainining the 
information, specific mention may be made of The 
Economic Times , New Delhi, Financial cjcpress. New 
Delhi, Business Standard^Calcutta, Capital, Calcutta, 
Commerce , Bombay, Eastern Economist, New Delhi, 
Lok Udyog , New Delhi, Drugs and Biarmaceuticals-
Industry Highlights , Lucknow, Indian Journal of 
Marketing , New Delhi, The Eastern Pharmacist, New 
Delhi, The Hindu,Madras, Indian Pharmaceutical Guide 
New Delhi, Kothari Industrial and Economic Guide, 
Madras, Times of India Directory and Year Book 
Bombay, and Survey report of National Council of 
Applied Economic Research ( NCAER ) New Delhi, 
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The present study has also mtdB use of the primary 
data gathered with the help of questionnaires and interviews 
with company officials. The ideas and opinions of the senior 
marketing executives on marketing policies and strategies 
of public sector drug industry, were ascertained with the 
help of interviews. 
Such interviews with senior executives of the company 
facilitated the research work to a great extent, A well 
designed questionnaire was sent to the Managing Directors of 
companies to obtain information in areas such as ; production, 
pricing, promotion, distribution,research and development and 
external environment of the drug ccanpanies. But as is usually 
the case, the response from the questionnaire was not good. 
Despite reminders, a return of about 29 per cent was obtained. 
Also, visits were made and discussions were held with the senior 
managers of the companies to obtain additional information. 
The personnel visits along with the questionnaire containing 
open ended questions greatly facilit^^ted the present work. 
The questionnaire used in the survey is given in the appendix. 
Scope of the Study ; 
The present study confines its scope to the marketin^t 
policies in the following centrally owned public sector drug 
units. 
19 
1, IDPL 
2, HAL 
3, BCPL 
4, BIL 
5, 3SPL 
The study also covers the following branches of 
these public sector drug undertakingss 
1. IDPL ( Madras) 
2. IDPL ( Hyderabad ) 
3. UPDPL( Lucknow ) 
4. RDPL ( Jaipur ) 
5. HAL ( New Delhi) 
6. HAL ( Hyderabad ) 
7. KAPL( Banglore ) 
8. BCPL( Hyderabad ) 
9. BIL ( Dehra Dun ) 
The remaining branches of the above mentioned 
centrally owned public sector drug companies have not 
been included because of the limitations of resources 
and time. However the sample is significant though it 
includes only fourteen out of more than nine thousand 
pharmaceutical concerns in the country because of the 
magnitude of investment in the public sector drug 
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coapanies which accounts for above 30 per cent of the 
total investment in the drug industry in the country, 
and in view of the fact that the drug companies in the 
public sector are the chief suppliers of bulk drugs and 
basic chemicals in the country, 
Limitations of the Study t 
Although every «ffort was made by the researcher 
to conduct as rigorously as pc^isible, certain limitations 
were however unavoidable. The important constraints are 
as follows I 
1. The information collected for the purpose of this 
study was obtained with the help of questionnaire 
addressed to the senior marketir^ managers of 
companies. As such the limitations of questionnaire 
method for collecting data obviously would apply 
in our case too, 
2. It follows from the above that some element of bias 
on the part of the Informants can not altogether 
be ruled out although wherever possible cross checks 
were used to warify the correctness of the information, 
3. The study is based on secondary sources of information 
although effort has also been made to obtain information 
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through questionnalr« and lntervl«w9, 
4, Th« prestnt study is basically quallta-
tire in nature but wh«rtvtr appropriate 
data wera used in support or otherwise 
of the statements aade, 
5t It would have been better to include some 
more units in this study but the choice 
was restricted keeping in view the limita-
tions of resources and tiae and the diffi-
culty of obtaining information from public 
sector undertakings, 
presentation of the Study i 
The study contains altogether nine chapters. 
Besides the first introductory chapter, the following 
eight chapters have been planned. Each individual 
chapter has its summary at the end. The analysis, 
discussions, findings and conclusions of the study 
are presented below s 
Chapter 2 descrllies conceptual framework of 
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the study, Conctpts relating to marketing strategy and 
public enterprises in India and the relationship between 
compaz^*s marketing strategy and its environsent have been 
examined* 
Chapter 3 deals with literature review. It aim* to 
review the studies carried out concerning marketing 
practices of public sector drug units. The work done in 
the areas of production, distribution^pricing, promotion 
and R & D activity of public sector companies has been 
reviewed. The important findings of such studies, their 
Sampl* size, methodology, objectives etc, have briefly, 
been mentioned in this chapter. 
Chapter 4 gives a profile of the public sector 
drug industry in India, It covers aspects such as 
structure of the drug industry, working and role of public 
sector drug companies, aiKi their research & development 
activities, 
Qiapter 5 focusses on the production strategy. It 
deals with the demand for drugs, diversification policies 
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of the companies, branding as well as Import and export 
policies of the companies and contribution of public 
sector drug companies to the total drug production in 
the country, 
adapter 6 offers an analysis of the promotional 
policy of public sector companies and discusses the methods 
of promotion and the tools used for product promotion. It 
also gives comparative figures of promotional expenditure 
incurred by different sectors of the industry* 
It also examines the distribution policy including 
the channels of distribution, selection of the dealers, credit 
policy and the cost of distribution. 
Chapter 7 offers are analysis of the pricing policy 
of public sector drug units. It focusses on issues arising 
out of price determination, pricing principles in public 
enterprises aiKi it critically examines the Crug Price Control 
Order ( DPCO ) enforced in India, 
Chapter 8 contains a detailed analysis of the information 
obtained with the help of questionnaires. Information 
obtained with the help of interviews has also been analysed, 
CJiapter 9 presents the summary and conclusions of 
the present study. 
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Growth of Public Entemrisea in India t 
The birth of public sector in India took place in 
the third decade of the nineteenth century. In the early 
days governmental enterprises concerned themselves with 
the lines of communication which were extended more or 
less keeping pace with the territorial expansion of British 
rule in the country. For the rest of the industrial revolution 
which *as transforming the economy and society in the iest, 
it was left to private enterprise, mainly through firms 
organised and controlled from U.K., to establish such indus-
tries in India as they thought fit. 
The first year of independence marked a surge forward 
in public enterprises. The government published its industrial 
policy resolution, declaring its intention of going into 
public enterprise in a strong way. In the firat year 19^8, 
the first step, and significant in the day to come lias the 
establishment of the Atomic Energy Commission, An act of 
Parliament created the Industrial Finance Corporation,and 
Indian Telephone Industries was also incorporated. 
There has been unprecedented growth of public enter-
prises in India, These enterprises are engaged in variety of 
activities, and they have, undoubtedly, come a long way with 
nearly 2 million employees, over 1,00,000 managers and 
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over te, 30,037.25 crores Invested in 209 (including 
insurance companies ) Central Governiaent undertakings, 
excluding all departmental enterprises like the railways, 
post offices, telecommunications and defence factories 
as well as more than 500 enterprises under the various 
State Governoents. Following tables throw more light on 
the growth of public sector in India '* 
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T A B L£ » 1.3 
Investment in Centrally Owned Public Sector Enterprises 
Plan Total : 
( In as. 
29 
81 
953 
3,902 
6,237 
18,225 
21102 
24916 
30,039 
33,567 
39,324 
Envestment 
Crores ) 
No. of 
Enterpr ises 
5 
21 
48 
85 
122 
186 
185 
205 
209 
214 
221 
First Plan 
Second Plan 
Third Plan 
Fourth Plan 
Fifth Plan 
Sixth Plan 
As on 31st March, 
1981 
As on 31st March, 
1982 
As on 31st March, 
1983 
As on 31st March, 
1984 
As on 31st March, 
1985 
Source t India* 1984, and Monthly Coomientary on Indian 
Economic Conditions, New Delhi,April 1986. 
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T A B L E - 1.4 
i^ ployatent and Average Annual Emoluisents In Public 
Enterprises 
Year 
1978-79 
1979-80 
1980-81 
1981-82 
1982-83 
No, of employees 
(in lakhs) 
17.03 
17.75 
18.39 
19.39 
20,09 
Average Annual 
emoluments (in gs.) 
11201 
12468 
14239 
16158 
18009 
Source I Beureau of Public Enterprises Annual Survey 
Report, 1982-83. 
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T A B L E -1.5 
Internal Resources Generation In P.Es, 1980-81 to 1982-83 
Year No. of enterprises 
generating internal 
resources 
Net resources 
available for 
reinvestment 
(in Rs.crores) 
1980-81 
1981-82 
1982-83 
102 
110 
115 
1095,63 
1922,87 
2270.83 
Source s BPE Annual Survey Reports, 1982-83 . 
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T A B L E - 1 . 6 
Contribution to Central Exchequer 1978-79 to 1982-83 
Year Total % Increase 
(in fis.Crores) from previous 
year 
1978-79 2887 
1979-80 3539 22,58 
1980-81 3302 6.7 
1981-82 4567 38.31 
1982-83 5529 21.06 
Source I B.P.E, Annual Survey Reports, 1982-83. 
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C H A P T E R -2 
C O N C E P T U A L F R A M E W O R K 
Introduction 
Strategic planning has emerged as an important 
element in the management process of almost all the private 
and public sector companies in India, It is the managerial 
process of developi23g and maintaining a viable relationship 
between the organisation and its environment through the 
development of corporate objectives, growth strategies aiid 
busine«« portfolio plans. Thus strategy formulation is the 
core of the total planning system of any organisation. 
The overall strategic planning comprises plans formu-
lated by senior executives in the functional areas of business, 
TIae marketing, finance, and personnel strategies of a company 
greatly affect the performance of a compary. The marketing 
strategy has a position of pre-*eminence as the success of a 
business depends largely upon the performance of its products 
in the market. 
Marketing strategy comprises the steps to be taken at 
the product and market level to develop effective marketing 
plans. It includes the formation and implementation of total 
marketing plan of a firm with a view to achieving the organi-
sational goals. It is a scientific and organised approach in 
the area of marketing. It calls for a continuous appraisal of 
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its tffectiveness to determine the consumer preference 
for the products of a company. 
Although marketing strategy is of critical impor-
tance, yet no generalisations about its formulation can be 
made applicable to all the companies. The product and 
industry characteristics are key considerations in the form-
ulation of market strategy. In addition, the company resources, 
its history and philosphy, its personnel policy and its tech-
niques of marketing products are the other factors of conside-
rable importance that determine the marketing strategy of any 
1 
company. 
Marketing managers of c<»Dpanies do not attach the same 
importance to key marketing variables, viz, products,pricing, 
2 
distribution channels and promotional activities. The purpose 
of this chapter is to define the concept of public enterprises, 
marketing strategy and its key areas in the context of the 
economic and non econtwic environment of business. 
Concept of Riblic Enterprises ( P,Ss.) 
• Public Sector* is an absolute term. It includes all 
governmental activities irrespective of whether they are public 
services or industrial or commerical undertakings. The term is 
sometimes, used as apposed to the term 'Private Sector* whereas 
it is most often, used as a synonym for public enterprises. 
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P.Es, can be regarded as an activity of the government, 
whether central, provincial or local, involving manufacturing 
of goods or provision of services in return of money. In a 
P,E, the charges for goods or services are expected simply to 
cover the cost incurred. If this is not possible, the cost is 
to be subsidised by the government concerned. In some cases 
the price fixed may not cover the total cost incurred in produ-
ction. Still it continues, to charge low prices with the aim 
that, in the long run, the enterprise should at least meet the 
break-even point. 
Social and administrative services of the government 
differ from public enterprises and hence the former do not 
qualify tbr the definition of the latter. Some non-economic 
activities like education and medical do not come under the 
he«d of P.Es., although sometimes fees are charged for their 
3 
services. 
If the Government takes over an enterprise temporarily 
the unit does not become a P.S, unless there is necessary 
4 
legislation to nationalise it. The Government in such a situa-
tion is simply its caretaker or trustee. 
Another term 'public undertaking' is often, used for a 
public enterprise. It is used with reference to the Committee on 
Public Undertakings ( CPU ), which was formed by the government 
t® conduct a detailed study of the working of public enterprises 
in the past. Public enterprise may be a subject of study 
cempxising of a number of academic disciplines. It is concerned 
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With public administration end political science, econouiics 
and business management and law and jurisprudence. Also, the 
connotation of the teria differs from one sphere of treatment 
to another and from one country to another,'' In Italian 
terminology public corporations and public enterprises are 
not synonymous expressiooB because there municipalities as 
well as certain autonomous government departments are also 
regarded as public enterprises. In French terminology, a 
public enterprise means an industrial or commercial enterprise 
of the state. Again, the Hoover Commission (U.S.A.) included 
all the state agencies engaged in providing goods and certain 
categories of services as public enterprises. In U.K. the term 
public enterprise is used for all public corporations as well 
as departmental undertakings. Because of these different conn-
otations, the group of experts which met at the International 
Institute of Administrative Sciences at Brussels, to discuss 
the term, spent considerable time in arriving at a precise ana 
satisfactory definition and ultimately decided to prepare a 
note explaining what is meant by a public enterprise. 
As pointed out above, Jae cormotations of the public 
sector,public enterprise, public undertakings and so on have 
to be determined clearly and specific meanings have to be 
given to the different terms. 
The public sector coopanies consist of enterprises 
either set up by the state or those which come under the owne-
rship of the government through nationalisation. Section 617 of 
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the Indian Companies Act 1956, defines a goverment 
company as one"in which not leas than 51 per cent 
of the share capital is held by the central government 
or by any state government or partly by the central 
governnent and partly by one or more state governments". 
The private sector ccaaprises those firms or companies 
that are organised on partnership or sole proprietor-
ship basis* 
Public sector companies or enteiprises also 
differ from public corporations. The basic difference 
between the two is that a company is registered under 
the Indian Companies Act, while a corporation is 
created by special Act of Parliament, Some public 
sector units in India are on a corporation model such 
as the National Industrial Development Corpoi^tion, 
the Heavy Engineering Corporation, the Life Insurance 
Corporation ( LIC ), the Indian Airline Corporation, 
the Industrial Finance Corporation ( IPS) and so on. 
It is also different from departmental undertakings, 
such as Railways, Post and Telegraphs etc. 
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Concept o£ Marketim Strategy 
The word 'strategy* is a term related to warfare. 
The appropriate application of strategy* is a plan to win a 
war. But in the business world, it refers to plans relating 
to marketing, financing and manufacturing operations. 
Executives of different business organisations concentra-e 
their efforts to win the biggest possible share of the targeted 
market. The field of strategic planning is much wider. It deals 
with the adjustment of controllable factors, viz, production, 
physical distribution, promotion and pricing within the environ-
ment of uncontrollable factors, viz, competition, economic 
situation, legal barriers, interference of diXierent behaviours 
and scientific and technological difierentiation. 
Formulation of business strategy is a job of crucial 
significance. Failure or survi^ of a business depends greatly 
upon the effectiveness of strategic planning, A successful 
decision requires vast experience on the part of the management. 
For example, to increase the price of a product to a significant 
extent, the management will have to explore and evaluate the 
reaction of competitors towards the change in price. If the 
change leads to market dominance, competitors will rush to 
snatch the market share by changing the prices of their products 
also. The management of a company should explore the defensive 
tools to be used to safeguard its n^rket position. This requires 
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a continuous review of controllable factors within the 
atmosphere of uncontrollable ones. 
The following are the two sets of factors that deter-
mine the elements of marketing strategy i 
1, Controllable factors j and 
2, Uncontrollable factors. 
These are the determining factors. Though seemingly 
quite separate, the two are very much inter-dependent, A 
change in the former affects the latter. Similarly a change 
in any segment of the latter must affect the former. This 
correlationship between the -cwo classes of factors varies 
from company to company because of the nature and character-
istics of a business. 
Controllable factors constitute the main decision making 
areas of management. Such factors are under the control of the 
management. They can change any time in proportion to their 
composiiion. The main components of controllable factors are as 
under, 
i. Product} 
ii. Physical Distribution. 
iii. PromotionJ and 
iv. Price* 
These are the four essential components which are taken 
into account for the formulation and implementation of marketino 
strategy. Though these elements are independent for the sake of 
3.9 
decision Baking, they art greatly influenced by the external 
enviroaaient through several coeplex interactive processes of 
the business. 
In the words of Kotler "Marketing Mix • is t)x8 set of 
controllable variables that a flna can use to influence the 
7 
buyers* responses,' 
McCarthy popiiferised these elements Iqr referring to 
thea as the American "four P»s, " i,e, product, prc»otion & 
price,®'^ '^ / ^ w ^ ,i^ /n.^ -^^ - • 
Uncontrollable factors aay have a great influence over 
controllable ones. The aain task of aanagenent is to take a 
decision concerning the optiaiM use of aerketing inputs in the 
context of the changing environment. The aanageaent is, there-
fore, required to give due consideration to external business 
environment which is uncontrollable in nature, 
A Coapany*s Marketing Strategy and its £nvironaenti 
A company, whether public or private, functions in an 
environment which is characterised by { 
1, Economic factors 
2, Sociological-C3ultural factors and 
3, Pol i t ical- legal factors. 
Management of a company has no direct control over 
these factors which create various opportunities, threats and 
regulatory guidelines within which the ccMpany must survive and 
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grow. The marketing strategies of the company should be 
formulated In "toe context of a careful analysis of these 
factors. At each stage of planning and &trate^ formula-
tion these external factors influence greatly the decisions 
taken. 
The coopanits included in this study are only some 
public sector drug unit* in India and their subsidiaries 
and identification of the environment ha« been made from 
the point of view of these companies. 
To determine tiie specific factors of environment that 
have affected the public sector drug companies in India two 
methods have been adopted. First, opinions of a cross-seciion 
of managers belonging to these companies have been obtained 
with the help of interviews. Secondly, a questionnaire was 
designed to seek information regarding the environment of the 
company. However, most of the executives of these companies, 
refused to furnish written infonaation because of policy of top 
management and the bureaucratic control over these enterprises. 
Several models have been evolved by the experts to 
analyse the nature of the interactive process between a company 
Q 
and its environment. Farmer and Richman' have proposed a model 
to explain the influence of the various environmental factors 
on a coiipany. The model relates to (i) Critical elements of 
management process,(ii) Key areas of managerial effectiveness, 
and (iii) Various environmental factors. 
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The various environmental factors have been classiiied 
as 'educational* 'sociological-cultural'•economic''political 
and legal'variables. Suphasis in this model is on segregating 
environmental factors from the basic management process. The 
management process includes both the functional policies as 
well as the functions of management. The application of this 
model in analysing the influence of environmtnt on a company 
involved designing a shape in which specific interactions 
between various environmental factors and elements of manage-
ment process are indicated. 
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Table 2.1 shows how environmental factors might affect 
managerial practices in similar situations. It is obvious that 
not all factors are going to be different in each situation,There 
will be some overlap in attitudes and practices. The degree of 
difference, Farmer points out seems to decrease in more economicallji 
developed countries. Hence managers should examine these constra-
ints as they afiect each aspect of management and should adapt 
managerial practices suitable to conditions in their own country. 
Another model designed to analyse the nature of interaction 
between a company and its environment, has been offered by Nagandhi 
10 
and Estafen, This model also focuses on separating the environ-
mental Variables from various managemant practices. The model 
suggests that both management philosophy and environmental factors 
influence management practices while the environmental factors 
also independently affect the managerial and over .11 effectiveness 
of an entejrprist, 
11 
The third model hao been proposed by Koontz , In this 
model the process of management is identified as two separate 
sets of activities. The first of these, referred to as 'managerial 
activities , include management techniques, ob;)ectives, policies 
and programmes of a company. The other set of activities is 
referred to as •non-managerial activities »which consist of 
specialised scientific and technical activities in areas such 
as marketing, engineering, production and finance. This model 
indicates a strong relationship between various environmental 
factors and the two areas of activities. 
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These models provide a systematic approach for designing 
the framework of the present study. Although these models were 
primarily meant for the analysis of the transferability of 
management process from a company operating in a given environ-
ment to another company operating in a different environment, 
yet they provide valuable insight for study in the area of mt-rke-
ting strategy formulation of public sector drug companies in 
the given environment of the country. In the present research 
work therefore, only the functional policies end their outcomes 
have been considered in the context of certain key environmental 
factors. 
Economic Factors 
All the economic activities such as production, distribu-
tion and consumption are affected by changes in the prices of 
products. In a free economy, prices act as a signal for the allo-
cation of consumption expenditure on the part of consumers and it 
is known as the demand side, and the allocation of the factors of 
production which is referred to as the supply side. While prices 
.are determined through the interaction of demand and supply, they 
in their turn, determine the relative distribution of income. The 
prices so determined would, however, be subject to change owing 
to changes in monetary and fiscal policies, and wage- income 
policies. They would be subject to change also due to the changes 
in variables like incomes, tastes, availability of complementary 
products and substitutes. 
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W';en one looks at complex interaction in the drug industry 
one finds that the above do not perfectly fit in with the facts 
since there are some other variables which play their roles, ihe 
intrinsic life-saving therapeutic value of a drug plays a dominant 
role on the demand side, which yields infinite utility to the 
consumer, rendering the demand for drugs completely inelastic. 
Decisions concerning marketing strategy are influenced by different 
competitive settings. Perfect competition is an extreme form of 
the marketing condition ac ording to the classical economists. 
It does not exist in real life situations because the conditions 
necessary for its existence are not found in actual practice. The 
basic conditions for the existence of pure and perfect competition 
are as follows s-
i, A large nuaiber of buyers and sellers j 
ii. Free entry and exit of firms; 
ill. Homogeneous products throughout the market ; 
iv. Perfect knowledge of a product and its price among 
buyers and sellers; intL 
V, Freedom from all artificial restrictions. 
This is a hypothetical situation which does not exist in 
the real world. If these assumptions hold good for a short period, 
no noticeable affect of the measures of competitors can be found 
in the market, 
- Offering of better products exploits the condition of 
homogeneous product, 
- Use of efiicient channels may be fairmful because it would 
yield lesser margin of profit to the sellers. 
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• Advertising for the purpose of giving information about a 
product & its prices may not be very benefic^l. 
• Price cut to influence the buyers' choice will leaa other 
seBers to follow suit. 
Monopolistic competition is a market situation which 
exists in the real world? It is also known as imperfect compe-
tition. Following are the main conditions of monopolistic 
competition; 
ii • There is a large number of buyers and sellers but not as large 
as in a situation of pure competition; 
ii)« Th re is only one product, 
iii)- There is product differentiation which is the main condition 
of monopolistic competition. 
Monopoly is the opposite situation of a market than that 
of the perfect competition. In this type of market situation 
there is no competition, A seller has full control over the supply 
of his proauct. Thus monoply may be defined as"a firm which controls 
the whole supply of a commodity for which there are no close sub-
stitutes". Following are the main conditions of a monopoly 
situation ; 
1, One seller; 
2, Full control over the supply of a commodity; 
3, No close substitute; 
A, No entry of other firms; 
5. Abnormal profit. 
48 
This market situation too Is a hypothetical one and it 
does not exist in most of the cases in real world. However, 
artificial conditions concerning monopoly can be ensured by 
necessary legislations as the case of railways, post and 
telegraphs and in some cases oil producing public sector 
undertakings such as Oil and Natural Gas Commission (ONGC ) 
and companies producing Iteas of the strategic nature, 
Mhen one looks at the typical structure characterising 
Indian pharmaceutical markets, e.g. high concentration of 
sellers, stiff barriers to entry ana peculiar conditions of 
the market forces, one finds that the above assertions do 
not perfectly fit in with any of the competitive situations. 
Although imperftct competitive condition* prevail in the 
drug market of the country. However, public sector drug units 
in India enjoy monopoly in the production of certain drugs 
in the country where entry of other sectors is prohibited. 
During visits to the establishments of the drug companies in 
the public sector discussions in this regard were held with 
the senior executives. They pointed out that market level 
factors such as demand and supply as well as competitions do 
not have any significant impact on the operations of their 
companies, for two reasons. First, the size of the market 
is large enough to absorb the existing production and about 
seventy per cent of the market, mostly rural areas, remains 
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untaped. Secondly, government licensing system has 
obviated the possibility of much competition in the 
market. The licensing policy ensures that there are not 
too many manufacturing companies competing for the sale 
of the same drugs. 
Managers in the public sector drug units also 
felt that external environment which had a dominant impact 
on the operations of the coKpenies was primarily legal in 
nature, and reflected Government's policy towards the 
public sector drug units in India. 
Sociological-Cultural Factors ; 
There are other factors also like the consumers' 
buying behaviour and social factors in decision making. 
In the case of other consumer goods, both the functions, 
the choice of a product and the payment of its price,are 
performed by the consumers themselves. The demand for a 
product is normally a function of relative prices and incomes. 
But in the case of drugs, 'the man who chooses does not 
pay and the man who pays does not choose'^ This divorce 
between the decision maker and the consumer -is due to 
an intervening factor between the two. This factor is the 
doctor, who diagonoses the disease and writes the prescrip-
tion. The consumer then buys the drug without exercising 
his own option, His role is reduced to simply that of a 
price taker in the market. 
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Similarly, the demand for drugs is also governed by 
several other factors such as disease incidence and its 
trends, quality of life, population characteristics, and the 
state of social and physical environment. Disease incidence 
and trends determine the mortality rate in a society. Birth 
rate, infant mortality rate and the prevailing diseases in the 
old age group greatly affect the demand for drugs, whereas 
the supply of drugs is mostly affected by factors such as the 
availability of raw materials, production technology and the 
12 progress achieved in R & D etc. 
Following are the sociological - cultural factors which might 
affect managerial practices. 
- Role of religion, view of management goals and contribution 
to culture j 
- Attitude toward management and managers; 
- Acceptance of change; 
- Attitude toward efficiency; 
- View of savings and investment; 
• Attitude toward material possessions; 
- View of time and change, use of new knowledge and statistical 
data, and population growth; 
- View of authority, group decision making, and interorganisa-
tional cooperation; 
- Interpersonal cohesion, class structure and individual mobility; 
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• View of achievement9 dedication to work, and language 
barriers to coiraaunication; and 
- Attitude toward scientific method, 
PolitiC8l»Legal Factors 
The Industrial Policy Resolution of 19^8, gave 
particular emphasis to the growth and development of the 
public sector enterprises in India, but no specific mention 
was made of establishing public sector drug enterprises. It 
was the Industrial Policy Resolution of 1956 which reserved 17 
industries exclusively for the public sector and any further 
private investment in these industries was banned, j^ another 
group of 12 industries, which included basic and intermediate 
products required for producing drugs, antibiotics and other 
essential drugs, the policy assigned a leadership role to the 
public sector. 
Guided by the policy of providing a leading role 
to the public sector, and with the objective of breaking the 
monopoly of foreign drug companies in the production of antibio-
tic and other essential drugs, the government established two 
public sector drug undertakings, Since then, these two units 
have been the major producers of essential drugs in the country. 
Furthermore, the revised Licensing Policy announced in 1973 
listed 19 industries as the priority industries. Their list is 
given in Appendix *1, The 1973 policy resolution restricts the 
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•ntyy of other sectors In the production of drugs listed in 
Appendix- 1 which are reserved only for the public sector. 
The iaqport and export policies of the government also 
0 fleet decisions concerning the manufacture and sale of drugs in 
India, During 1970, the government nationalised the imports of 
essential bulk drugs. The import policy of the goverrunent for 
the pharmaceutical industry has two objectives, to provide the 
public sector a greater control on pricing and distribution of 
imported essential bulk drugs, and to discourage iorport of other 
drugs by inqposing heavy custom duties^ Since under the restricted 
import policy of government, nearly 70 percent is now handled by 
the public sector on the basis of a cenallscd import system. 
The export policy of the government is guided by the 
primary objective of miximisicg exports from the country, but in 
such a manner that its economy is not adversely affected. Export 
of drugs that are greatly needed within the country and production 
of which is inadequate is banned. This export policy applies to 
the drug industry in the public sector. These units have been 
exporting drugs and pharmaceutical specialitiis, to the South East 
Asian nations and many countries of Africa and West Asia, Export 
of drugs is also governed by the Dangerous Dnigs (Import, Export 
and Transhipment Rules 1957) which prohibit the export of unlawful 
and narcoitic drugs from the country. 
The drug policy of the government is one of the important 
tools through which the functioning of pharmaceutical industry is 
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regulated. Following the reconmendatlons of the Hathl Committee 
the Central Government announced a comprehensive Drug Policy on 
29th March, 1978. This policy of the government has enabled the 
indigenous sector to be in a more favourable position as ccmpared 
to foreigh firms and has assigned a leading role to the public 
sector drug unit, besides reserving 25 product lines exclusively 
for It. Slmilary, to promote the indigenous sector, excluding 
public sector, licences for the production of 23 drugs are to be 
given only to companies in this sector while 66 drugs have been 
left for all types of companies, including foreign drug companies• 
Pricing policy of the government too, has adversely 
affected the public sector drug companies to a large extent,The 
executives argue that the decision concerning prices of drugs is 
largely influenced by the government policy and pricing mechanism 
which is quite tight. Concerned with improving the health of the 
people, the government is trying to ensure that the prices of 
drugs are not beyond the reach of the common men. Keeping this in 
view, the government, through various Drug Ei'ice Control Orders, 
announced from time to time, has attempted to keep the prices of 
drugs within reasonable limits and to bring about uniformity in 
the prices of similar drugs produced by different manufacturers. 
To make the price control mechanism more effective, the government 
has also imposed restrictions on the profitability of the drug 
companies, 
The Central Government announced a new drug policy in 
December 1986, relaxing its rigid control over this industry. 
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As a result of It, the prices of drug formulations are likely to 
go up by 12 to 25 per cent. The newly established National Drug 
Authority has been vested with the discretion to decide, from 
time to time, upon the list of drugs to be included under the 
ambit of price control, 
A Framework of the Study j 
"Health for all by 2CX)0 AD" has been accepted as the 
13 
national goal of the country's new health policy, "^  The main 
objectives of this health policy are ; (1) to reduce the death 
rate, infant mortality and the birth rate and (2) to increase 
life expectancy from the existing levels. 
For achieving these objectives, a multi-dimensional 
strategy has been evolved. The main elements of this strategy 
include augmentation and strengthening the health care facilities 
both in rural and urban areas, provision of filtered water. 
Sanitation, etc and ensuring adequate supply of medicines to the 
needy. 
As the coverage of population under the health care 
programme is expected to increase substantially consumption of 
drugs would receive a further fillip during the next two decades. 
Since independence, greater attention has been paid 
towards rapid industrialisation of the country with a view to 
achieving self reliance in key areas. The drug industry was 
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assigned an imptxrtant task by the planners in the economic 
development programme of the country. In 1975»the Hathi 
Committee was set up to study vital issues and working conditions 
prevailing in the industry. On the basis of the report submitted 
by this Committee, a new Drug Policy was announced in 1978 to 
activate the units working in the industry. The various press-
ure groups and vested interests involved did not allow the 
effective implementation of this new policy. It is in this 
context the role of the public sector drug units is to be examined 
However, it would not be unfair to point out at this 
Juncture that the contribution made b/ the public sector drug 
units is not upto the mark. This sector which has been primarily 
established for the welfare of a country inhabited by poor messes, 
must fill the gap created by vested interests through efficient 
marketing management which is the key factor on which the success 
or failure of a business largely depends. This applies to all 
undertakings, whether in private or in public sector. In private 
undertakings the chief aim of the producers is tb maximise profits 
through customer satisfaction whereas the public sector does not 
have profit making as its primary concern but both of these are 
basically business concerns and so they have to take decisions 
with on eye an the market. Managements of all modern business 
units are therefore, becoming marketing oriented and the public 
sector undertakings, for obvious reasons, are no exception to 
this. 
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It can be concluded from the above discussion that 
marketing strategies of the public sector drug industry revolve 
around the following parameters, 
a- production policy; 
b- Price Planning j 
c- Distribution System and, 
d- Promotion & Development Plans, 
Product development and planning in drugs and pharmaceuti-
cal industry needs the development of the processes of the 
preparations of drugs, their effective delivery system and impro-
vement in the quality of the indigenously produced drugs. The 
drugs and pharmaceutical industry 'being a life-line industry, 
should take great care while preparing its products. To safeguard 
the products from the adulterations and infection day to day tests 
are carried out in the national laboratoreis. Since there is a 
high rate of obsolescence in this industry, greater attention should 
be given on the R & D activity in it. 
As far as efficient delivery of the drugs is concerned, 
efforts are being made to transport them directly to the targeted 
organs in the body of the patients. The first component in the 
drug delivery systems is their selection on the basis of their 
effectiveness, biological and physico chemical properties, 
desirable for the effective transfer of the agent from the site 
of adtinistration to the target site. The second ccanponent is the 
drug delivery module. The third component is the platform which 
houses the drug delivery module. 
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Improvement in the quality of the iiKilgenously produced 
dznags is greatly needed. Since 1951» continous efforts are being 
made for the development of drug therapies, which have resulted 
in the fact that India has reached a nearly self-reliance stage 
in this field* This is the result of the product development 
strategy formulations in the drug Industry, Product development 
in the industry does not merely depend upon chemists and pharma-
cologists. It is also related to marketing conditions. Favourable 
market attitudes enhance the value of drugs and in turn theAr 
production too, which can only be possible when proper planning 
is done. Production planning involves diversification strategy, 
import and export strategy, branding strategy and research and 
development activity. 
Pricing strategy is one of the crucial elements of 
marketing strategies. It requires that the drugs and pharmaceuticals 
should be available at reasonable prices. Drugs needed by most of 
the people should be priced lower than other drugs. Keeping this 
in oind government through the Drug Price Control Orders has 
categorised the drugs into three major groups. But the industria-
lists do not like this arid keep approaching the government for 
reconsidering its policy in the matter. 
Distribution strategy is concerned with the transfer of 
drugs from the place ox manufacture to the place of consumptions. 
Various aspects such as the type of distribution network to be 
adopted, means and the cost of transportation, commissions, credit 
terms for various intermediajcies and all other factors which are 
involved in deciding on the distribution strategy of a company. 
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A distribution policy should ensure that quality drugs are 
available in the market at reasonable prices. 
Continued promotional and developmental activity is 
most essential for the success of a business. It is a two fold 
activity i.e. attracting the potential customers through 
advertisements and publicity and inCuencing them simultaneously 
through personal contacts. Drug companies have to be very careful 
in designing their promotional policy. If they promote some of 
their essential and life saving drugs too aggressively, thise 
drugs may be regarded as unethical. The main task of a company's 
promotion and development policy is to create awareness in the 
minds of the doctors about a drug, 
SUMMARY t 
The concept of strategic planning has emerged as an 
important element in the management process of almost all the 
private and public sector companies in India, The overall 
strategic planning comprises plans formulated by senior executives 
in the functional areas of business. Marketing strategy consists of 
the steps taken at the product and market level to develop 
effective marketing plans. 
The public sector is an absolute term. It includes all 
government activities irrespective of whether they are public 
services or industrial or CMamercial undertakings. The term is 
5.9 
sometimes used as opposed to the tern » Private Sector*, 
It is most often used as a synoym for 'Public enterpirises*, 
The word»strategy* is related to warfare. The 
appropriate application of the word is planning to win a war. 
However, th the business world, it refers to plans relating 
to martteting, financing and manufacturing. Executives of the 
different business organisations concentrate their efforts 
on winning the biggest possible share of the targeted market. 
The field of strategic planning is very wide. It deals with 
the adjustment of the controllable factors viz,' production, 
distribution, promotion and pricing, within the environment 
of uncontrollable factors viz; competition, legal barriers and 
behavioural influences. 
Any company, whether public or private, functions 
within an envireivt&t which is characterised by economic and 
social^competitive and political or legal factors. The management 
of a company has no direct control over these factors which 
involve opportunities, threats and regulatory guidelines within 
which the company «DSt survive and grow, 
"Health for all by 2000 AD" has been accepted as the 
chief goal of our national health polipy. The main objectives 
of our health policy are (1) reducing the death, infant 
mortality and birth rates, and (2) increasing the life expectancy 
from the existing levels. For achieving these ob;)ectives, a 
multioodimensional strategy has been evolved. The main elments 
of this strategy are production, distribution, promotion and 
pricing strategies. 
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C H A P T E R «3 
JLillJSlllill £11111* 
A review of rtlated studIts in the field of phenna-
ceutical industiry in India ihows that with the except-
ion of few studies and stray articles appearing occasion* 
ally in the press, very little work has been done in the 
subject. The govemaent reports, with the exception of 
the Hathl Ccomittee report, relating to the drug industry 
are either too old or contain too little to provide an 
insight into the working of the industry, 
Soae studies relating to the working of drug sultin* 
ationals in India have been conducted by Johri (1985), 
Singh (1985), Lall and Streeten (1977), Sengupta (1978) 
and Mehra (1975), A brief review of scmie important studies 
conducted in the area of our reseei^h is given below, 
^ 5 The first Enquiry Conuaittee, * set up under the Chaiman-
ship of General IJhatla, submitted its report in 1954,Aaong 
other things, this 6offlmittee recooaaended that a systea of 
fair trade prices be established, that price cuts be stopped 
and consumer prices of all drugs and oedicines be fixed by 
an organisation representliag both the govemaent and the 
trade and that any deviation fro© these prices should entail 
the cancellation of tht licence of the drug company concerned. 
The Govemaent of India accepted the recommendations of this 
Ceofflittee and promulgated the first price control order for 
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for drugs in 1962, making it compulsory for all the raanuf-
acturers to publish their prices and for the traders to 
display them. In 1966, this statutory control was enforced 
throu.'ih the Essential Coumodities Act, under the Urug Prices 
(Display and Control )Order. 
Tov/ards the end of the sixtees, the Government of Inaia 
set up a commission known as 'Tariff Commission' to examine 
the cost structure of 18 essential drugs and to explore the 
possibilities of reducing their prices. The Government accepted 
the recommendations of the Tariff Qcwimission and passed the 
Drugs (Price Control) Order-1970, This or-der consisted of 
three main elements, viz;(l) Prices of bulk drugs were controlled; 
(2) prices of selected formulptions were controlled; and (3) a 
ceiling on overall profit was intro<Juced, The DPCO-1970 worked 
for a few years and subsequently another committee known as the 
Hathi Committee, w s set up to look into the working of the 
drugs anc pharmaceutical industry in the country. 
This Committee, which was constituted under the Chairm?»n* 
ship of Shri Jaisukhlal Hathi, submitted its report in 1975. 
The Hathi Committee came to the conclusion that from the time 
that they were brought under statutory control, the profitability 
of many drug cMipanies on the sale oi formulations declined 
from 15,47 per cent in 1969-70 to 8.3 per cent in 1972-73. The 
Committee also found thnt there were wide variations between 
the profits of individual companies. 
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- To foster and encourage the growth of the Indian sectorj 
• To ensure that drugs are available In the market in suff i -
cient quantities to meet the health needs of the people; 
- To make the drugs available a t reasonaMe prices to the 
needy consumers j and 
• To keep a careful watch on the quality of the drugs being 
produced by different ccwsipanies in the country,to prevent 
these drugs from adulteration and to curb other malpractices 
occasionally indulged in by some manufacturers to meet the 
increasing demand. The reccanmendations of Hathi Cciamittee^ 
i f enforced properly, will undoubtedly go a long way in 
revamping the drug industry. But the Committee did not suggest 
any specific mechanism to overcome the problems of adulterated 
and duplicate drugs, a r t i f i c i a l scarcity created by the manu-
facturers and so on. 
o ^ " There are a few Unitec Nations reports whijch deal with 
the drug industry in general and with the Indian pharma-
ceutical industry in part icular . Of special relevance to IiKiia 
is "Case Studies in the Transfer of Technologyi The Phanaa-
2 
ceutical Industry in Indie ", As the title suggests, it deals 
primarily with the problem of technology transfer relating 
to the pharmaceutical industry in India. The first part of 
this U.N, publication is devoted to the structure of the 
Indian pharmaceutical industry. The remaining three parts 
deal respectively with technological dependence and the policy 
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framework needed for the transfer of technology^ The report 
highlightsthe great imbalance betwetei the pattern of drug 
production and the prevailing diseases, relatively low 
expenditure on research and development and a big gap bet-
ween the institutions of R & D of the local and foreign 
producers, 
3 Q A publication entitled "A Growth Plan for the Indian 
Pharmaceutical Industry" by the Organisation of Pharmaceutical 
Producers of examines alternative, strategies to those propo-
sed by the Hathi Committee and discusses various Issues rela-
ting to the drug industry, including pricing, distribution of 
drugs in rural areas, R & D , foreign exchange inflow and 
outflow, siile of drugs under brand names etc» This publication 
differs from the report of the Hathi Committee on issues such 
as those of abolition of brand names and the formation of a 
National Drug Authority, which as this publication claims, 
5 
would only increase bureaucratic control. 
y \ A study entitled,"Business Strategies of Multinational 
Corporations in India-A case Study of Drugs and Pharmaceutical 
Industry", was carried out ly Johri in 1983, The author looks 
into the busineas strategies of drug multinationals in India, 
The sample of this study includes 2k multinationals based in 
7 countries which account for more than 75H of direct foreign 
investment in this industry. This sample of 24 companies 
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comprises 5 compani'es with more than 74 per cent foreign 
equity, 9 with foreign equity between 51 per cent and 7^ 
per cent and 10 ccmpanies with foreign equity between 40 
per cent and 51 per cent. Thus in this sample there are 
14 companies with m;.;}ority foreign equity as on 1974, The 
numbers of companies originating from the 7 countries are ; 
10 frcan U.S.A. , 4 each from Switzerland and West Germany, 
3 frooa U,K, and 1 each from Bulgaria, France and the Nether-
lands ^  
The objectives of this study arej (1) to analyse the business 
environment of drug multinationals;(2) to analyse the business 
policies pursued by them; (3) to analyse the outcome of 
the business operations and (4) on the basis of the above, to 
examine the corporate behaviour of the companies sampled. 
The findings of this study indicate that the ma;Jority 
of the companies sampled fc^ve been affected by controls on 
prices of drugs. According to this study , the features of 
the environmentally oriented policies of the companies are; 
(1) restricted distribution of profits and divtiends, (ii) 
low foreign exchange remittances,(iii) production of drugs 
in conformity with the disease incidence in India and (iv) 
production of bulk drugs from basic stage. The findings of 
this study concerning the policies pursued by the drug 
companies are based on certain quantitative indicators, 
which could lead to wrong conclusions being drawn. For 
instance, the financial policies have been analysed on the 
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basis of relevant financial ratios. By following this approach 
that the author has bten able to analyse is the design of 
policy after its implementation and not as it was initially 
planned. At times there may be significant differences between 
the planned policy and the policy as evidtnctd by certain 
broad iiKiicators of performance with should alsc be taken 
into consideration. Similarly, the plan targets relating to 
growth and profitability may be different from the actual rate 
of growth and profitability calculated on the basis of sale 
and profit figures as provided in the annual reports of the 
companies sampled. 
In teras of the policies that have been toolMtd into, this 
study has failed to examine the research and development 
operations and the social and persoanel policies of th« compa-
nies. Another limitation of this study is that it does not 
deal with the influence of the parent companies on the policies 
pursued by their subsidiaries in India. 
•^jUT^ A study entitled, "Multinational Coporations and Indian 
Drug Industry" was conducted by Singh in 1985 wherein he has 
looked into the development of pharmaceutical industry in India 
and has examined is:-ues arising out of the activities of 
multinational corporations in the industry. The sample of this 
study covers 27 ccanpanies which have been divided into three 
groups, viz, , Small, medium and large with paid up capital 
upto fis, 75 lakhs, between fe, 75 lakhs and Rs,150 lakhs and 
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fe.150 lakhs or above respectively. The number of companies 
falling In these groups are 11,8 and 8 respectively. In the 
small group 11 companies ere minority owned ones with average 
foreign equity participation of 44 per cent. The companies in 
the latter two groups are majority owned ones. The second 
group of companies hold on an average of 54 per cent foreign 
equity while the third ones hold on an average 68 per cent of 
foreign equity. The average foreign equity holding for all the 
three group- taken together works out at 55 per cent. 
There are two objectives of this studyj (1) to examine, 
in an international perspective, the econ(^ics of the pharaaceu-
lical industry in India, tracing the role ai^ the market power 
of drug MKCs^ (2) to analyse the implications of this market 
powpr on the financial performance of drug transnationals 
operating in the country. 
The study is primarily based on secondry data which has 
been collected mainly frcm the annual reports of the companies 
sampled, legal documents concerning the operations of MNCs in 
India and reports of the Organisation of Pharmaceutical Producers 
of Indie, Different sources such as the office of the Registrar 
of Ccxapanies, and the Bombay Stock Exchange Library and some 
libraries have also been made use of. 
The main findings of the study are as follows i ( 0 Drug 
MNCs enjoy tremendous 'market power* in India, This is reflected 
in their monopolistic arsi oligopolistic hold on various sub-
drug markets of the country, (ii) Drug MNCs in India have not 
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<y\X Sengupta' carried out a study entitled,"Structure» 
Growth and Working of European Companies in India" in the 
year 1978, The sample of this study includes subsidiaries 
of European multinational companies belonging to different 
industrial sectors including the pharmaceutical sector. 
The objective of the study is mainly to analyse the 
growth and structure of the companies of European origin, 
as well as to analyse the research end developmfent ac t iv i -
t i es undertaken by these transnationals, I t s findings 
are two. F i r s t , that these ccxapanies most often undertake 
research and development act iv i t ies but only for the purpose 
of increasing the saleabi l i ty of their products. Second, that 
canpanies which focus on the requirements of the market have 
groi*i better than others. For inst nee the drugs produced by 
European drug companies in accordance with the disease pattern 
of the host country have succeeded in the market arKi, as a 
resu l t , the i r growth has been a t a higher rate in companison 
with that of other companies which did not follow this pro<k4-
uction strategy. However, the findings of this study can not 
be applied to nations where a host of environmental factors 
and the changing needs of time determine the coxporate policies 
and management practices of these firms, 
Ufi;) k study conducted Iqr Mehra i s directly related to the 
pharmaceutical industry wherein he analyses the pricing policies 
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of the mult inat ionals and wholly owned Indian drug companies. 
However, the study does not provide a companywise analys is o£ 
the marketing polteies and pract ices of public sec to r drug uni ts 
as has been carr ied out in the present study. 
- ^ i o In his book entitlex. "Drug Pricing in India", published 
in 1982 , Shah examines the pricing norms of the govermient 
through the Drug Price Control Orders, The author studied 
different categories of bulk drugs and formulations prepared 
by the authorities concerned. He reproduces charts relating to 
drug pricing and gives a complete lists of bulk drugs and 
formulations under three categories, viz, I,II, III as well 
as of decontrolled drugs, notified prices of bulk drugs and 
leader prices of drug formulations etc. 
This study does not go into the impact of the different 
Drug Price Control Orders on the perfonaance of the public 
sector drug units and it is merely concerned with pricing 
which is part of the overall marketing strategy of a company. 
Performance is a function of different variables, some of which 
are economic while others are non-econoQic in nature, 
7 / A book entitled "Good Health At Low Coit^" published in 
10 1979, by Balstead, Walsh and.War-cpn (eds) attempts to assess 
the relative values of health development strategies pursued 
in different countries. However, the authors lend support to 
"selective primary health care •, through Identifying the 
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the Interventions responsible for the comparatively low 
infant mortality retes in China, Costa Rica> Sri Lanka 
and the state of Kerila in India, where the gross national 
product was low. This work leans heavily on available 
statistics especially relating to China, and attempts to 
assess the achievements of health services in each area. The 
authors conclude with general statements about the influence 
of particular factors on health improvement. The overall view 
is that much more research is needed and that new measures will 
have to be undertaken for revapming the health care systems, 
Warren and Foege explore ways of improving health through what 
may be termed the mechanical medical model, that is, in terms 
of cause and effect, although many are not convinced of the 
relevance of this approach in the context of rapidly changing 
environment, The authors of this work make the following 
recemendations for the development of health programmes in 
different countries: 
1- Countries should have a clear political and social 
commitaent to the equitable distribution of resources among 
their citizens, 
2- Such distribution should ensure, to all the strata of 
society, access to health care from the primary to the 
teritiary level, education from the primary level upwards, 
and adfquate nutrition. 
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The authors conclude t h a t Intervent ions against 
diseases and p r i o r i t i e s t o quick and cheap neans of 
heal th improv^ent cannot be c l ea r ly iden t i f i ed . Of the 
many reasons given for t h i s , an obvious one i s t h a t 
s t a t i s t i c s , especia l ly in the cases of Kerala and S r i 
Lanka, are unrel iable* Hence no de f in i t e conclusion can 
be drawn and any in te rpre ta t ion of such data would be 
quest ionable . Another reason i s t h a t i t i s d i f f i c u l t to 
quantify p o l i t i c a l , soc ia l and econoiBic factors which 
have c r i t i c a l bearing on heal th outcomes but depend 
on spec i f i c c u l t u r a l , and h i s t o r i c a l experience of each 
country, A th i rd reason is tha t heal th Improvement 
c l ea r l y r e su l t s from a learning process influenced l^ 
s o c i a l , p o l i t i c a l and economic conditions ra ther than 
from any blueprint for heal th , 
'iflK A study en t i t l ed " Regulation of Pharaaceuticals 
'^< in Developing Countries, Legal Issues and Approaches,", 
.11 
conducted by Jayasuriya in 1985, provides a much needed 
introduct ion to some of the important l ega l issues concerned 
with the regulat ion of pharmaceuticals in developing 
countr ies arKi describes some possible approaches t o es tab-
l i s h i n g a manageable regulatory framework. Despite the 
complexities involved, the approaches suggested by the 
author go a long way towards determining and simplifying 
the process of formulating regulatory measures. According 
t o the author, due consideration ought to be given to the 
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administrative and operational mechanisms needed to 
translate the laws into action. 
This study traces the laws and experience of a 
number of the developing countries to assist the 
policy makers and to show what can be done with limited 
resources in the context of corKiltions prevailing in 
the different developing countries, 
12 \.^ Mallick in his work entitled '• Medical Lecture 
Notes for Medical Representative and Othersx An 
Introduction to Medicine and Their Uses " stresses the 
crucial role of medical representatives who in most of 
the cases are not pharmacy graduates. 
In this study, stress has been laid on the Importance 
of the knowledge of drugs and of the human body In relation 
to the ;Job of a medical representative. It contains short 
paragraphs on cells, tissues, different systems of the 
body and their functions and also the development of the 
various systems of the body. This book mainly focusses on 
the general awareness of subjects such as anatomy, physiology, 
pathology, pharmacology and so on. The method adopted by 
the author to introduce the basic knowledge of these subjects 
is calculated to help medical representative Increase their 
effectiveness. 
'-•] 
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At the end, the author concludes t ha t oedlcal 
representa t ives f a l l shor t of the basic knowledge of 
drugs aiKi of the systems of the human body. However, 
? ^ though s t range , they are the ones who promote potent 
substances l i k e drugs to qual i f ied medical p r a c t i t i o n e r s , 
1 •5 Raman and Uma c a r r i e d out a s tudy e n t i t l e d "Problems of 
Drug Industry published in 1986", The ob3ectives of t h i s 
work ar t? ( i ) to ascer ta in the reasons for the shortage 
of essen t ia l drugs j ( i i ) to look into the extent of the 
presence of the spurious and sub-standard < r u g S j ( i i i ) t o 
find out the government po l ic ies regarding the above; 
and ( iv) to suggest remedial measures to tackle the above 
problems, 
A questionnaire was designed l^ the authors which was 
followed by personal interviews and an opinion poll regard-
ing the availability of drugs was also conducted. The 
main findings of the study arrived at with the help of 
questionnaires and interviews, are as follows j 
(a) The existing pricing policy has made manufacturing of 
essential drugs unattractive due to low returns.(b) There 
has been a diversion of investments to the production of 
nonessential drugs and formulations for higher returns-
(c) There is a proliferation of spurions and sub-standard 
drugs due to ineffective enforcement of quality control by 
the authorities concerned,(d) There is imbalance^beiMeen the 
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supply aiKi demand of drugs, (e) Tbere are no sptcific 
plans for catering to the rural requirements, (f) Users 
run the risk of being administered spurious and sub-
standard drugs with serious consequences to then. 
These findings clearly indicate that th«re are 
some critical problems being faced by the drug industxy 
for which remedial measures need to be taken, 
v^^ Sen and Mikherjee' in their paper entitled«i>tructure 
of the Drugs and Pharmaceutical Industry-An Overview", 
published in 1986, have looked into factors affecting the 
growth and development of the drug industry. They have 
attempted to evaluate the perfonaence of the pharmaceutical 
industry, taking into account trends in the production of 
bulk drugs and formulations and technology development by 
different sectors of the industxy. They have criticallly 
examined the role played by the public sector drug units 
in reducing drug prices, providing medical facilities on a 
mass scile, achieving self-sufficiency in drug production and 
earning foreign exchange from exportable surplus. 
The authors have made use of secondary data in arriving 
at the findings and conclusions of this study, Thtir find-
ings are, that, during the VI Plan period the drug industry 
only achieved 56,7 per cent of the target »*t for the pro-
duction of bulk drugs, the corresponding figure for formula-
tions being 7^.5 per cent. They have stressed the need for 
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increasing the production of the public &x^ Indian private 
sectors drug units, saying that the growth of the industry 
in the future hinges largely upon these two sectors .They have 
strongly emphasised the need for giving incentives to petro-
leum and chemical enterprises to produce raw materials, 
resolving the brand name versus generic name controversy, 
and allliwing the drug producing firm to increase their 
capacities at regular intervals, 
^I^Beri, Juneja and Lal^ in their article entitled "JPriclng 
of Drugs and Pharmaceuticals" published in 1986, have critica-
lly examined the pricing policy relating to drug industry,They 
have looked into the factors responsible for escalation in 
the prices of drugs. They argue that the high promotional 
expenditure* ranging between 15 and 25 per cent of sales 
turnover of the companies on activities such as Journal adver-
tising, direct mail advertising, representatives, gifts etc 
is greatly repponsible for high drug prices in the country. 
They consider impressing particular brands on the consciousness 
of the doctoFi and creating goodwill at the cost tif the ailing 
community shameful. 
This study is mainly qualitative and no evidence concem-
ning the effect of different pricing policies on the marketing 
practices of firms have been furnished in it. The main objective 
of this study is to evaluate the effectiveness of the pricing 
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policies pursued by the drug enterprises in IiKiia, and 
to examine the cost structure of the public sector drug 
units. 
Its main findings are that the price control mechanism 
of the government has to be mace more efficient if social 
objectives are to be achieved. For this they have recommended 
a multipronged approach. In their opinion, competition between 
different brands involving larger expenditures on sales 
promotion has lead to higher prices for drugs. 
SUMMARY I 
A review of the work done in the field of pharmaceutical 
industry in India shows that with the exception of few studies 
that have been carried out by Singh(1985), Johri (1983) and 
Lall & Streeten (1977), very little woric has been done in the 
area of marketing strategies of public sector drug enterprises 
in India. 
The present study, unlike several other generalised 
macro level works, is based on the data obtained with the 
help of questionnaires and interviews concerning the perform-
ance of and strategy of drug companies in the public sector. 
In this regard, special mention may be made of the study 
carried out by M, Johri(1983). His work is based on multina-
tional corporations engaged in the production of bulk drugs 
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awi formulations in developing countr ies . He has invest igated 
the d i f ferent business s t r a t e g i e s which are being adopted 
by these multination=!l within the given environmental cons t ra-
i n t s . The present study "Marketing S t ra teg ies of Drugs and 
Pharmaceutical Industry in Public Sector" d i f fe rs from the 
study of Dr. L. J o h r i , His work Has concerned with the 
mul t inat ional corporations while the present wortt i s concerned 
with the marketing s t r a t eg i e s of public sec tor drug enterpr ises 
in India , Thus the coverage of J o h r i ' s study i s wider,whereas 
t h a t of the present work i s more spec i f i c . 
Similar ly , s tudies carried out by Singh (1985)t 1-all and 
Streeten (1977)/Sengupta (1978), Shah (1983), and Jayasuriya 
(1985) have looked in to the po l i c i e s and prac t ices of the 
drug industry to general and of the drug mult inat ionals in 
p a r t i c u l a r . None of the above-mentioned s tudies focusses 
p a r t i c u l a r l y on the marketing s t ra tegy of the publ ic sec tor 
drug uni ts in the context of a developing country l i k e India. 
Thus the area of the present study, per ta ining to the marketing 
p rac t i ces of public sector drug uni t s in India,assumes a 
spec ia l s igni f icance . 
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Introductloni 
Public sector has been assigned a vital role in the 
economic planning of India. In view of this,it becomes imper¥ 
ative that the public sector should make a significant contribu-
tion towards the economic progress of the country. To achieve 
this objective, the Government must initiate suitable measures 
for improving the performance of public sector drug companies. 
Industrial policies of the Government, are aimed at providing 
a leadership role to the public sector. Public sector contributes 
a small but significant share towards the output of drug industry. 
The efficiency of public sector drug units will go along way in 
determining the performance of the pharmaceutical industry. 
The role of public sector in the production of 
drugs cannot be overemphasized. The two public sector drug 
units viz., Indian Drugs and Pharmaceuticals Limited (IDPL) and 
Hindustan Antibiotics Limited (HAL ) are mainly responsible for 
the production of drugs indigenously. Besides these two, the 
other three units viz,, Smith Stanistreet Pharmaceuticals Ltd. 
(S3PL), Bengal Chemicals and Pharmaceuticals Ltd, (BCPL) and 
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Bengal Immunity Ltd. are also contributing significantly 
towards drug pn>duction In the country. These three companies, 
besides, being sick, are a liability for the national exchequer. 
The public sector has recorded a significant growth 
In production during the last few year| .This Increase in the 
production of bulk drugs and formulations has been achieved 
particularly after the enforcement of the New Drug Policy of 
1978 by the Govwrnment, This chapter deals with the history, 
performance and production capacity of drugs and pharmaceutical 
units in the public sector. 
Importance of Public Sector Drug Industry 
The Indian drugs and pharmaceutical industry occupies 
a primary place in the econcaiy of the country. During the past 
few decades, it has grown rapidly. At the time of Independence, 
the Indian pharmaceutical Industry was not developed tod It 
could hardly be called en industry. Pharmaceutical operations 
at that time were mainly concerned with repacking and bottling. 
But since then it has developed rapidly. The Indian pharmaceutical 
industry is now ranked by the UNIDO as being the largest and 
most modem industry in the developing countries In terms of 
range of products and technology and sophistication of Items 
manufactured by it. The structural growth of the industry In 
tenas of both horizontal and vertical expansion is noteworthy. 
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During the post-independence period, industrialisation 
in India had to rely on the import of technology from abroad, 
and the drug industry was no exception to this, Thi Indian 
pharmaceutical industry has been importing technology in recent 
decades from advanced countries Init it is no longer totally 
dtpendent upon them. Efforts have been made consistently to 
dtvelop the indigenous technology in the field. Moreover, a tiumber 
of drugs manufactured by foreign coapenies, identified as high 
technology items by the expert conmiitttt in 1978,are now being 
reclassified as low technology products. For inst^ce, Ethoheptazim 
citrate, an analgesic drug, produced by Wyeth Laboratories, has 
been relegated to the category of low technology. Other items 
which appesr to be on their way out of the high technology list 
include halothane, chloroquin phosphate, resotrcn substance, 
diethyl carbamaxine citrate, pyramethamine, phanquone and magest " 
rol acetate etc. It is argued by the manufacturers that the above 
drugs are no longer high technology drugs becaust indigenous 
technology is now available for then. This shows that the 
Indian drug industry has developed at a rapid pact. It is making 
a significant contribution towards achieving the objective 
of self-reliance in this vital sector of the economy. 
The Indian pharmaceutical industry ' comprises 
various sectors, namely the public sector, tha Indian private 
sector, the foreigh sector, the small scale sector and the Joint 
sector. The public sector consists of Hindustan Antibiotics 
Limited (HAL), Indian Drugs and Pharmaceuticals Limited (IDPL) 
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and t h r i t sick units v iz . Bengal Cbeaicals and PhamftC«uticals 
Lifflittd (BCPL), Bengal Immunity Limited (BIL) and S«ith Stanist-
reet Phamaceuticals Limited (S3PL) which have been taken over 
recently, 
3^ he importance of the public sector drug indultry 
ar ises out of i t s objectives. This sector has been established 
with a view to reducing drug prices, providing medical f ac i l i t i e s 
on a mass scale, achieving self-sufficiency in drug production 
end earning foreign exchange from exportable surplus. For this 
purpose, the public sector units started extensive research & 
development ac t iv i t ies and developed backward linkages in techno-
logy generation, PrOf^ress in these two directions has been 
commendable. This sector has immense structural importance and 
i t s role in producing essential bulk drugs is crucial . 
The importance of the public sector drug industry in 
the context of the production of essential bulk drugs, can be 
gauged from the emphasis laid on the industrial policies of the 
Government which aim at providing a leadership role to the public 
sec tor . The Industrial Policy fonnulated in 1956, entrusted this 
sector with the job of producing essential bulk drugs which were 
being imported. I t i s the responsibility of the Government to 
take firm measures for improving the performance of public 
sector drug companies. 
I t i s equally true that the public sector has contr i -
buted a sizable and significant share in the to t a l bulk drug 
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production In the country. In 197^-75 » about 36,67 p«r 
cent of the to t a l bulk drug production in India was contrib-
uted by th is sector. The share of public sector dnig companies 
declined to 26,11 and 23.8 per cent in 1979-80 and 1982^83 
respectively. However, the situation improved in 1984-^5 when 
i t s share in the to ta l production of bulk drugs in the country 
came to 32,33 per cent. 
Public sector drug industry plays a crucial role 
in removing regional dispari t ies and for achieving balanced 
growth in the economy. Private investment most often takes 
place in areas where fac i l i t i e s of cheap labour, avai labi l i ty 
oi raw materials and a more conducive corporate environment 
exis t . Areas other tTian those with aforesaid f ac i l i t i e s lag 
behind. Public sector has established units in such less develo-
ped areas. The Indian Drugs and Phanwceuticals Limited (IDPL) , 
has established a number of branches which are situated in places 
l ike f^zzaffarpur (Bihar ) , Rishikesh, (U.P,) Gurgaon, 
(Haryana), Madras and Hyderabad, To achieve the objective of 
balanced growth of the economy, IDFL has established Joint 
venture units in colloboration with the s ta te goverraient. Such 
units are Uttar Pradesh Drugs and Phanaaceuticals Limited (UPDPL), 
Lucknow, Punjab Maize Products limited, (PMPL), Sangrur, 
Rajasthan Drugs and Pharaaceuticals Limited (RDPL),Jaipur, and 
Orissa Drugs andCompany Ltd, {oDCL), Bhubaneshwar, 
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Public sector enterprises in the drug industry-
are important sources of employment in India. Indian Drugs 
& Phanaaceuticals Limited (IDPL )eiBploys more than 12,720 
workers, out of which 205 are those whose salary b i l l s amount 
to more than h, 36,000 per annum each , Bengal Chemicals 
end Pharmaceuticals Limited (BCPL) had more than 2,195 employ-
ments in 1983. Similarly, Smith Stanistreet Pharmaceuticals Limited 
(SSPL ) employ** 1,166 workers in 1985, out of which 128 workers 
were recruited frcsn SC/ST category and 7 from the category of 
physically handlcaped persons. 
Public Sector enterprises in the drug industry make 
a significsnt contribution towards the well-being of the 
society. For example. Smith Stanistreet Pharmaceuticals Limited 
(S3PL), offers a number of services to different kinds of 
customers. 
The consumer i s one of the most important segments 
of the society. What the consumers want is that effective and 
safer drugs should be provided to them. Nevertheless, consumers 
of the drugs are patients who take medicines, but do not make the i r 
own decision about the choice of drugs, ^^ecision for the 
selection of a drug comes from the side of the doctors, not 
from the patients . Doctors, therefore, are persons who indirectly 
influeiice the consumption of drugs. 
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Drug manufacturers are, therefore, placed in a 
tight-comer in this situation, ^ hey cannot misguide the 
doctors who are qualified and have a deep knowledge of the 
drugs. Different manufacturers of the same drug have to compete 
in the open market, which is full of the knowledge of the 
various aspects of the drug market, Thus, consumers need the 
following services from the drug manufacturers for their welfare: 
- Reasonable prices of drugs, 
- Quality drugs in sufficient quantity and 
- ii?sy accessibility (i.e. regular drug 
supply , even in the rural market). 
The role played by Indian public sector drug units 
is foremost in protecting the interests of the ccmsumers frc»n 
the harmful effects of increased drug prices that are charged 
by private Ixisiness enterprises. Official control over the 
drug prices is a great relief to the consumers. Whenever any 
public enterprise increases the prices of drugs even marginall|r, 
the government protects the interests of poor masses. The 
government regulates the prices of drugs through the ^ r^ug 
Price Control Order, ( DPCO-1979), 
This order has divided all drugs into four categories 
and has fixed their marks-up. Categories I and II, with 40^ 
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and 55% marks-.up, includ* the most essential drugs, Category 
III with 100% mark-up, has less essential drugs and Category 
IV wich Is sometimes called decontrolled, coaprtses drugs 
which are not much needed by patients and it has been left to 
the manufacturers to decide their prices in a coapetitive 
environaient. 
Furthermore there is a concept of leader prices 
of drugs in DPC^1979. It sioply means that an efficient 
manufacturer of a particular drug would fix its price lower 
than the fixed mark-up of that drug,This leader price would be 
the ceiling for the price of that drug,All the manufacturers 
of that drug are legally required to follow the leader price of 
that drug strictly. In this way, the pricing laechanisa has 
been further tightend up,The benefit of this goes to the public. 
The importance of public sector drug units is 
evident from the fact that they supply drugs to consumers 
sometimes even at prices which ar« lower than the leader prices. 
Smith Stanistreet Pharmaceuticals Ltd,(3SPL), Calcutta, is a 
centrally owned public sector drug enterprise and the only 
drug unit in public sector that earned a profit in 1984-85. 
It produces many drugs which are priced lower than the leader 
prices of those drugs. Table- 4,1 given below confirms this. 
T A B L E '•4,1 
Pt lee Difference Chart in SSPL-Calcutta 
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S.No, Name of Preparation Pack Size SSPL Price (to.) 
1 • Trimethoprim Tablet 50 aal 
SMZ. Suspension(Disabac) 
2 . Cotrimoxazole Tablet(Plain) 10x10 
3 . 1>,S. 
4« Sulphtguidine Tablet SOOmg 
5, Sulphdimidine Tablet 
6 . PredsolcHie Tablet Jog 
?• Analgin Tablet 500iBg 
10x10 
1000's 
1000's 
1000's 
500«3 
1000»s 
8. Paracetamol Tablet 500mg 10»s^trip 
500 pack 
9, Erythrcwycin Stea Tab.250Bg, 500 pack 
lO.Erythrolate 250mg 10 »s 
11,3enamlzol« Tablet 20QBg. 10x10 
12,Metronidazole Tablet 400Bg. 10x10 
1 J.Metrronidazole Susp^(5Cteg/5sl)50al 
l4 .Ampici l l in Capsule I,P.250Bg.ia«10 
Aapic i l l in anhydrous 10x10 
Ampicillin Tryhydrate 10x10 
15.AEipicillin Susp. 4Qnal. 
5.75 
6.52 
58.41 
95.84 
118,98 
159.15 
139.00 
183.97 
1,54 
42.10 
sane 
15.50 
19.85 
33.47 
4.83 
99.40 
7.31 
13.10 
51.80 
40,95 
337.25 
52.41 
Leader 
Price 
(fc.) 
6,62 
58.32 
108.20 
135.20 
201.39 
59.91 
224.83 
1.82 
aaae 
16.02 
20.60 
38.60 
5.19 
147.20 
131,84 
Afflpicillin anhydrous (125!ig/5ffll)^,, 
Ampicillin Trihydrate(125mg/5ml)», 
16.Chlorpht|clraffline Tablet Sag, IDOOJs 
17,Tetracycline capsule 250iBg. 10x10 
IS.Chloraaphenicol capsule 25aBg,10x10 
1000»a 
19,Qxytetracycline capsule 10x10 
SoUJtCfi I ^te ihe present researcher ' s paper e n t i t l e d 'Public 
Sector Drug Units and Societal Marketing,Eastern 
owor^arict. . Nnw Delhl-Auff. 1 9 ^ . 0 . 4 1 . 
8.04 
7.40 
18.60 
51.85 
49.90 
440.23 
52,41 
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Th« above Table highlights the fact that the prices of 
drugs fixed by SSPL are in nany eases lower than the leader 
prices of those drugs, Analgin tablet SOOoig, for example» is 
produced at the rate of Bs* 183,97 per 1000 tablets whereas i t s 
leader price is fis,224,83 per 1,000 tablets,Siali larly, SSPL 
produces chloramphenicol capsules 250 mg, at Bs, 337t25 per 
1000 capsules whereas i t s leader price is te, A40»23 per 1000 
capsules. I t i s important to note that a drug which is sold 
at a very low leader price i s sometimes offered by a public 
sector unit at a s t i l l lower price for the benefit of the 
pat ients . 
The Government has enacted many legislat ions and has 
promulgated many rules and regulations for the manufacture and 
sale of drugs to ensure the quali ty. These ordinances aret 
• The Drugs & Cosmetics Act| 1940 
• The Pharmacy Act of 19^81 
« The Dangerous Drugs (Import, Export and 
Transhipment Hules 1957) 
• The Poisons Act of 1919| 
- The Medical & Toilet Preparations Riles -1955» 
• The Epidemic Diseases Act- 1897. 
The above mentioned enactments, rules and regulations 
ensure the quality,quantity and safety of drugs. The problem 
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of tht liVBllablllty ot drugs to consustftrs and rural catering 
of the quality drugs can easily be tacked by the aaaufacturers 
and the government through an effective distribution systens 
and by opening rural dispensaries. The public sector drug unite 
are now«.a*daya ejE^aged in and are kaea for institutional sales* 
Thrtugh institutional selling, essential drugs are supplied 
directly to hospitals and governaent run dispensaries. This 
system, therefore, has to a great extent, solved the problen of 
irregular supply of drugs to rural areas. 
Technological development is another important areas in 
which the public sector drug units have occupied a prestigeous 
place. These units have succeeded in evolving backward linkage in 
the generation of technology to a large extent. 
The public sector ccaipenies have established R & D 
centres in various parts of the country. These research centres 
have not only ensured efficient absorption of imported technology 
but they have also improved the existing technologies and have 
generated new ones. So far as technology adaptation and generation 
is concerned, the perfoniance of the public sector has always 
been satisfactory. The role of Hindustan Antibiotics Ltd(HAL), 
for example can be cited in this connection, which has not only 
developed a new antifungal antibiotic*Haaycin* but has also 
improved upon the existing technologies. The performance of 
IDPE in this regard has bten reasonably good, which is clear 
from the following Table. 
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T A B L E * 4.2 
Ttchnological Efforts of IDPLJ 1982 
Institutions and their Achitv«m«nts Nuabtr of Casts 
IDPLJ 
Technolo/ay Adaptationt 
a) Iffiprovenents in Procassing 9 
b) Altamativa /Better Procasses 7 
Tachnolojgy Ganerationi 
a) In production 22 
b) Success at Pilot Plant 14 
c) Intaraadiates 14 
SOURCE t The Eastern Pharmacist, New Delhi, Jan, 1986 
Tab, 7, p.110, 
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Froa the above Table, it is evident that IDPL 
las imported technology from abroad. This has been done 
in coUoboration with the USSR which has not been upto the 
desired level. The company has improved upon these imported 
technologies in 9 cases and has evolved better processes in 
7 cases. Moreover, it is produoking 22 new bulk drugs of all 
the four categories and 14 intermediates based on indigenously 
developed technologies. It has also perfected pilot scale 
that 
technologies for another 14 drugs. It is important to note the 
IDPL and Bengal Immunity Ltd, (BIL) are also conducting basic 
researches and have been able to develop new drugs. The aiost 
important gain in this respect is the production of drugs by 
public sector units from the basic stage. 
The other important contribution of the public sector 
drug enterprises is that this sector has transferred process 
development technology to other sectors of the economy particu-
larly to the mmoL small scale sector. The R&D ejqpenditure of the 
public sector drug units amounted to Rs, 297.77 lakhs in 1979-80 
and to fis, 253*63 lakhs in 1982-83. This may be treated as a 
significant contribution in this direction. 
Structure of Drug Industryt 
The Drug industry in its present form has evolved 
into three broad sectorsj (1) the large scale, sector (2) 
the small scale sector and (3) the infonnal sector, According 
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set-up of the Industry and laid particular emphasis on the 
costs and prices oX drugs. It pointed out that rigid price 
ccmtrol avBr drugs be relaxed to provide for 0|«n compttltlon 
In the interest of the growth of the industry. In view of the 
suggestions aade by the Bhatia CootidLttee regarding the struc-
tural iabalances la tha drug industry , the Govemaaent took 
several measures aiaed at creating an environment conductive 
to its growth. As a result, a rapid pace of developaent was 
attained by the industry towards the beginning of the seventies. 
Towards the end of seventies, the prices were again 
brought under the control of the GovernBaent, This was an out-
cone of tha reC0Banendations made by the Hathi CoBnittee in 
the year 1975. Although the Drug Prices Control Order promulga-
ted by the Governnent was undoubtedly a rational approach for 
solving certain problems , it discouraged proauction to a certain 
extent and indirectly affected the structural set-up of the 
industry. 
Despite the price controls imposed by tha Goverranent, 
the drug Industry maintained a fairly high tempo of growth 
during the last decade. This is evident froo Table 4,3 given 
below showing selected parameters of growth. 
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Proa th« above Table it can be seen that the Vftlue 
of drug formulations which was aerely fis» 100 crores In 1962, 
increased to fe, 360 crores in 1972, arwi went upto te,1,300 
cror«s in 1982 and to as,2450 crores in the year 1985. 
The above aentioned Increases in the value of formul. 
at ions have been due to the fact that there was no production 
of basic drugs towards the beginning of the fifties. In early 
eighties, there were 60 units which were producing a number 
of basic drugs. These drugs were used for the preparation of 
forouletions within the country. Similarly in 1982, over 
150 essential drugs were produced in the country. These covered 
a wide range of thereapeutic gn>ups like antibiotics, sulpha 
durgs, antileprotic drugs, hormones, analgesics, anti-pyretics, 
vitamin*, tranqullisers, phytochemicals and various other 
pharmaceutical chemicals. 
It is also evident from Table 4,3 that the value of 
imports increased from a mere te. 11 crores In 1962 to Rs,35.0 
crores in 1972, registering an increase of 218 per cent during 
the period. But the rate of increase in imports declined in 
later yeax^. Between 1972 awi 1982 the increase in imports 
was 116,7 per cent as against 218 per cent between 1962 and 
1972, The main cause of this decline in the rate of increase 
]04 
•f iaports wai the indigenous production of many esscntiiil 
drugs which substituted the imported bulk drugs. Similarly, 
ra tes of investments and exports show declining trends 
between 1962 and 1972, from 301 per cent and 9^5 per cent 
t o 122,2 per cent and J28»3 per cent respectively between 
1972 and 1982, which further declined to 55 per cent and 
134,09 per cent respectively in 1982-85 compared with the 
period 1972-82, 
I t can be argued on the basis of the above discussion 
that the structure of the drug industry has undergone a 
change. A significant transfoz^ation has taken place and the 
public sector drug entei^srises have expanded rapidly. I t is 
the policy of the Government to assign a predominant role to 
the public sector drug uni ts . Their share in to ta l investaaent 
rose from 30 per cent in 1972 to more than 33 per cent in 
1979-80, 
INDIAN DRUGS & PHARMACEUTICALS LTD, ( IDPL ) I 
Indian Drugs & Phamaceuticals Ltd, (IDPL )» the 
largest phaimaceutical complex in India , is operating 
under the full patronage of the Government of Indie, I t 
en;}oys a dcxsinant position in the f ield ef dzMgs and 
pharmaceuticals among Indian as well as overseas competitors. 
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Brief History; 
IDPL, employing ovtr 12, 720 workers, comprises many 
plants in India, I t Is largest and the most sophisticated 
pharmaceutical complex in the third world. I t was established 
as a company under the Indian Companies .Act , 1956 in c^llobo-
4 
ration with the U,S,S,R, in April 1961. Besides the Rishekesh 
plant for ant ib iot ics , Hyderabad plant for synthetic drugs 
and fine chemicals, Madras plant for formulations as well as 
for surgical Instruments, Curgaon plant for pharmaceutical 
special i t ies and Muzzaffarpur plant for the drugs and chemical 
intermediates, IDPL has four subsidiaries In the Joint sector. 
They are located at Lucknow in U.P», Sangmir in P«n;3ab, Jaipur 
in Rajasthan and Bhubneshwar in Orlssa, 
Indian Drugs and Pharmaceuticals Limited has played a 
key role in introducing the system of Inst i tut ional sel l ing 
in India. 
This has led to the development of another form of 
martcet segment which was lilther to untaped. 
Organisation and Management i 
Indian Drugs & Pharmaceuticals Limited (IDPL ) has 
9,50,000 equity shares of fts, 1,000/» each, (Xit of which 
8,76,633 shares were subscribed and were fully paid-up by 31s 
iOS 
March, 1982. The coapany further d«cideci to issue and 
subscribe more equity shares. As a resu l t , the number o£ 
subscribed equity shares increased frcrai 8,76,633 to 
9,24,133 faulty shires which were fully paid up at the 
end of the financial year 198J-64", 
The to ta l number of the workers employed and 
getting sa lar ies , Rs.36,000 P,A, or more, was 138 a t the 
end of the year 1982-83» This number stood at 192 a t the 
end of th* year 1983-84, Part t iae employees who were 
getting salaries of aore than fe, 3000 p»B, , were 9 in 
number as on 31st March 1983» Their number atood a t 13 as 
on 31st March, 1984.^ 
As mentioned ea r l i e r , the company has four subsidiaries 
vizf UPDPL djucknow), PMPL( Sangrur ) , RDPL ( Jaipur ) and 
ODCL (Bhubaneshwar ) . The IDPL had 3»25,329 XuUy paid up 
equity shares of te.10/- each in UPDPL as on 31 March, 1984, 
Of the 25,00,000 equity shares of »s,10 each, floated by PMPL 
(Sangrur ) IDPL has 12^75 ,000 shares. The equity shares of 
IDPL in nWL and ODCL were 2,55,000 out of 4,86,100 and 2,78,500 
out of 5^34,000 out of 4,86,100 and 2,78,500 out of 5,34,000 
respectively on 31st March ,1984, Thus the equity holdings 
• t the Indian UrxxgB & Phamaceuticals Ltd, in i t s Lucknow, 
Sangrur, Jaipur and Bhubaneswar subsidiaries are 5^ % , 5^ % 
52,4j6 and 52.1 % respectively at the end of 1963«84, 
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Fig. 4,1 dfitpicts the organisational chart aitd the 
nanagament hierarchy of the aarketing departaeat o£ lAdiaii 
Drugs aad Pharaaceutlcals Ltd. It appears that a marketing 
department occupies unique status in the structural set up 
of the cocapany. 
The marketiag departaent of IDPL is headed by i>irect»r 
(Marketlag) who reports to the Chairman aad Maangiag Director 
of the company. There are seven 3r, Marketing Executives 
under the supervision of the Director (Marketing ) who deal 
in their respective areas of finance, commercial dealing 
veterinary and allied products, marketing research, institu-
tional selling, trade and training and development of the f 
field personnel, ..11 these senior executives are stationed 
at the head office of the marketing department, 
IDPL has in all six Divisions, each headed by a 
Divisional Manager who reports directly to the Director 
(Marketing ) , Divisional managers are responsible for all 
marketing operations as well as finances in their respecti¥t 
jurisdictions. Each division has been sub-divided into 
regions headed by a Regional Manager, who is responsible 
f©r promoting the sales of the company in his region and 
reports to the Divisional Manager of his area. The total 
number of regions is sixteen which are aasisted directly as 
well as indirectly by the Medical Representatives of the 
company. 
10.9 
Production Capacltyt 
IDPL is th« singlt largest producer of 13 «iitibio-
tics in the ccHintry, It products 45 synthetic drugs on a 
Xarg« seals• Its rsaga of pharaacautical specialities 
has iacrtased over 150 la the various dosage forss. 
IDPL has aa aanual iaatallea capacity of 6,650 
Billion tablets, 1,100 aillioa capsules aad ia^ectibles, 
1000 kiloliters of oral liquids, 30 toajies of oiatnents 
aad 450 toaaes of powder packs to provide for large 
therepeutic raage ia various dosage forms to the 
nedical professioa. 
IWL aaiatalas quite high standard ia quality aad la 
•aay cases its products are superior to those produced ia 
some of the developed ceuatries of the world. The ladiaa 
Medical Associatioa has reported that aaay aatioasl as 
well as iateraatioaal pharmaceutical firns operating ia 
ladia rely oa IDPL bulk daags to formulate thair aedicies, 
IDPL is the single largest supplier of aediciaes to 
the hospitals and public dispensaries ia ladia. It meets 
no less than oae third of the total aediciae requirements 
of the couatry's defence services, 
ICPL also offers technology and consultaacy to the 
developing countries for drugsj pharmaceuticals and cheaical 
pleats aad provides project consultancy for key operations. 
JIO 
H«ac« IDPL provides a sound bast for the dawlop-
maat of Indian drug' Industry, Its •anufacturing capacity 
hava nada the Indian drugs industry salf-raliant, 
Tba Indian Drugs and Phamaceuticals Ltd,(IDPL ) 
racordad a production of lis. 121,43 ceras which was higbar 
than avar bafora during tha yaar 1933->84, Its tumovar 
during the yaar was of fe, 108#41 croras/ Although this 
yaar was not as good as the previous one because of the 
increase in input costs. Certain Concessions on excise and 
custoBS duties which were previously enjoyed by the Conyary, 
had also been withdrawn by the Govemsient, Besides these 
factors, expenditure on salaries also increased during this 
period. 
Despite these constraints , the coMpaay was able to 
reduce its losses to Rs,21 crores in the year 1984*63 as 
against Rs,24 crores in the previous year. The following Takle 
gives figures of losses of the different units of IDPL 
during the . period 1980-81 to 1982^3, 
I l l 
T A B L£* 4>4 
Loa«t» in IDPL Units (Rs, la lakh* ) 
Unit 1980-81 1961«62 1982«83 
IDPL («)898.81 (•)1519.34 (-)869,83 
(Rishiktsh) 
IDPL (-)666.28 (-)716,41 (-)759.84 
(Hydtrabad ) 
IDPL (.)56.90 (-) 69*85 (-)212.97 
(Madrai ) 
IDPL (-) 63.26 (•) 6.12 (•) 10.68 
(Gurgaon) 
IDPL (.) 98,95 (-)239.61 (-)286.09 
(Muzzaffarpur) 
SOURCE s Drugs & Pharaacauticals- Industry Highlights, 
Lucknow, CDRI, April 1984,p. 185. 
m 
T«bl« 4.4 given abov« shows that four ualts of 
IDPL viz. Rishikesby Hyderabad, Madras and Muzaffarpur 
incurred Xossas throughout the period except for the 
unit at Gurgaon which nade a small profit of &.10.68 
lakhs in 1982-83. 
One of the reasons, for the losses, advanced by 
the public sector drug coapanies was the rigid price 
control. OH account of the tight pricing policy followed 
by the Goversaent certain ccapaniss preferred to curtain 
their production and to go for diversification. This 
practice led to the scarcity of essential drugs in the 
Indian drugs aailcet. Furthermore, public sector units 
were obliged to produce even when they sufferred 
losses. 
Table 4,5 below gives the production figures of 
IDPL units which indicate their contribution to the 
drug production in the country. 
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T A B L E - 4.5 
Preductioa in IDPL Units ik» in Ukhs ) 
Unit 19${?>91 1S>g1-^ 2 1992*9? 
Target Actual Targtt Actual Target Actual 
IDPL 3,991 3,216 3,785 3,558 4,885 4,664 
(Hiahtkesh) 
IDPL 4,918 4,379 5,255 5,342 5,844 5,368 
(li/darabad ) 
IDPL 544 457 739 787 1045 953 
(Qurgaon ) 
IDPL 197 130 349 182 215 183 
(Muzzaffarpur) 
IDPL 521 490 763 665 874 639 
(Madras ) 
SOURCEi Drugs & Pharmaceuticals- Industry Highlighti Lucknow, 
Central Dtugs and Research Ins t i tu te , April 1964,p,104, 
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Table 4,5 given above shows th« t a rge t s of production 
which were fixed for d i f ferent un i t s of IDPL in the public 
sec tor for three consecutive years i . e . from 1980«81 t o 
1982-83. The Table also h ighl ights the ac tua l perfonnance 
of these uni ts during the said period. I t can be noted from 
the above Table tha t none of the uni ts except IDPL (Hyderabad) 
and IDPL ( Gurgaon ) in 1981-82, could achieve the t a rge t 
l a id down. The sho r t f a l l in the production can be a t t r i b u t e d 
t o p a r t i a l u t i l i z a t i o n of ins ta l l ed capacity ana high 
input cost of raw-oater ia l s , I t is worth noting tha t on 
account of the remedial steps taken, the IDPL achieved a 
record production of drugs worth Rs. 121,45 crores in the 
year 1983-84 as against i t s production amounting to te,117.4? 
7 
crores in the previous year i . e . 1982-83. 
Working of IDPL 
\ 
Indian Drugs and Pharmaceuticals Ltd, (IDPL) S t a r t e d 
i t s operations with Imported known-how for producing 20 
drugs, IDPL has developed 30 more drug formulations «ad 
improved upon ex is t ing technology for many drugs. During 
1984 IDPL was the s ingle l a rges t producer of 13 a n t i b i o t i c s 
and 45 synthet ic drugs. The range of pbnmaceut ical 
s p e c i a l i t i e s has gone up to 150 in various dosage forms. 
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T A B L E » 4.6 
Statemeat Showiag R«ductioii 1* Price ( IDPL ) 
S.No, Products f^cklag Exlstiag 
pric* 
for stock* 
Ists aMcL 
hospitals 
(8s.) 
Reduced Exteat of 
price reductloB 
(8s,) (&.) 
1, Be«2yl Pe»icilliM 
Sodium Salt IP 
5 Lac lU 1vial 1.72 1.50 0.22 
(12.79J4) 
2.Benzyl Peaic i l l i i i Ivial 2,37 
Sodium Salt IP 
10 U c TU 
2,10 0.27 
(11.39%) 
3»Fortified Procai» Ivia l %57 
Benzyl Penlcillift 
4 Lac lU 
1.35 0.22 
(14 ^ ) 
4,Tetracycli«e 
Caps, 250 «g. 
5.Tetracycline 
Caps.250 mg. 
6.0TCIM Injection (oxy-tetra cycline 
7.Indi»ox Caps,250iig, 
(Aoexycillin Caps.) 
10x10 
1000»a 
10 ml 
, 2»s 
41.48* 
40.30* 
383.10* 
328,75** 
3.12 
4.96 
35.00 
290.00 
2,80 
4.50 
6.48* 
. (15.26%) 
5.30** 
93.10* 
(24,3%) 
30,75** 
0.32 
(1025 %) 
0.46 
(9.27^) 
SOURCE : Drugs and Phamaceuti call-Industry Highlights, 
Lucknow. September, 1984. p.438. 
• Stockists 
• • Institutions 
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FroM th* abttv* tabl* i t Is elMr that IDPL has vactuead 
tha prioas of drugs la 7 easas to tba axtaat of 12«79,11,39 * 
14.0, 15,62,24.30, 10,25 aad 9»27 paroaat raspactivaly. This 
would particularly giva a raliaf to tha poor aad dewaboddaa 
sactioas of tha soclaty. 
The IDPL started supplying aedicinas mostly to the 
Government Institutions instead of going a l l out for the 
open market trade. It ini t ia l ly served that segments of the 
market which were not being tapped by other drug manufacturing 
companies . Consequently IDPL earned much credit in this 
untapped market. The government institutions had never received 
such a preferential treatment at the hands of any other 
company before. Thus , IDPL led the market for drugs and 
i t succeeded in i t s efforts in this respect. 
There are about 9000 big and small companies in the 
drug industry in this country. Prior to the establishment of 
IDPL, these firms were operating in trade sailing,IDPL was 
the f irst to start institutional sale. Due to the expansion 
in the Nationalt Health Programme of the country the Govern-
ment institutions received huge funds. Many companies came 
forth later and started institutional sell ing. Consequently, 
IDPL had to face keen competition from these companies, (Juita 
a few of such companies were the subsidiaries of multinationals. 
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Within the first 2 to 3 years of institutional 
selling on the part of the IWh , it captured a major 
share of the market. But other companies also started 
their activities and therefora, the institutional sale of 
the IDPL started declining. The reasons behind this were 
many. Other companies could afford to sell their drugs 
at lower prices by lowering the quality of their products 
and gained the favour of the purchasing official of the 
institutions by offering bribes to them. These coeipanies 
•Hen used to submit their bills on the basis of fictitious 
supplies. They often took their drugs back from the institu-
tions aiKi sold th^i in the open market, 
R—earch and Developaentt 
Ilesaarch & Developnent has always formed the backbone 
of IDPL, A team of 300 highly qualified scientists, technol-
ogist and engineers in various disciplines are working in 
its R & D establishments. Its total expenditure on B&xJ 
was more than %. 300 lakhs during 1935-86, which formed 
about 2,5 per cent of total sales turnover of the company. 
In the initial stage, IDPL started producing 20 drugs 
with imported know-how. Within a decade, its Research & 
Development unit had developed 30 more drugs and improved the 
technology of many drugs including vitamin B,, B^ and folic 
acid. 
There is hardly any technology in the original product-
mix of the company which has not been improved so far, IDPL 
has developed the technology for vitamin E-6 through its 
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Vitamin was s t a r t ed for the f i r s t time in the country 
in November 1983, Three novel compounds, having promising 
therapeut ic value, are in lidvanced stages of biological 
evaluat ion, A non-s te ro ida l , anti-inflammatory compound i s 
a l so undergoing c l i n i c a l t r i a l s , 
IDPL has developed process technolgies for several 
e s sen t i a l drugs l i k e N-Methyl Peperzine, Frusemide, 
Trimethoprim, Aminophylline, Theophylline, Neomycin Sulphate, 
Diazepam, Glybenclamlde, Thiamine Mononitrate e t c , o«veral 
of these drugs are rraw being commercially produced. 
The R&D uni t of IDPL a t i t s Antibiot ics p l an t , 
Rishekesh, has f a c i l i t i e s of conducting research work in 
various d i s c i p l i n e s . I t has establ ished labora tor ies for 
research in mycology, microbiology, biochemistry, organic 
chemistry and pharmacology. Also i t has the f a c i l i t y for 
developing newer drugs and be t t e r formulations. The 
Synthetic Drugs Plant , a t Hyderabad, has R&D f a c i l i t i e s 
in the d i sc ip l ines of chemistry, and biology and i t has 
a p i l o t plant a lso to develop new drugs. 
According t o one repor t , the IDPL uni t a t Gurgaon 
spent fts, 45,50 lakhs on research and development a c t i v i t i e s 
in 1981-81, on the whole, the IDPL spent &. 129,29 lakhs on 
R&D a c t i v i t i e s in 1982-83,® 
121 
The Fine Chemical Processing Unit located at Hyderabad, 
well equlped with modem process technology and sophisticated 
analytical instruments, net aids the industry and its R&D 
activities by ensuring the purity and quality of laboratory 
chemicals, Due to the development of process technology the 
products of IDPL have gained a prestigious position in the 
overseas drug markets. The World Health Organisation(IIHO ) 
has also commended the IDPL products by saying Jlyour products 
have been examined for quality very carefully by the developed 
countries.,•• • .and many of than want to buy frcra here". 
The United Nations Industrial Development Organisation 
(UNIDO ) too has praised the IDPL in these words. "India 
today ranks first and foremost among the developing countries 
in technological ccmpetence, in the establishment end operation 
of a modem pharmaceutical industry that matches the world*s 
best in range, variety and quality," 
These commtnt regarding the m technological competency 
of the IDPL shows that the Research and Development activities 
undertaken by IBPL have ensured superior quality of its 
products, 
HINDUSTAN ANTIBIOTICS LTD. (HAL ) 
HAL is the second largest drug company in the public 
sector. In order to reduce the dependency on imports and 
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incrtase the production of antibiotics, specially penicillin 
and streptcxnycln, Hindustan Antibiotics Limited (HAL ) was 
set up in 1954 at Pune, The cost of this project was 
estimated at Es, 2 crores and it was expectea to prouuce 
4 lakh mega units of penicillin per month. 
Brief Historyt 
In the development of the Indian drug industry, the 
public sector has played a significant role. The first public 
sector company, the Hindustan Antibiotics Ltd, was set up 
at Pimpri near Pune for the production of penicillin. The 
company is now producing several antibiotics. It has three 
subsidiaries, established in collaboration with the govern. 
raents of Maharashtra, Kamataka and Goa and their financial 
institutions. 
The research laboratory of Hindustan Antibiotics Ltd, 
was set up in 1955 with WHO and UNICEF assistance. It is 
a pioneer in the manufacture of penicillin, atreptanycin, 
ampicillin and now gentamycin. It has to its credit the 
original discoveries of hamycin ( anti-fungal antibiotic;, 
aureofungin (fungicide ) and nancy-kit (for early, safe 
and reliable detection of pregnancy ), Apart from the manufa-
cture of and marketing of bulk drugs and formulations 
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I t i s evident from Table 4 .8 tha t HAL produced only 70,74 
MMU of Pen i c i l l i n »G' 1st c rys ta l s in 1970-71. However, i t s 
production increased to 134,99 MMU in 1980-81, o iml la r ly , 
streptomycin produced by i t was only 6,0971 metr ic tonnes 
in 1970-71 which increaseu t o 91.01 metric tonnes in 19dO-ai, 
This increase in the production value was aue t o the fact tha t 
Hindustan Ant ib io t ics Ltd, took cer ta in hard s teps and s t reng-
thened i t s Research & Development a c t i v i t i e s over the decade 
from 1970-71 t o 1980-81. 
Under the Fourth Five Year Han , the vitamin 'C» projec t 
was undertaken with a licensed capacity of 125 tonnes per annum 
a t an estimated cost of fe,1l8 lakhs. This probject was scheduled 
t o be completed in September 1972. But i t s completion suffered 
a s e t back because some essen t i a l equipment oraered for the 
p lant were impounded due t o Inao-Pakistan h o s t i l i t i e s , 
consequently. I t was ul t imately completed in March 1973»at 
a cost of as, 163 lakhs . Table 4,7 shows tha t the production of 
vitamin »C' was 27.55 metric tonnes in 1980-81,' ' ' ' 
Government had already approved the expansion in the 
capacity for the production of p e n i c i l l i n , streptomycin, and 
ampici l l in and the manufacture of gentamycln. Expansion of 
the p e n i c i l l i n plant was ccaipleted in June 1979 and commissioned 
in Oct. 1979. Similar ly, the streptomycin p lant was to have 
been completed and commercial production to have s t a r t ed by 
the end of April , 1981 .The rated capacity of 180 tonnes of 
the streptomycin was expected t o be achieved gradually during 
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Production Capacity? 
The Bengal Chemicals and Pharmaceuticals Limited proposes 
to raise its existing capacity of 30 crores tablets and 1 crore 
capsules to 50 crores and 5 crores respectively. It has received 
new licences for formulations other ttmn the basic drugs it 
proposes to njaiwfacture. In the chemicals division, the BCPL 
wants to integrate the two sulphuric acid plants at its panihati 
|i factory into one for efficient running and to improve the 
pollution control devices. 
In the home products division of the organisation, the 
production capacity of the phenol will be raised from 70 kiloliters 
to 200 kiloliters in a month. The target of the company was to 
reach a turnover of fe, 26 crores in 1984-85 (i.e. Rs, 6 crores 
in chemicals division, 8s,5 crores in heme products wing, fe.2,p 
crores in basic chemicals and Rs, 12,5 crores in the pharmaceutical 
division). The company has also evolved a strategy under which 
samples of pharmaceutical products worth a few lakhs will be 
17 
distributed among doctors. 
The company has improved i t s installed capacity in the 
following areas i 
i ) Tablet making from 15 crores to 20 crores per annum ; and 
ii)Capsules from 80 lakhs to 200 lakhs per annum | 
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TJiws company has four manufacturing unitf^ located at 
Manlktala and Panihati (Calcutta)^ Btmbay and Kanpur, It 
has three aain divisionii^ 
Division I t Chemicals and Bulk Drugs | 
Division II : Pharmaceuticals j and 
Division IIIJ Cosmetics & Home Products 
The main products in each division are | 
Division I sjChemicals • Sulphuric Ada, Alum, Chrome salt, 
euCs 
Drugs f Dapsone, Caffeine, falbutamide, 
Nikethamide, etc. 
Division IIJ•Pharmaceuticals- Ampicillin, Doxycycllne, 
Tablets, Capsules, Liquids 
Orals and Herbal Medicines. 
Division III: JJosmetics & HcHne Products-
Soaps , Hair Oil, Perfumes, Surgical Cotton-
phenol, etc. 
The Table 4,10 shows the production figures of the 
Bengal Chemicals & Pharmaceuticals Ltd. during the years 
1980-81, 1981-82 and 1982-83. The production figures 
ere arranged division-wise. 
TABLE - 4 . 1 0 
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Dlvisionwlsg Production in BCPL (Bs.in lakhs) 
DlvisiCHi 
1980-81 
YEARS 
1981-82 1982-83 
First 
Second 
Third 
212.26 
427.18 
516.11 
241.03 176.45 
573.51 567.92 
402,22 401.06 
TOTAL 955.55 1216,76 1145.43 
( • Samples 9.50) (+ Samples 10,6o) ( • Samples 4,60) 
Source s Annual Report, 1982-83, Bengal Chemicals & 
Phariaaceuticals Ltd., Calcutta 700013 p.4 . 
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Table 4.10 shows t h a t the t o t a l production during 
1982-83 declined to Rs. 1145.43 lakhs as compared to the 
previous year i . e . 1981-82 when the production was valued a t 
&. 1,216,76 lakhs . This dec l i i» was due to severa l f ac to r s . 
The factors most responsible for t h i s were continued d i s t u r -
bances and loss of production during prolonged negotiat ions 
for new wage sett lement on the expiry of the term of the e a r l i e r 
one. There was also d i f f i c u l t i e s in the procurement of some of 
the essen t i a l raw mater ia l s , cicroe of the pharmaceutical items 
l i k e Ant ibiot ics and Tinctures were produced less in comparison 
t o t h e i r estimated demand because of the high leve l of finished 
stock inventories of these i tems. The production f igures for 
the four uni ts of the ccsapany are shown in the Table-4,11, 
T A B L E - 4.11 
13.9 
Unltwlse Production at BCPL (i^. In lakhs) 
Manufacturing Unit Y E A R S 
1980-81 1961-82 1982-63 
Maniktala (Calcutta) 457.82 605.54 563.94 
Panihat i (Calcut ta) 
Bcaabay 
Kanpur 
349.79 445.07 400,20 
80.03 
67.91 
96,72 
69,43 
94.93 
86.36 
TOTAL 955.55 1,216.76 1345.43 
(•»• Samples 9.50)('i' Samples 10,60)( + Samples 4.60) 
Source s Annual Report 1982-831 Bengal Chejaicals & 
Pharmaceuticals Ltd. 6-G,C. Avenue, Calcutta 
700013 p . 4 . 
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A Close aerutiny of the Table reveals t h a t Maniktala and 
Panihati are the two main manufacturing uni t s of BCPL, located 
near Calcutta, Production of these uni t s declined frcm Rs.605,54 
lakhs and Rs. 445.07 lakhs during 1981-82 t o fis. 563.94 lakhs and 
Rs, 400,20 lakhs during 1982-83 respec t ive ly . The reasons for 
t h i s decl ine were more or l e s s the same as discussed e a r l i e r . 
Working of BCPL : 
An evaluation of the working of BCPB reveals some 
sericHis gaps in i t s functioning. The caopany has become sick 
and i t s p r o f i t a b i l i t y has declined over the pas t few years . 
The symptoms of sickness became clear in 1968-69 when on the 
sa les amounting to Rs, 2,90 crores , i t could make a meagre 
p ro f i t of 8s,0,8 lakhs . During the following years i . e . , 
1969-70, 1970-71 and 1971-72 i t suffered a loss of Bs.23.66 
lakhs on the sales t o t a l l i n g Bs.3,07 crores , of te,24,90 lakhs 
on the sa les amounting to Ss, 2,78 crores and of Rs, 50,52 
lakhs on the sa les t o t a l l i n g Rs, 2,78 crores respec t ive ly . 
In 1977-78 when the Bengal Chemicals was taken over by 
the Government the sa les turnover was Rs. 3.88 crores while 
the net loss suffered by i t was 8s, 1,97 crores , '^ The 
amount of loss suffered by Bengal Chemicals was Rs, 3,96 crores 
in 1934-85.''^ 
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Ther« has been an appreciable growth In proc^ction and 
sales since the management of the ccaipany 'was taken over by the 
Union Qovemment, Effective managenient and long range planniE^ 
have to a some extent improved the performance of the company. 
But i t i s s t i l l facing d i f f icul t ies . This is at t r ibutable to 
the following factors, 
• Increase in the wage b i l l | 
• Increased cost of the raw oateriala and services } 
- Increased burden of the interest charges on the 
borrowings from the Oovernment of India to «eet the working 
capital requirements. 
The company is trying hard to return to health under the 
care of the Government, but the disease is so acute that i t 
may nttd a long period of convalescent* for complete recovery 
to take place. 
According to the Jfemoranduia and Articles of Association 
of the company Bengal Chemicals and Pharmaceuticals Ltd. 
has a share capital of 8s,aD crores, out of this 5.02 crores 
hasbeen subscribed by the company. The entire amount of 
%, 5.02 crores paid by the Government of India as compansation 
for i t s take over has been treated as equity inv*st»ent in the 
company. In addition, the Government invested Us, 50 lakhs as 
share capital for the plans ik schemes of the company,^ *^ 
H2 
The total number of the employees working in the 
Bengal Ch^icals & Pharmaceuticals Ltd, stood at 2,195 as on 
31st March, 1983.^'' 
Bengal Chemicals and Pharmaceuticals Ltd. has three 
aain divisions, 
• Chemicals & Bulk Brugs Dlvlsion^^ 
• Cosmetics and Home Products Division 
• Pharmaceuticals Division, 
Its chemicals Division produces sulphuric acid. Oleum, 
alum and other things, of which alum and sulphuric acid have 
good demand ell over the country among the industrial users. 
The Cosmetics and Home Products uivisicai of the company makes 
phenol, soaps, hair oils and many other things, of which 
phenol and hair oils have a very high turnover. 
The BCPL has a wide range of phanaaceutical products. 
The comapny enjoys a monopoly position in anti-ltprotic 
drugs, snake venom antiserum and in some antibiotic drugs. 
The range of its pharmaceutical products Is gradually 
being narrowed on the ground of l)eck of profitability. 
Previously, the company had one more division for 
manufacturing surgical appliances end hospital accessories and 
it used to take contracts for hospital set-ups. Now this 
business has been given up ly the Bengal Chemicals, 
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SMITH STANISTREET PHAI^IACEUTICALS LTD I 
Smith Stanlstrctt Phanaaceutlcals Ltd. ( SSPL)» 
another public sector drug company, was initially established 
as a private company but it was taken over by the government 
in 1977. As far its age is concerned, it is oldest among all 
the five pharmaceutical companies in the public sector. 
Brief Historyt 
In 1972 Smith Stanistreet & Company Ltd, was brought under 
the management of a Govensaent owned canpany i,e, the Indian 
Drugs & PhaxTaaceuticals Ltd(n)PL} end was nationalised on 
October 1, 1977. In the year 1978 its name was changed to 
Smith Stanistreet Phannaceuticals Ltd, ( S3PL ), 
Smith Stanistreet Pharmaceuticals Ltd, was an English 
company formed in 1821, It was a private concern till 1971. 
With the name of Smith Stanistreet & Co, Ltd, As the name 
suggests, it was Jointly established by Drs, John Smith and 
Thomas Dawson Stanistreet, 
Because of the legacy, dedicated hard work and research 
in basic processes and formulations of Dr, Smith and Dr, Bawson 
Stanistreet, this firm became a pioneer in many of these fields. 
The alkaliids extracted in its premises were sold in export 
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markets. The company grew at a very :Caat rate. In the past 
Smith Stanlstreet & Co, Ltd, used to supply various finished 
products ui»3er the loan licence system to many companies such 
as I.C.I. , Fulford, Grlmaults, Muller & Phllps, Duphar and 
Phillips, uiMier their brand names. 
Performance i 
Training of its employaes has been a continuous 
activity in Smith Stanistreet Pharmaceuticals Ltd, to improve 
and update the knowledge, skill and methods of work at all 
levels. Many employees of the company have attended training 
programmes organised by the leading Management Institutes in 
India, 
There has also been a continuous emphasis on planting 
of trees to maintain ecological balance. The main functions 
of Smith Stanistreet Pharmaceuticals Limited are production 
of drugs in different forms. It has many departments viz. 
Tablets Department, Capsules Department, Injections Department, 
Galenical Department, and the Research & Development Wing, 
In each department latest and most sophisticated machiaes are 
used. Some of them are automatic while other are manually 
operated, A few products of the comapny are very popular 
throughout the country. For instance, Aminovin Tonic of 
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di f fe ren t pack s izes which has ah a t t r a c t i v e colour and 
«lelicious t a s t e , produced by the company, i s used throughout 
the country for d i f ferent age groups • Similar ly , i t s ehicken 
Essence prepared from the young and f a t l e s s chicken, which 
i s produced in the form of ampoules, i s the preparat ion only 
of t h i s company. These products contribute a high share of the 
turnover of the company. 
The authorised share cap i t a l of Smith & S tan i s t r ee t 
Pharmaceuticals Ltd, i s fe. 4 crores , out of which shares amount-
ing t o as. 3,20,74,000 were ful ly paid up and subscribed t i l l 
the end of 1964-85. During the year 1934-65 coopany received a 
plan loaA of Bs.4o lakhs from the Government, The t o t a l Government 
loans t o the company outstanding as on 31st March 1985 incluaing 
i n t e r e s t thereon amounted to h, 341 »71 lakhs against fis. 274.73 
lakhs in 1983-84, fis, 218.6 lakhs in 1982-83 and Bs, 180.05 lakhs 
in 1981-82, A sum of te,60 lakhs was a lso taken by the company from 
M/s Rashtriya Chemicals & F e r t i l i z e r s Limited auring the year 
1984-85.^* 
The t o t a l number of employee as on 31st March, 19Q5 
stood at 1,166 against 1144 on 31st March ,1984. The number of 
employees belonging to SC/ST in 1985 was 128, seven employees 
belonged to the p lys ice l ly handicapped category in accordance 
25 
with the Government directives. 
At present the company has 14 branch offices throughout 
India, all of which are located in the large cities of the 
country. Both the over-all production and sales in SSPL showed 
an increasing trend between 1980-81 and 1984-85 as is clear from 
Table 4.12 given below. 
US 
T A B L S » 4>12 
Production l a SSPL from 1980"61 to 1984»85 
(Xn Ks. Lakhs) 
Ytar Production Sales 
1980-61 
1981-82 
1982.83 
1983-84 
1984-85 
676 
741 
727 
801 
977 
616 
735 
757 
9^7 
1,183 
Source I Figures were provided by the works Manager in SSPL 
1i7 
Thfe above figures Indicate tha t the production , 
which was merely Rs, 676 lakhs during 1980-81, increased to 
ite.977 lakhs in 1984-85. Similarly the sales of the company•« 
products increased from Rs,6l6 lakhs in 1980-81 to Rs. 1,183 
lakhs in 1984-85, which shows a growth of about 9^% over the 
5 year period. Because of the increased production and sa les 
the SSPL i s the only drugs uni t in public sec tor which recovered 
from continuing losses and showed a marginal p r o f i t in 1984, 
In 1972, i t s production was merely Rs.1.5 crores.By 
1983-84 i t has r i sen to Rs,8 crores . Later the Government 
intplemented an scheme of expansion, on the completion of which, 
the production was to increase to fe. 14 crores making i t 
the l a rges t of the drug coiirpanies of Eastern India , 
Production Capacity t 
The SSPL (Smith S tan i s t ree t Pharmaceuticals Ltd.) has 
improved i t s capacity for the production of drugs belonging 
to a wide range of therapeut ics . The company now produces 
different items in the form of t a b l e t s , capsu les , in jec t ib le s , 
ointments e t c . Recently i t imported an automatic encapsulation 
machine with a capacity of 40,000 capiules per hour. This 
macbine has boosted the production of capsules ten times 
tha t of the manual]^ operated machine which was being used eaiiiBH 
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Table 4,15 shows that the company is more keen towards the 
production ot injectables. The installed capacity o£ this 
item is 5,50,000 litres per year, but the production has 
exceeded this limit. It was 6,18,728 litres in 1980-81, i.e 
58728 litres more tnan the installed capacity. The production 
of injectables further went upto 12,24,093 litres in 1981-82 
and 1,199,193 litres in 1982-83, 
Contrary to this, the production of other forms 
of medicines was far below the installed capacity. For 
example, formulation prepar»tations of the company like 
liquids, solid ointments, tablets and capsules, were not 
upto their installed capacities. Ointment preparations 
had an installea capacity of 95 tonnes per year but the 
actual production for the years 1960-81, 1981-82 and 198^-83 
was 40,88 tonnes, 34,68 tonnes and 26,59 tonnes respectively 
Labour unrest, power cuts, non-availability of raw 
materiels and inefficient management were the main factors 
that led to these shotfalls in production. 
Working of BILi 
An analysis of the working of the cwnpany reveals 
that 75% to 80;*^  of the products of the company are sold 
through institutional selling. The remaining 25^ or 20^ are 
]59 
31 
sold on the basis of the trade sales through the retailers'^  , 
The management of the company does not consider Institutional 
selling to be as beneficial as trade selling. In an 
institutional sale, a substantial part is routed through 
private distributors who take away a good portion in terms 
of commission and also buy the products for institutions 
at the prices lower then traae prices of the proaucts, 
Bengal laanunity Ltd. has undertaken «any projects 
for its expansion, A project for the manufacture of 80 tonnes 
of chloroquin phosphate has been approved ly the government 
which is being undertaken at a cost of Rs.3.5 crores. Another 
project 'Tetnus Antitoxin ' has also been undertaken by Bengal 
Immunity at its Dehradun unit, fk 
The manageii.ent of the Calcutta based company engaged 
in the manufacture of chemicals, drugs and pharmaceuticals 
had earlier been taken over in 1978 in the wake of serious 
financial and other difficulties due to mismanagement, labour 
tirouble and lack of proper resource management and long-term 
planning. In 1984, the BIL was nationalised. 
During the period 1982-83, tne company spent 
te. 29,97 lakhs on the Research & Development activities, 
BIL has been granted industrial approval for the manufacture 
of 6-APA, The licenced capacity for the production of this 
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a n t i b i o t i c drug for the year 1983-84 was 1CX) t o n s . 
During 1985» Cholera Vaccine, Diptheria a n t i - t o x i n , 
Gas Gagrene Antitoxin, Tetanus an t i - tox in anct TAB vaccine 
have been produced by th i s public sector company a t the 
competitive cost of Rs.77.65 per l i t r e , Rs. 17730,0 per MU, 
fe, 2822.0 per MU, fis, 8^3,07 per MU anu Rs. 77.59 per l i t r e 
respec t ive ly . The production i s intended to meet the aomestic 
needs of the country ana the canpany has subs t i tu ted the 
import of these drugs. 
Table 4.16 given below indica tes t ha t the overa l l 
production and sa le of BIL has increased from 1981-82 to 
1983-84. 
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f i r s t plan which increased to approximately, fts,43,000 
crores a t the end of the s ix th plan, Thfta indicates several 
hundred fold increase in the investment in publ ic en terpr i ses 
over the l a s t 30 years . 
The Indian drugs and pharmaceutical industry holds 
a place of pr ide in Indian economy. Like other indus t r i es 
i t i s divided into the public sec to r , the p r iva te sec tor owned 
by Indians, the M£ MNCs, the small scale sec tor and Joint 
sec tor . The importance of public sector drug enterpr ises i s 
due to the fact tha t t h i s sec tor has been spec i f i ca l ly 
established to produce drugs a t low p r i c e s , t o proviae medical 
f a c i l i t i e s , to achieve se l f -suf i ic iency in prouuction of 
formulations and to earn foreign exchange from exportable 
surplus . 
The drug industry in i t s present form tH has 
evolvea in to three broad sec to r s . In the publ ic sector two 
u n i t s , namely, IDPL and HAL were established by the cen t ra l 
Government, The other three u n i t s , namely, BCPL, SSPL and 
BIL were irtfcially pr iva te concerns but they ware taken over 
by the cent ra l Government l a t e r . 
The Indian Drugs and Pharmaceuticals Ltd,(lUPL) 
i s the l a rges t pharmaceutical complex in the country. I t 
operates under the fu l l control of the Government of India. 
I t en;Joys a unique pos i t ion today in the f i e ld of drugs and 
pharmaceuticals both among the Indian as well as overseas 
competitors. 
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The Hindustan Antibiotics Ltd. (HAL) is the 
second largest among the public sector drug units is the 
country. It was established with foreign assistance. It 
was setup in 195^ at Pyne for the production of 
Pencil!in. 
The Bengal Chemicals and Pharmaceuticals Ltd, (BCPL) 
is another public sector drug company which was Jjiitially 
established as a private concern during the British period. 
It became sick and its management was taken over by the 
Goverranent during the late seventies. It was later nationalised 
and is being managed as a public enterprise from iciigai 
April 1, 1981 . 
The Smith Stanistreet Pharmaceuticals i-td, (SSPL) 
was an English firm formed in 1821, It was a private concern 
upto 1971 with the name of omith Stanistreet & Co. Dtd, 
It was Jointly established by Dr, John Smith and Thomas JJawson 
Staiilstreet. Its management was taken over by IDPL in 1972, 
Ultimately it was nationalised on Octobfer 1,1977. 
Bengal Immunity Ltd. now a public undertaking, 
has gone through many phases of development. It was establishec 
in 1919* Its management was taken over by the central 
Government on 18th May, 1978 .It was finally nationalised In 
October, 1984, 
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C H A P T E R »5 
P J i O i ^ i l C T ^ N L ) MA R_K_£_T i l U L R S ^ F I C A T I O N 
Production po l i c i e s are the general ru les tha t 
makes 
management.to ..:uitie i t s e l f in making product decis ions . Develo-
ping new products, modifying ,ind improving upon the existinf^ 
ones, diversifying into new areas and markets branding,anu 
survey of aartcet demand are some of the key sureas of product 
planning. "Product pol ic ies may be s ta ted in the form of a 
s e r i e s of e i t he r short def ini t ions or of questions arraneed as 
• check l i s t " , spy Cundiff anu S t i l l ' ' , A prouuct pol icy , according 
p 
to Kline, " i s the s t ra tegy for improvin e company's over a l l 
sa les and prof i t posi t ion in respect of a pa r t i cu l a r product as 
.(.ell as to promote the sale of the coopany's other pro'-ucts, and 
in case t h i s policy hinders the sale of other products of the 
company, i t K« should have a .greater po ten t ia l long-range 
p ro f i t thr-n the products in confl ic t with i t " . 
Product Plannin: and Development; 
'Health for All % 20000 AD' has been accepted as 
the main objective of the Government's health policy,An 
important aspect of th i - policy i s to briag about an increase 
in the l i f e expectency of the peo-le frcxn the exist ing l eve l 
and to provide be t te r health care f a c i l i t i e s both in ru ra l as 
]6'.9 
well as in urban a reas . To achieve these objectives , a 
multi-dimensionsl s trategy has been evolved by the govern-
ment , Product development forms ^n important aspect of 
th i s s t ra tegy , 
Proouct development i s one of the basic consider-
a t ions of products pol icy. Product development i s necess ry 
owing to changes in demand, technological chan!;;e and p r o f i t -
less pr ice competition. In a highly competitive market i t 
i s r isky for a company to rely exclusively on i t s ex is t ing 
products. Customers want and expect a stream of new and 
improved products. Keen competition in the market r e s u l t s in 
new and improved products for the customers, A company's 
programi.'ie v^hich ensures searching for new products i s , 
therefore , a necess i ty . 
Product development has been defined in a number of 
ways. Kotler'.i de f in i t ion of new products i n d u c e s o r ig ina l 
products, product improvements, product modifications and 
new brands tha t a firm brings in to existence through i t s o.^ n 
R & D ef fo r t s , 
iJefining product planning and prouuct development 
5 
Stanton says that the former embraces all activities which 
enable producers and midalemen to determine that should 
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constitute a company's line of products, requiring an 
estimate of the industry's market potential, company's 
sales potential* cost requirement, and profit possibilities, 
whereas the latter i.e. , product development, is a more 
limited term,Compassing technical activities of product 
research, engineering and design", 
c 
Stanton adds that the scope of product planning 
£.r3dproduct develo]:ment activities Includes decision making 
£ind programming relating to the following : 
i) v.'hich products should the finn make and which 
should it buy ? 
ii) Should the company expand or simplify its line ? 
iii) v.hat new uses are there for each item ? 
iv) nhat brand name , package, and label should be 
usea for each proouct? 
v) What should be the product style, design, size 
and colour^ , and 
vi) How should the product be priced? 
Proauct development in drug industry does not 
merely depend upon chemists and pharmacologists. It is also 
related to marketing conditions. Favourable attitudes of the 
various market segments towards a particular product affect 
its nsprket value and, in turn, its proauction too. The 
development of di-ug therepy is a symbol oi the movement 
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tousrd& the good health of inhabitants. Since Independence , 
considerable improvement has taken place in this vlirection, 
•Accordiai to a UiilUQ report, Inaia .atan. s fifth in the world 
market in the development of its drugs and pharmaceutical 
industry. It is bein^ g recognised that Indiaii is about to reach 
the stase of self-sufficiency in the procuction of drugs -^nd 
pharmaceuticals, 
l-eveloping product strategy in a life-line industry 
like the drug industry is most crucial. Its formulation and 
implementation is the task of the economic planners of our 
country , ThU has been clearly stated in the Industrial Policy 
resolution of 1948 which includes this industry in the category 
of basic industries requiring "consider.ble investment and high 
degree of technic.l skills". In the initial stages of til 
its development , In>.ia was short of technical skills. Thus 
in beginning, technical knowhow from foreign countries was 
urgently needed and the government invited foreign investment 
on Indian soil. As a result of this policy of the Indian 
viovernment, drug produ. ing urdts were established in the country 
in collaboration with foreign drug companies. 
The Demgnd For Drugs s 
During the past decades the demand for drugs 
has consiaerably increased in the country mainly due to an 
increase in the level of consumption of dru^s. Several factors 
172 
such as tLe Increase in the size of population, better health 
care facilities, rise in per caoitn incorae and greater employ-
raent opportunities etc, have enhanced the demand for drugs. 
Public sector enterprises have the obligation to 
take care of the health of their employees. Plan outlays on 
the health care provisions and an increased consuiaotion rate 
are the two important factors th t influence the demand for 
drugs, 
A study conducted by the Indian Drug Manufacturers 
Association h j^s shown tha t "the output of formulations would 
reach Rs, 13,000 cro s a t constant 1973-79 pr ices by 2000 AD 
and per cjipita consumption of drugs would increase t o r.5,190 
in rura l areas and fe, 445 in urban a reas . The requirements 
for addi t ional investment w:rked out by the llMA were estimated 
t o be Hs, 7,570 crores . Of t h i s , investment required for 
i s producing bulk drugs 'estimrted to be te, 4,000 crores v^hile 
the balance i s to be u t i l i z ed for manufacturing formulations". 
A survey conducted by the National Council of 
8 
/ipolied Economic Research ( NCAER) has shov.n the projected 
values of per capita outlay on health and employment in the 
organised sector by 2000AD would be as follows : 
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T A B L E >5.1 
Demand for Medicines 
Years Value of drugs (fe. in crores) 
1980-81 1,239 
1984-85 2,162 
1989-90 4,112 
1994-95 8,500 
1999-2000 15,996 
O^UHCE : NCAER Survey Reports s The Economic Times 
( Saturday supp.) New Delhi , 13 Aug, 1933, p . I I I , 
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Table 5.1 shows the level of demand for medicines 
from 1930-81 to (<? 99-2000, In 1980-S1, drugs demanded were worth 
Ps, 1239 crores. DUG to the expected changes in the per capita 
income , and per cepita outlay on health the consumption 
of drUiiiS, and their demand is likely to go upto Rs.^ ,112 crores 
in 1989-90, about 3 times the demand for 1980-81, The demand 
for medicines is further likely to increase to Rs, 15,996 crore 
hy 1999-2000, an increase of about 13 times between 1980-81 
am 1999-2000. 
The increasing of demand by 14 per cent at cumulative 
rate per annum is based on the projected values of the above-
mentioned variables. This trend in the d©nand for drugs requires 
an increased rate of production and higher level of productivity 
in the indigenous sectors of the industry, which alone can 
ensure adequate supply of drugs in the country. 
The demand for drugs is governed by several factors 
such as disease incidence and its trends, quality of life, 
population characteristics and the strte of social and physical 
environment. Disease incidence and its trend detemine the 
mortality rate in a society. Birth rate, infant mortality rate 
and the prevailing diseases in the old age group greatly aifect 
the demand for drugs,^ 
Owing to a number of factors, the demand pattern of 
drugs in a developed country is different from that of the 
developing countries. For instance, differences in value 
systems, social and economic conditions, life in en affluent 
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society is more complicated, leading to drug adciftion, 
increased crimes and violence. Consequently cctemon ailments in 
such p society are found more in the form of cordiovascular 
diseases, ALJO, respiratory problems, and ct-ncer. 'iscoessive 
use of drugs may cause health hazards in such a society. On 
the other hand, a number of diseases in all age ;^roups in 
a poor country are the direct outcome of polluted water, un-
hygienic conditions, poor sanitation, lack of sewag.e t facilities 
inacessibility to pu lie health centres, adulteration an. 
malnutrition etc. The demand for drugs in such a country is 
found more in the form of anti-infective ones like enti-biotics, 
10 
vitamins ana anti-bacterials. 
As far as the nature of demand for the drugs is 
concerned, it is supposed to be not only price inelastic, but 
also income inelastic. In actual practice, however, it may 
or may not be inelastic. The extent to vhich income and better 
health care are related, the demand for dru^ s^ may be inversely 
elated to rise in real inccme. The demand for drugs may viell 
be income elastic because, as inccraea rise, people become more 
health conscious, As a result, the frequency of availing of the 
medical aid may sharply increjise. Out of four strata in the 
society i,e, the rich, the upper middle, the lower middle ano 
the poor, the demand for drugs might be income inelastic for 
11 the first two groups and elastic for the other two. 
It is an axiom that the demand for any commodity 
determines the supply of thot commodity. Similarly the denand 
for medicines detennines its cumly. The demand for drugs 
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presents the consumption side while Its supply represents the 
production side. The msnufacuurers are require- to formulate 
their proauct strategy in a v;ay that cein match the demand of 
the consumers. The product development, strategy comprises the 
following I 
1, -roduct line extent ion strategy^  
2, Diversification strategy; 
3, Brand strategy; 
Product Line Extentlon Strategy i 
Groups of products that are used together, sold to 
the same customers and marketed through the same channels 
are known as product lines. Extension in these product lines 
is said to oc ur when some ad. iti :ns in their width or depth ere 
made for holding their position in the market. Their width relates to 
the number of product Iri^ s %t^ the depth refers to the number 
of item.; in each line. 
In product line extension strategy , different aspects 
are to be taken into consideration which may vary from fins 
to firm and from one situation to another, A drug manufacturing 
company normally plans to produce many product lines such ss 
antibiotics, analgesics, anti T.B,• drugs and vitamins. 
177 
Each of these therapeutic groiips represents a particular 
product line while in each line a nunber of drugs are 
produced by a firm. 
Most of the drug producing firms generally do 
not prefer to go to the maxisjum possible extent in their 
product line extention strategy. Rather, they prefer to 
adopt 0 strategy which gives greater emphasis to the products 
which are more profitable in each product line, while the 
less beneficifrl products are neglected and sometimes they 
are totally dropped. Some companies go for the production 
of those drugs only for which they have technical expertise. 
Such units may enjoy more favourable marketing situation 
and achieve better results due to this strategy. For 
example, I,i),P,L. hes its major production centres at 
Hyderabad, Maoras and Rishekesh and each of these units 
has been set up to proUuce a single product-line i,e, synthetic 
drugs in Hyderabaa, surgical instrume ts in Madras and 
antibiotics in Hishekesh, 
Diversification Strategy : 
Dive-sification strategy involves diversifying route 
of production and market peneteration. Whenever a company is 
endangered by internal or external factors and starts losing 
profitability, it becomes necessary for it to go in for 
diversification. However , decision concerning diversification 
is not merely dependent on rofitabillty \Mt on other factors 
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also. Some compenles may add new product lines purely for 
the purpose of growing big in teras of size whereas some 
others may decide to diversify for capturing a greater 
share of the market. 
Internal factors neceasitatiiig diversification 
include scarcity of skilled labour force, obsolete technology, 
introduction of close substitutes etc whereas external 
factors are abolition of brand names policy of the government, 
licensing problems and rigid pricing, policy of the fovernment 
Product Diversification Strategy t 
Diversification in terms of products has taken place 
in a number of areas in the drugs and pharmaceuticel 
industry. Product diversification activity in the drug industry 
has been undertaken in areas such ap agro-chemicals, cosmetics 
anc toiletries, food products, industrial chemicals, »-yes 
and synthetic resina, Indian rhamaceutical companies do 
not en;3oy complete freedom to diversify in new areas because 
of the strict regulation of the activities of drug units 
by the government. The opportunity for diversification in 
the case of foreign drug companies is all the more limited 
because of the Government policy of regulating their 
activities on the basis of priorities. For public sector 
drug units the licensing policy has been liberalised compared 
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with that for other sectors of the drug industry. This 
preferential treatment to the public sector in respect 
of licensing is likely to aid in the growth and expansion 
of the drug industry. 
Since independence , the Indian drug industry has 
faced both internal as vjell as external constraints. Till 
the seventies, the industry lacked technical knownhow, and 
therefore, depended on foreign technology based proouction* 
In the past the drug industry operated un-er government 
pressures. The drugj [ olicy of the Govornment has compelled 
the manufacturers to diversify their production. Its policy 
of fixing a ceilint, on profits, of th« rug manufacturers 
has discouraged them and this may lead to product diversifi-
cation. The Drug Price eontrol Order ( DPCO ) i^ras promulgeted 
in the year 1979f under which prices of the essential drugs 
were controlled. But many drugs remained outside the purtiew 
of this order, anu, consequently, the manufacturers diverted 
their ctivities tovrards the production of such drugs. 
Market Diversification Strategy j 
Market diversification is as essed in terms of 
overseas expansion either through import and export activities 
or by overseas acquisitions or in tems of selling the drujs 
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In overseas •arkets. It offers new opportunities to 
drug companies to increase their sales turnover. Market 
diversification activity msy help, create consumer 
aw&mess and enhance the image of a company. In some 
cases the overseas markets may also Compensate losses 
arising out of declining sales of a drug company in the 
domestic market. For drug com anies other than the public 
sector units an additional motivation to enter foreign 
markets is that part of import entitlement of ravf 
materials and spare parts which is dependent on their 
export performance. If © multinational drug company derives 
60 per cent of its total sales from exports, the Government 
permits it to retain majority share in its equity holdings. 
But in the case of public sector drug companies it is not 
so,These enterprises can Import raw materials end oth€?r 
spare parts that they need without any obligation to export. 
But export activity is encouraged in this sector* also. 
Further , public sector drug undertakings are entitled 
to import bulk drugs on s mass scale and fix a quota for 
other sectors of drug Industry to utilise raw materisls 
f^ m^ them through a system of canalisation. For non-canalised 
bulk drugs direct imports are allowed but heavy custom 
uuties are imposed on such drugs. 
181 
Frc«a the point of view of both, proauct and market 
diver, ific tion, the public sector d ug companies have played 
a feir role, Hinuuston Antibiotics Ltd., one of the public 
sector drug units, has diversified into the productijn of 
agro-chemiccas; and Aurofungin, an antifungal for agricultural 
use, has also been produced by the company. Similarly , Indian 
Drugs and Pharraaceuticr-ls Ltd. has diversified into fine 
chemicals. Its Muzzaf^rrpur plant has been established 
particularly for the pro^-uction of such chemicals. Similarly, 
IDPL has established a Joint venture, Punjab Maize Proaucts 
Ltd, (San,:nir) , to produce food articles, vj-hich is another 
exam|ile of pr::.cuct diversification, Bengal Chemicals and 
Ph.naaceutiCils Ltd, has diversified into areas such J^ S 
cosmetics, toiletries and fine chemicals. It also produces 
soaps, h,Tir oils Dhenol etc, ;.s far as the efforts of 
public sector drug units in m3rket diversification Qve concerned, 
their perforj:v-nce in terras of s-les in the internati:..nal market 
is not impressive. However, this sector has shown its 
keenness to meet the drug requirements of the country rather 
than CLptu-"in greater market share. Table 5,2 .-iven belo\' 
inuicates this. 
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Table 5.2 above ;:;ho ,s that public sector produces 
10.5, 4o.O and 24.0 per cent of the total production of 
Vitamins, Antibiotics and Analgesics respectively whereas 
its share in the total market in these areas stood merely 
at 2,1 , 3.8, and 2,4 per cent respectively. The crse of 
multinationals is ouite different. This sector produced 
merely 7.2, 11.0 and 4,0 per cent of Vitsmirs, Antibiotics 
end Analgesics respectively but its mfirket shares « for these 
items were as high as 79.3 , 38,4 and 46,3 per cent 
respectively. The Indian Private Sector produces 82,3, 49,0 
and 72,0 per cent o^  Vitamins, Antibiotics and Analgesics 
respectively, but its market shares for these were 18,6,57.8 
and 51.3 per cent respectively. This shows that public sector 
drug companies have followed the policy of increased production 
with less emphasis on capturing Increased market share of 
drugs. 
Import Strategy t 
The drugs and pha.rmsceuticals industry in India 
».as dominated in the past by the foreign ^ ruf companies 
mainly due to their control over the production and import 
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of essential bulk drut^ s. Since 1970, the number of bulk 
drurs which csn only be imported by the public sector 
trading agencies haa increased. Approximately between 60 
and 70 per cent imports of bulk drugs are now handled by 
these agencies. Even the local distribution of these 
canalised bulk drugs is unuer the control of the public 
sector drug enterprises and other government sponsored 
agencies, and preference in respect of locs.1 distribution 
of imported bulk dru:rs is given to Indian drug companies. 
Direct import of non-canalised drugs by actual 
users is allowed provided they have the necessary approval 
from the Government agencies. The drugs which can be 
imported directly by actual users carry customs duty 
ranging betv/een 60 and 120 per cent oili their Cartiage Inward 
Freight (GIF) prices. It is evident from the above discussion 
that the import policy of the government concerning pharma-
ceuticals has two ob.ectives, to give the public sector a 
greater control on pricing and distribution of imported 
essential bulk drugs and to discourage the import of other 
drugs by imposing heavy customs duty. Since these policies 
have been implemented, the public sector has faced the 
problera of hUj-^e stocks lying •ith it. Drug manufscturers 
other than those in this sector, cropped their idea of 
producing these drugs and cid not lift their quota which 
were fixed by the public sector for them. 
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Sectorwlse Production and Imports of Bulk iJrugs t 
The drug industry in India has la ,gea behind in 
the production of bulk drugs as compared with formulations, 
>'hile the total value of production of formulations 
increased from &. 400 crores in 1974-75 to RS, 900 crores 
in 1977-78 and went up to Hs, 1200 crores and fe. 1760 croes 
in 1980-81 and 1983-84 respectively, the value of total 
bulk drug production in the country increased from Rs. 90 
crores in 1974-75| to &. 164, ife, 24o and Ffe. 355 crores 
in 1977-78, '930-81 and 1983-84 respectively, registering 
on average increase of 58,82 per cent as compared with 
68,32 per cent in the case of formulations. 
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T A B L E » 5.3 
Yearwise Value of Bulk Drug Production & Imports 
From 197^-75 19r4-85 (te. in crores ) 
Year 
1974-75 
1975-76 
1976-77 
1977-78 
1978-79 
1979-80 
1980-81 
1981-82 
1982-83 
1983-84 
1984-85 
Productions (96) 
90(72,45) 
130(78.20) 
150(78.10) 
164(72.10) 
200(57.14) 
226(65.31) 
240(67.98) 
289(67.84) 
325(61.90) 
345 
377(67.92) 
Imports (%) 
34.21(27.55)* 
36.26(21.80)* 
42,19(21.90)* 
63.57(27.90)^ 
150.0(42.86) 
120.0(34.69) 
113.0(32.02) 
137.0(32.16) 
200,0(38.10) 
N.A. 
178.0(32,08) 
Total 
124,21(100%) 
166.26(100%) 
192,19(100%^ 
227.57(100%) 
350,0(100%) 
346.0(100%) 
^53» 3:100%) 
426.0(100%) 
525.0(100%) 
-
555,0(100%) 
SOURCE i Indian Pharmaceutical Guide, PUmposh Publications, 
New Delhi, 1985,p.5 
* Value of iraoorts at GIF prices. 
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Since IOCEI production v;,:s not adequate to meet 
the uomestic needs of the bulk drugs m rke t In the 
country, Ini^ir-. hed to take cecourse to imports. The above 
Table sho.»s th" t during the period from 1974-75 to 1977-78 
the bulk drug needs of the country which were met through 
imports ranged between 22 t o 28 per cent , while during 
the pe.iod from 1977-73 to 1930-81 and from 1980-81 to 
198^-35 the import of bulk drugs ranged betv/een 32 and 42 
per cent . The m^in re son for t h i s import trend v^ es inadr^.uae 
production at tnined by v-rious indigenous sectors of the 
industry . 
Import Dependence in i-irug Industry t 
I t i s evident from the above discussion the t the 
pro<^uction l eve l s achieved b/ the indigenous drug uni t are 
not adequate to meet the requirements of drugs in the country. 
To make up for the shor t fa l l in domestic production, the country 
has had to import considerable quan t i t i e s of drugs. The t o tp l 
valu-? of imports, primarily consist ing of bulk drugs, increased 
from Rs.63.57 crores in 1977-76 to fe. 137.0 cror s in 1931-82 
snd further to 03, 178.0 crores in 1964-85, 
Imports of essen t ia l bulk drugs end drug intermedia-
tes under ma j^or therapeut ic groups are given in Table 5.4 
belov." s 
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From Table 5.4 it can be seen th-t Import 
dependence of drugs in 1979-80 was below 20 per cent 
for 13 prouucts, whereas im ort substitution for the 
IfjtS and 4 products above 20,41 and 81 per cents 
respectively in that ye- r» Similarly the import depenc-
ence in respect of 4 major products w;-s above 81 per 
cent in 198 -82 , whereas 2,5>9 and 13 products were 
imported to meet the domestic demands above 61,4l, 20, 
percent and below 20 per cents respectively during the 
year. 
The above trends .sugfjest that the country's 
dependence on imoorts for meeting its domestic require-
ments hfs risen. This is mainly du'^  to the lack of progress 
on the production front. Import dependence in drug industry 
has alao risen due to the fact that foreign drug companies 
like to import basic drugs from the countries they originally 
come from, h large i^am portion of the Imports is consumed 
by this sector, for foreign companies are not -..'illLrjg to 
establish plants in India that ccn produce basic drugs 
and they continue to import these drugs from abroad. 
However the Indian companies including public 
sector ones) have started the production of basic drugs 
and this has led to a decraose in their import dependence in 
these drugs. 
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The sector.wlse breakup of the value of proauction 
of bulk arugs i s sho.n in the above Table, The share of 
public sector drug companies in the production of bulk drugs 
consis tent ly declined, from 36,67 per cent in 1974-75 to 
24,50 per cent in 1978-79, However, in 19?9-80 i t increased 
s l i g h t l y to 26,11 per cent trcm 24,50 per cent in the 
preceding ye^ ^^ r. 
This trend was witnessed in sp i t e of the government's 
policy of reserving several essen t ia l bulk drugs exclusively 
for the public sector drug companies. In 1984-65 the share 
of the public sector in the production of bulk drugs increased 
to 32,56 per cent , The share of mult inat ional drug companies 
in the production of bulk drugs was 37.78 per cent in 1974-75 
and i t increased to ^ 40 per cent and 42.4 per cent in 1975-76 
and 1976-77 respect ively , Subsequently, the s h r e of t h i s 
sec tor in production of bulk drugs declined to 28 per cent 
23.45 per cent and 20,42 per cent in 1978-79, 1979-80 and 
1984-85 respect ively . The Indian pr ivate s ec to r , including 
the small sec tor , did wel l , during t h i s per iod. Their combined 
share increased form 25,55 per cent in 1974-75 to 50.44 
(39.82 plus 10.62) per cent in 1979-80. But a decline of 
3,22 per cent i . e . (39.82 + 10,62)was noticed in 1984-85, 
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-.ne of the important reasons for the declining 
trend in the production of bulk drugs by foreign drug 
companies has been that they have shown a keen interest in 
formulation activities rather than producing twlk drugs, since 
the fonner is more profit yielding than the latter. Contrary 
to this, the Indian private sector, including the small scale 
sector,has sho^n better performance in this respect, in viev. 
of the importance of indigenous production of bulk drugs. 
Public Sector drug companies have not shovm any 
consistent trend in the production of bulk drugs. This is 
mainly due to their inability to achieve the targets set for 
them. From 197^-75 to 1978-79 a declining trend in the proau-
ction of bulk drugs in this sector can be seen which was due 
to v;rong trade policies, improper technology, poor marketing 
arrangements and organisational inefficiency. However, from 
1979-80 to 1984-85 there v,-as an increasing trend in bulk drug 
production, This was mainly due to the fact that some important 
bulk drugs have been earmarked for public enterprises and 
other sectors are not allov/ed to proauce them. 
Export StrateAT i 
Export activity in the field of pharmaceuticals 
is of comparatively recent origin in the country, though 
Indian has a long tradition of exporting raw materials 
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to the technologically sdvanced countries which, in turn, 
converted the© into value- added products for export to the 
developing nations. The In inn phennaceuticsl industry is 
An exception to this tendency. This hiS been primarily due 
to the fret that India does not have petro-chemical based 
raw materials which are used for the pro uction of bulk 
drugs. Even today, the couritry's organic chemical industry 
is not sufficiently developed to meet the requirements of 
bulk drug production. 
Despite these constraints, there has been a favourable 
growth pattern in the production of bulk drugs in the country 
The number of bulk drugs and drug chemicals manufactured by 
to 
the Indian sector (Public as well private ) increasedy782 
in 1983-84 , produced by 252 drug companies. In the folbwing 
year '58 new items added to this numberP 
As a result of the growth of output and changes 
in t'le pattern of p oduction, India has now emerged as an 
exporter of basic chemicals, intereeaistes and fonnul tions. 
The indigenous drug industry has been able to build up an 
export market for Indian pharmaceuticals despite the severe 
competition it faces from economically advanced countries 
of the world. The Indian drug industry ts now able, due 
to its :increased range of products and facilities, to cater 
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to the needs of the International drug market, But^^ 
is has not been able to realise this export potential fully. 
The volume of its drug exports is modest compared with the 
total Value of drug production in the country. This cpn 
be Seen from the following Table i 
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T A B L E -5 .6 
Vf.lue of Drug Production and Exports (Rs.incroTes) 
Year Production 
{&,in crores ) 
Export 
(Rs.in crores ) t 2 to 1^ 
Percentages^ columii 
1966-67 
1969-70 
1972-73 
1975-76 
1}78«79 
1981-88 
1984-35 
175 
250 
500 
540 
1000 
1430 
1827 
3.75 
7.16 
11.50 
25.29 
39.58 
55.40 
180.17 
2,14 
2,86 
3.83 
4.68 
3.96 
3.9 
9.8 
SOUHCE t Indian Phanaaceutic-l Guide, New Delhi, 1985 p.10 
and The Eastern Pharmacist, New Delhi, Oct, 1986 p.66, 
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The above Table reveals that the percentage of 
exports to total production of Indian pharmaceutical 
industry increased from 2,14 per cent in 1966-67 
to '^ .68 per cent in 1975-76 , Exports were highest in 
1984-85, at fe, 1'-^ 0.17 crores which was ebout 9.8 per cent 
of the total value of drug production in the country,This 
Table shows that export performance of the Indian drug 
Industry during the seventies and till 196-82 was insigni-
ficant though in 1984-85 tt recorded an impressive grovith 
of 9.8 per cent. 
There are a number of reasons why exports has not 
keep pace with the increase in production. The Indian 
pharmaceutical industry suffers from some major handicaps. 
The cost of pharmaceutical preparations in India is high. 
The reasons for this high indigenous costs compared with 
intemstional prices are the high cost of inputs, obsolete 
technology, low levels of productivity and irrationally 
^reduction strategy. Other reasons for this include nationa-
lisation of import trade in countries like U,A,E.^Iraq^Bunna, 
Combodia and Indonesia, scarcity of foreign exchange and 
protective import policies which restricted the scope for 
long term direct export to these countries. 
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Sectorv/lse Production of Fpnnulatlons; 
As pointed out e a r l i e r , India has lagged behind 
the developed countries in teniis of bulk drug prod.ct ion. 
Exports from India mainly consist of formulations. The Table 
given beloiv shows the contribution of public sec tor drug 
uni ts in the ^ t i l production of rug formuletions in the 
country. 
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It is evident frofn Table 5.7 above thnt the 
public sector maintaineu its share of production of 
formulations consistently between 6 and 7 per cent frai! 
1974-75 to 1980-81, This v/es nainly due to the fact that 
its manufacturing activity was directed towards the production 
of bulk dru.iS and not towards fonnulrtion activities. But 
this practice w J ebondoned later. Public sector co tributed 
about 13.^7 per cent of the total production of formulation 
in 1984-35. This was mainly due to the product and market 
diversificatio startegi'es of the public sector drug ccnnpanies 
adopted to safeguard their interests. The share of the small 
sector in the production of forraulations increased from 
17 to 27 per cent between 1976-77 rand 1980-81.Foreign 
sector Showed the opposite trend, Thoujh its contribution 
was higher than th.-^t of other sectors, at 5D 75 per cent 
and 53,57 per cent in 1974-75 and 1975-76 respectively, 
it declined to 29.39 per cent in 198#-85. The main cause of 
this decline was a oecrease in the number of foreign drug 
companies operating in Indie, 
BranQinR Strategy: 
A brand name is e term, sign, sytsbol, design or 
combination of any of them. It is intended to identify 
the prouucts of ohe seller or group of sellers and to 
differentiate them from those of its competitors. 
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A brfind name may be defined as that part of the 
brand which may be vocalised H and uttered easily, A 
brand m rk, as differ nt from & brnd name in that pert of 
a brand v;hich can be recognised but ia not uttersble,such 
83 8 symbol, design, aistinctive colouring and lettering. 
Br' ndiiiL' strn legy refers to the task of product 
differentiation i.e. distinguishing the products of one 
mnnufr cturer from those of others, Branaing all the products 
very often puts an extrf burden on the customers due to the 
heavy expenuiture involved in promotional activities. It has 
its ultimate effect on prices which a customer ur-Hcess-^ rlly 
pay for the branded articles. This strategy is generally adopted 
by the companies operating in developed countries where the 
product differentiation is very necessary for the profitable 
growth of p. business, for people in these countries p.re mostly 
quality conscious rather thfn price conscious. 
In developing countries like India, people nre 
mostly price conscious. Branding str teify in t is type of 
environment turns out to be a controversial issue, since 
mobilisation of financial and human resources merely for 
promotional activities unnecessarily increses the total 
cost of 8 product, BrandinL strategy in Indian drug 
industry was adopted particularly by the foreign drug 
companies. They branaed their products for capturin,:: u larger 
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Share of the m rket. The validity of branding in Indian 
drug industry is, now being c^ uestioned by msny v/ho argue 
that consumers are forced to pay higher prices for the 
same drugs that r5re sold cheaper uncJer generic names. 
In this connection it WOUIJ be appropriate to 
mention the reconr endr-tions of the Hathi Committee, irtaiich 
opined that all single ingredient dosage forms of the 
following 13 drugs should be sola under generic names: 
1, CJilorsmphenicol and its casters such as palniitate 
monestearoyl glyoollote, succenate and steargte^ 
2, Tetracycline, oxytetrecyline, chlortetracycline, 
itemythlcholotetracycline end Deoxy-oxytetraCj^^llne . 
3, Ferrous sulphate. 
4, A3pirin (Acetyle salicyline acid ). 
5, Clorpromszine, 
6, Roserpine, 
7, Tolbutamide, 
8, Anslgin 
9, Piperzine and all its sr-lts such as adapate citr te • nd 
phosphate, 
10.Crystalline penicillin G, such as procaine, long; acting 
benzethene pencillin including semi-sjmthetic penicillins. 
11,Streptomycin. 
12,1 N H 
14 
13.Combination of IMH Thaiacetazone", 
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The above drugs were recommended to be sold 
under the generic names with a view to controling their 
prices. 
Branding strategy formulation v/hich is basic 
to product development strategy should ensure that the 
interests of ultimate consumers ane safeguarded. Although 
brsndini^  involves substantial cost spending dn the part of 
the manufscturers, still they go for branding mainly because 
of the following reasons ; 
i) - A brand mark is used for iiientific-.tion purposes, 
ii)- A brand name may be used as a legal trade m^rk to 
protect the unique features of the product from imitation, 
iii)-A brand name may be used to identify a certain ouality, 
so as to pronote repeated buying, 
iv) - Brandin. may be used ss a basis for price 
differentiation, 
v) - Branding may be used for enhancing the image of the 
product and the reputation of the firm, 
Criterl-. of a Good Brand Mame i 
A brand name should fonn an integral part of 
product development and designing. The desirable qualities 
of a brand name may be st ted as unaer s 
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1- It should suggest sotaething about the characteristics 
of the product. The following may be given as examples of 
this : 
a) The product 'Epileptin' suggests thet it cr.n be used in 
cases of epilepsy, 
b) »Threocyclin* suggests that it is a tetracycline which 
is to be administered three times a day, 
c) 'Suckcee' su,:.,ests th t it is a something which is meant 
to be sucked and that it is a medicine with a good taste. 
In addition, it can be said th??t a product name 
should bot be suj estive oi a wrong characteristics e.g. the 
product ^ Vitabiotic • manufactured by IDPL has been named so, 
since it is a vital antibiotic. But actual:y this name is more 
sug estive of a ccmpound which is a combination of vitamin 
•nd an antibiotic. Such «np wrong names should be avoided 
in product brnndins because they are misleading and may lead 
to faulty prescription. 
2- A brand name should be easy to pronounce, apell and 
remember. It should be short, nimple and easy to recall, 
orally and in writing, J-1SO a product name shoulu be distin-
naMd 
ctive, e.g. 'Calmoa* has been/^ by Ifll^L in accordance with 
the existing competitive product »Calmpose'. As a result •Calmod» 
could not estcblish its individuality in the market. In 
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fact, its introduction by IDPL gave a boost to the sales 
of 'Calmpose ' because of the similarity in the names. The 
product promotion campaign for *Calmod' could not establish 
the image of the product as intended , 
3- In pharmaceuticals, the name of the drugs should be 
phonetically anglicised. Allopathic preparations carrying 
indigenous names, (herbal drug name ) failed to capture 
the market. Irrelevant brand naming was a major factor 
in the failure of these products :-
a) Calmod- suggests that it confers peace and tranquility 
on the singer and the audience, 
b) Sardilan- A preparation meant to combat colds, failed 
to establish itself because of its indication of local 
language and Verbal drugs name, 
c) Avedrn - A medicine meant to relieve pains did not attract 
the attention of the people and hence it was unaccetptable 
in the market. 
All these products are being manufactured by IDPL 
ana they failed to achieve the desired objectives in the 
market. On the contrary, Ayurvedic preparations manufactured 
by the Himalayan Drug Company (An Indian Ayurvedic firm ) 
carrying anglicised names have been able to capture a large 
share of the market and they are in fact very popul&r in the 
medical profession. 
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Examples of these drugs are : 
i ) Liv 52 
i l ) Cistone 
i i l )Tentex Forte 
iv) Speman Forte t a b l e t s , for Incr-easiv the rp.te of 
sperraa t o i, enes i s, 
4 - In pharmaceuticsls industry, a br«nu name should not 
i n u i c t e the diseases for which i t i s metnt, par t iculaiV 
the diseases l ike tubercu los i s , leprosy nnd vener^l diseases 
which carry a social stigma. Moreover, i f a brand hii:,hlights 
the disease , i t is also bad for sens i t ive p a t i e n t s , since they 
keep them reraindinti tha t they are the victims of a pa r t i cu l a r 
disease and t h - t they are di f ferent from the normal people. 
This might have psycholOiiiCr;l imolic?t ions. Doctor.3 also do 
not prefer to prescribe such drugs, bxnT.ples of such dru^s 
are given below : -
a) Tibafen- manufrctured by Suhrid Geigy and recommended 
for tuberclus is fa i led to come up in the mertcet because of 
the £bove implic-ition, 
b) Epi lept in- m nufactured by lb L end recommended for 
epi lepsy, could not be considered a sound brand name, 
5- A brrnd name should not have any other meaning in o ther 
languages. 
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Bases for Selecting a Good Brand Name t 
A band name should be sX selected on the following bases : 
1, It may be selected on the basis of certain selient 
features that a product possesses .These features may 
include the action of the product, itB dosage, its advantages 
over other products and features that distinguish It from 
the products of the competitors, Sicamples are given below { 
i) Deacos - It is cough syrup which cares congei^ tion, and 
clears the throat. The name itself highlights this fact» 
ii) Ingestion- This product is used for the indigestion. 
Tuus, a rightly s lected brand name is often self-
expianrtory and wi'l be a plus point in promoting the product. 
2, Another basis for selecting a good brand name is the 
contents of the prodact. It should be such that it is 
able to highlit^ -^ ht the various cooponents of the drug, 
oome Examples are given below i 
i) Cebexin- B complex + Vitamin C 
ii) Apidin- A.P.C. + Codine 
iii)Hexavit-A product of six vitamins 
iv) Cemi2ol- Vitamin C + Metamizole 
v) Throoycin-Ery thromycing 
All these products ;. re prepared by IDPL, The basis 
of their brand names is determined keeping in view the integral 
207 
components of the drvgs, 
3 , Another point to be kept in mind while se lec t ing a brand 
mme, i s the name of the roanufr cturing company. 
Examples ere given bilowi 
i ) Idifulvin-IDPL + ."Jriseofulvin 
i i ) Idicin-Indomenthocin of IDPL 
i i i ) Iditol-IDPL + Ethambutol 
iv) Glaxene- Semia of Glaxo 
Brand name of cirugs should be decided keeping the above 
considerations in mind. They wi l l go a long wny in se lect ing 
effect ive and successful bnnd n mes. 
Summary ; 
Production policies are the general rules thot 
a management makes to guide itself in making product 
decisions. Planning concerning production, developin^ r new 
products, modif|:ing and improving upon the existing ones 
diversifying the route of production, branding and survey 
of market demand are some of the areas of product 
policies, 
Procuct development in the drug industry does not 
merely depend upon the chemists and the pharmacologists. 
It also depends upon the efforts and effectiveness of Biarketing 
personnel, Kavcurable attitudes of the various market 
segments towerds a particular drug enhances its market value, 
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and in turn, its production :. too. iJevelcpin: prodntt 
strate y in the dru^ - industry is a crucial job. Its 
development largely depends on the successful implemantation 
of the following strategies : 
- Product Line Ext-.ntion Strategy, 
• Product and Market Diversifiction 
Strategy, 
- Import end Export Strategy and 
- Branding Strategy 
Groups of the products that are used together, 
sold to the same customers and marketed through the same 
channels are known as product lines, Extension in the e 
product lines is said to occur when ad itions in the number 
of product lines or increase of the nuaiber of product in 
each product line ere made to ca utre an increased share of 
the market. Product and market diversification strategy 
involves diversifjfccation of the route of production and market 
penetration. Product diversification activity in the public 
sector drug units has taken place in areas such os agna-
chemicals, food products, industrial chemicsls, dyes 
and syntehtic resins, Msirket diversification is assessed in 
expansion in 
terms o. /the seles either through import and export 
activities or by oversease a ecu is it ion, or by acquiria^ ,^ 
a greater market sh-. re. The public sector drug units have 
done well in this ar too. 
The drug industry in Inciir as Q . hole has lag ed 
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C H A P T E R » 6 
P O L I C I E S 
Intceductlon i 
Promotion is a key element In marketing strategy, 
l^e first step in marketing Is fitting the product and its 
features to market needs end preferences| the second is 
availability of the product in the market through distribution. 
Successful promotion is the third essential ingredient in 
overall marketir^ g strategy. Prospective buyers must learn about 
both the product's distinctive want satisfying characteristics 
and its availability while maintaining links with target 
market segments. These are the key tasks that are associated 
with promotion. 
The American Marketing Association defines promotion as "the 
personal or impersonal process of assisting and/or persuading 
a prospective customer to buy a coaimodlty or a service or to act 
favourably upon an idea that has commercial significance to the 
seller,« 
While describing the importance of piromotion in the modem 
n 2 
marketing system, Sta;fcon points out that "basically, promotion 
is an exercise in information, persuasion, and influence," ThesB 
three terms are linked with each other in the sense that to 
infonn is to persuade and conversely, if a person is being persuaded 
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he Is probably also being Infomed and Influenced, 
In this ©ontext Prof, Neil Borden' says that "the use 
of influence in commercial relations is one of the attributes 
of a free society. Just as persuasion and counterpersuasion 
are exercised freely in many walks of life in our free 
society-in the home, in the press, In the class room, in the 
pulpit, in the courts, in the political forum, in legislative 
hells and in goverrment agencies for information*, 
Promotion is basically oeant for conmunication.The communi. 
cation of the product and its distinctive want-satisfying 
characteristics, the company as a whole, its nature and 
business, the targeted customers, the place where the product 
may be available and the price which a cwapany charges for the 
product, constitutes promotion , Promotion is different from 
sales promotion. The latter is only part of the former. It is 
different from advertising and publicity too. 
4 
According to Kotler the four major tools in marketing 
cwnmunications mix are as under i 
i) Advertising! Any paid form of non-ptrsonal presentation 
and promotion of ideas, goods or services by an identified 
sponsor, 
iiji Sales Promotions Short term incentives to encourage 
purchase or sale of a product or service, 
iii) PublicityI Nonpersonal stimulation of demand for a 
product, service or business unit by planting commercially 
significant news about it in a published medium or obtaining 
favourable presentation of it upon radio, television, or 
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stage that is not paid for by the sponsor, 
Iv) Personal Selling t Oral presentation through conversation 
»lth one or more prospective purchasers for the purpose of 
making sales. 
Promotion Is the process of managing a communication system 
to improve the image of the company among the various groups 
of the society. It communicates the knowledge about the company, 
its product , activit^ t , prices , and policies. In marketing 
tenas, it aims at conveying to the consumers s .ise^ sage abcwt three 
elements of the marketing mix , viz , the product,(including the 
product's distinctive wants satisfying features ) place, (the 
availability of the product) and price, at which the product is 
offered. 
The manufacturer has got at his disposal a very wide 
range of promotional methods. Some of the important ones 
include j personal selling ; advertising j point of purchase 
5 
displayj direct mailling, and packaging. Most of the promotional 
cappalgns involve a combination of two or more of such methods. 
The factors that affect the optimum level of promotional strategy 
are the product, the market, the stage of demand and the relative 
cost. All business organisntioni give special emphasis to the 
sales promotion department. In some business houses it is attached 
to the marketing division, while in others, it functions as 6 
separate department. For instance, in pharmaceutical Industry almost 
every leading firm has a separate sales promotion department. 
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Promotional Policy: 
PiTomotional policy is meant to create awaWKes in the 
minds of targetted custoraers about a company ana its products 
with the objective of increasing sales.This is the most vital 
area of marketing in pharmaceutical industry, A phanaaceutical 
company cannot afford to ignore prcwjotional activities in a 
competitive busingss environment. The most widely used promotion 
metrod for small companies is personal selling, aided by sales 
promotion and sales incentive techniques, while the role of 
advertising in this industry is mostly of the nature of public 
relations publicity is useful for research oriented products. 
Furthermore, selling and advertising must be co-ordinated. 
Advertising portfolio must be prepared, but it is not of much 
use unless medical representatives follow it up with personal 
contacts and capitalise it. 
Designing and iaplementin s comprehensive marketing 
programme calls for the use of techniques which aid in moving 
drugs from producers to consumers. Solution to the problem how 
to communicate effectively depends upon the creative promotional 
strategy adopted by different pharmaceutical houses, such as 
setting up store displays, holding trade shows and exhibitions, 
using samples and premiums, packaging of the product, price 
of the product and brand names etc. 
Promotion in Pharmaceuticala t 
Sales promotion is the nucleus of the pharmaceutical 
industry. It is the pivot round which successful mBifcetin^ of 
pharmaceutical products rotates. Many companies have itparate 
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sales promotion departments, or, alternatively the product 
manager of the company looks after the sales promotion 
functions. Choice of sales promotion techniques suitable for the 
pharruaceutical products aalnly depends upon the nature of the 
products. These .^techniques differ i'rom product to product, from 
company to company,and tvmt one place and market to anothpr. 
Since the pharmaceutical industry has the following two 
types of products, their promotional strategies may also be 
different from each m other's .They are as undert 
1, Ethical products 
2- ^Son~Ethical products 
Promotional Strategy for Ethical Products j 
Ethical products are those for which the doctor's advice 
i s required and without the recommendation of the doctor they 
are not to be purchased. In principle, a r e t a i l e r should not 
se l l such drugs without the prescription of a registered 
medical practi t ioner , l^ese include ant ibiot ics , anti-hypertensives, 
antidiabetics, antiasthaaatic drugs and so on. Sales promotional 
strategy adopted for such products i s different from that of 
non-ethical products. I t heavily re l ies en personal contacts and 
interactions of sales representatives with doctors and hospital 
staff, i^sign, presentation and display receive less attention 
as compared with personal selling and publicity directed to 
doctors and hospital!• 
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IDPL and HAL, both public sector drug enterprises, 
promote their products mainly through teams of medical 
representatives, "^ he Manager (Marketing )in HAL says that 
"since thisk.s indirect kind of sales promotion, it is done 
mainly through personal contacts". 
Promotional Strategy for Hon.Ethical Products t 
Sales promotion strategy for non-ethical products is 
concerned with such products for which the prescription of 
the doctor is not required. These products are generally adver-
tised freely. The techniques of sales promotion are adopted 
either at the level of the retailer or at the level of the 
stockist. Such products are generally pjromoted through adver« 
tising in several ways such as : 
a) Advertising through the press j 
b) Advertising through Radio and T.V. | 
c) Window display at the cherrist's shop; and 
d) Hoardings at busy and crowded places 
Sales promotion strategy of non-ethical products is 
very similar to that of consumers goods, A study of 
advertising compaign of the BCPL, a public sector drug unit, 
220 
reveals the following unique se l l ing propos i t ions . To bui ld the 
image of the ccwnpany, slogans l ike "your t rus ted favouri tes frexn 
B e n ^ l Chemicals ——™N««.« and "I cannot take a r isk with my 
ha i r I en t rus t i t to Bengal QieiBicala care " are being used,To 
show awareness of soc ia l respons ib i l i ty slogans l ike "Bengal 
Qieffiicals——«—-•-. a veteran in the service of the country" are 
and 
used/ to es tab l i sh the product image "Unchanged over 60 years 
with changing s ty les , (Product | or "Uengal Chemicals'* 
Broad Spectrum Antibiot ic , , " e t c , are devised by the 
company. 
Methods of Promotioni 
•ihere are several methods of promotion, d i r ec t as well 
as ind i rec t , which public sec tor drug companies fse for building 
t h e i r corporpte image pnd promoting t h e i r s a l e s . These methods 
are discussed below, 
1) Vis i t s of Medical Jiepcysentatives 
In each month or every quar ter , a company's medical 
represen ta t ives v i s i t doctors to give them l i t e r a t u r e and 
some samples of i t s dru-.s ,They maintain a constant touch with 
the doctors and keep reminding than of the main features of the 
corBpan|'»s products and i t s pa r t i cu l a r brands. In t h i s way they 
in 
help/ increaseing the sales turnover of the company. 
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( i ) Litrature /Visual Aids:* 
The l i t r : ture of the coiipany providts a l l the informa-
tion concerning the products of the cospany, including i t s 
pharmacological end clinical aspects. The l i t e ra tu re 
also gives the dosage ae t a i l s , indications, contra-indica-
t ions, the likely side effects of a drug and the essential 
precautions to be taken before using i t 
( i i ) Saiaples s-
Samples of a pi^duct contains the original proQuct, but 
in small pack«, These san^les are given to a medical 
representative to dis tr ibute them among the doctors so 
that they can try the© on their pat ients . But due to 
increasing competition and low ethical standards, sometimes 
these saiaples are aisused and aishandled, 
(iii) Novelty Iteras j-
These items have becorae very coramon in the drug iniustry, 
Nearly a l l the craipanies provide some coaapliiaentaries /g i f ts 
to the doctors. These g i f t s generally include pens, 
calendars, thermometers, diar ies , prescription pad and 
pen stands e t c . 
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(Iv) Updated ikita t-
I'hese days cooipanies also provide published reports 
concerning the drugs produced by the company and their 
applicability in India as well as abroad. Medical repre-
sentatives are well-equlped with such data and they try to 
explain the distinctive leatures of their products in 
ccaapaaision to the products ot other companies, 
2) Mailing Literature directly to Doctors 
This is generally done when a new product is launched 
or there is soae signii^ ic nt ioprovercent or development 
or chaj^e in the price o£ the product which has already 
been introduced in the market, 
3) Advertising in Professional Jouri^ls 
The advertisement of a product and its composition 
is done in Journals which are published by different 
medical associations and intemptional advertising agencies, 
4) Arranging Medical Fjlai Shows end Exhibitions 
This type0 of promotional strategy is generally launched 
for a new procuct developed by a compai^, it is also 
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resorted to when the ctmtany faces a keen ccrepetitlon.in 
order to regain the market share of a particular brand, 
5) Presenting Noveltleai 
Attractive presents /g i f t s are offered to the doctors 
to keep reminding the® of the products of a company, ihis 
is the ffiost widely used tool by the pharmaceutical industry 
for promoting the sales of i t s products. 
Most public sector drug conpanies have a countrywide set 
up of sales broasotion officers under whoa there are teaas 
of medical representatives to proaiote the sales of different 
products through personal representation. For instance, 
Beng«il Qieiaicols and ftiarmaceuticals Liisited (BCPL), one 
of the centrally owned public sector drug companies, has 
classified a l l the doctors into three groups- A,B, and C, 
This classificrtions i s based neinly on the i r popularity 
end the number of patients attending their clinics , 
According to a cilculation of the BCPL about 70 per cent 
doctors are in category A, 20 per cent in B and 10 per cent 
in C, The C category doctors cover about 80 per cent of 
the patients while B cover about 10 per cent and A the 
remaining 10 per cent. 
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For promotion purposes, physicians in B and C categories 
are contacted v?hilt those in the A category are ignored. 
However amphasis on doctors in categories B and C is not 
the same. More frequent visits are paid to physicians 
in category C than to those in category, B, 
i^ch medical representative is alloted a particular 
territory, with a detailed list of doctors in it, They 
usually visit eight doctors daily. They also try to 
find out the different doctors* attitude towarAs their 
coiBpai^  with the help of the neighbouring dheraists and drug-
gists and their subsequent visits to these doctors are 
ad;Ju6ted accordingly. 
Advertisements and other prcMsotional tools are also 
used for the pnwiotion of noxwethical pn>ducts of the 
company. In the natter of advertising, BCPL tftkes decisions 
regarding^^products that should be promoted (2) aoney 
to be spent on advertisements and (3) the aedia used for 
advert ise^ nent. 
There are two other promotional tools which are being 
used by this public sector drug unit,(JBoi»as offered to 
dealers which is a caamon technique,of sales pronotlon. 
This is given in the fora of gifts made on the acquisition 
of some fixed quantitiii of drugs.(2) Some medical Infomatlo 
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generally for new products which i s printed and sent 
to medical pract i t ioners . 
Promotional iibcpenditure t 
The to ta l expenditure incurred by the drug companies 
under the he^ads of salaries of field staff, the i r travell ing 
and conveyance expenses, cost of l i t e ra ture and samples and 
expenses incurred on the publicity and advertis4ng of over 
the counter drugs cottstitute their proreotionsl expenditure. 
While figures regrrdin^i total expenditure m promotional 
ac t iv i t ies of puldic sector drug companies are available , 
no date Ji concerning different heads of expenditure on 
these act iv i t ies is available, 
A Survey report published by the Organisation of 
Pharmaceutics^ Producers of India (OPPI ) shows tha t , on an 
average, roughly 12.4 ^ of the to ta l turnover of a pharmace-
ut ical company i s spent on sales promotions and distribution 
ac t iv i t i e s . The break-up of th is expenditure i s given 
belows 
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T A B LE »6>1 
Break-up of Promotional Expenditure Ifaring 1980»82« 
It^ss Percentage 
of Total 
Turnover 
1, Medical t^presentatlves 
2, Direct Hailing shots 
3 , Advertisements In Journals 
4, Free Samples 
5, Other Promotional Activities 
(Film Shows, Exhibitions e tc . ) 
5.93 % 
1.36 % 
0.82 % 
2.46 % 
1.82 % 
TOTAL t 12.4a % 
Source s OPPI Report, Bombay, 1^3. 
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I t is generally believed that the phsrraaceutical 
companies spend a i l l ions of rupees on sales prcaotion 
ac t iv i t ies by way of employing medical represeotitives, 
distribution of free samales, mailing of expensive 
l i t e ra ture etc» The above table shows that only 5,93^ 
2,46 % and 1»36 1^  of the t o t a l turnover was spent 
on sending Medical i-tepi^aentatives^free sampling and moiling 
of costly l i tera tures , during 1960-62, The above Table 
also shows exper»dlture of 0.82 'P of sales turnover under 
the head of sdvertisements, which indicates that very 
l i t t l e Bioney is spent on th^ itera. The Bengal Chemicnls 
spent 
and Phamaceutical Ltd, a public sector drug unit* 4 per 
cent of the sales of the company on advertising during 
1980 to proaote strae non-drug iteaas produced by the cc«ipany. 
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TABLE ^ 2 
Publicity and Advertising Expenses as Percentage of 
Net Sales (1373-78) 
S.HO, Company Cbde 
1, Company H, 
2, Company K, 
3» Company A 
4, Company T 
5» Company B 
Year Ending 
June 1973 
June 1978 
August 1973 
August 1978 
I)ec. 1973 
Bee, 1978 
^eb. 1973 
Feb. 1978 
Dec, 1973 
^c, 1978 
Publicity and 
Advertising 
Expenses as 
percentage of 
Net sales 
12.92 
7.60 
6,89 
^ ^.08 
^.03 
1.08 
3,37 
a.2i 
3.05 
Nil 
Sources t Johri, L.M, : Multinationals in India (A 6ase Study 
of Pharmaceuticals Industry ), Vision Books, fJew 
Delhi, Tab.5.6, p.85-
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The Table gi^en above shows the trends in expenditure of 
drug companies on advertisement from 1973 to 1978, It is 
clear from this Table that advertising expenditure of diff-
erent drug companies ranged between 2,2 and 7.6 per cent of 
the net sales in the ye: r 1978 .This offers a contrast with 
the figures shown in Table 6,1 under this head where expen-
diture on this head was just 0.82 per cent of the net sales, 
during 1980-82. This decrease in promotional expenditure 
may have taken place mainly because of the Government^ 
strict enforcement of the provisions DPCO-1979 concerning 
the profitability cielings of drug companies , 
R & D Activity for Product Positioning ; 
Research and Development activity is of crucial 
significance for the pharmaceutical industry. This is 
becaUcie the quality of products of the drug industry are 
linked with the health of the people . Production of 
spurious and adulterated drugs may cause serious damage to 
the health of the people. 
Research and development activity in this industry is 
also essential because of the high rate of obsolescence of 
the products manufactured iSytt.A drug which is meant i for 
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the treatment of malaria today may beco«e out of date 
after some time due to i t s adverse side effects which could 
endanger human l i f e , I t should, however, be emphasised here 
that a prescribed course of treateent for a specific 
disease is necessary to fully coabat the related bacteria in 
the body, ^ i t th is becomes ineffective because the bacteria 
gets isanune to the drugs used to fight thwa and 
therefore i t ceases to be efficacious., Hence the need 
of never dnags. Continuing R & £> activity i s necessary for 
product innovations leading to the discovery of new and 
more effectual drugs, 
A person may be suffering froa aany diseases at a time. 
For instance, a patient suffering frora tuberculosis 
Blight be a chronic patient of hypertension and bs aay 
be diabetic as well. Thus, instead of giving him separfite 
medicines for the three diseases one medicine which may 
cure a l l the three diseases would be more suitable 
for him R & i) activity is needed for discovering such drugs 
which axe •'.uitable for the treatment of aany diseases at a 
time. I t i s therefore essential that greater ©nphasis 
Is laid on research and development activity in the drug 
industry. 
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In india great emphasi:. i s l a id on ^ & D a c t i v i t y 
re la ted to t m d i t i o n a l medicines, l i ke Ayurvedic, Unani 
e t c , Allopathy i s a branch of medical science In which 
much of the investment i s made by mult inat ional companies. 
For various reasons R & D in drug industry i s d i f f e ren t 
from similar c t i v i t y in other f i e l d s . I t i s time consuming 
and i t s r e su l t s are unpredicatble . Nevertheless, i t requires 
t rained manpower and equipment which involve large expenditure. 
iio i t i s r isky in terms of re tu rns . A study car r ied outlin 
the u «;v USA has shown tha t out of 5,336 new drufs introduced 
in the market between 19^8 and 1963, only 11 per cent were 
new chemical e n t i t i e s which were not previously known, M s t 
of the regaining products were e i the r duplicates or s l i g h t l y 
d i f fe ren t from the existing; compounds. Public sector crug 
enterpr ises have made a notable contr ibution towards the R&D 
a c t i v i t i s in Indian pharmaceutical industry . For example, 
Smith o t an i s t r ee t Pharmaceuticals Ltd, ( SSPL ) set up 
a pl^nt in 1920 for the extract ion of strychnine and brucine 
fro»ri the seeds of nux vomica which i s the ol<^iest p lant of 
i t s kind in the world. The company has an i n s t a l l ed capacity 
of 7,000 kgs, t o r strychnine and brucine each. The Bengal 
Immunity Ltd, , (BIL ) introduced diphtheria an t i tox in serum 
and a n t i - b a c t e r i a l sera through indigenous technology for 
the f i r s t time in India in 1928, BIL si so introduced a n t i -
menlngococcus and tetanus an t i tox in serax with ics own il&D 
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a c t i v i t i e s In 933. Slroilarly, Hindustan Antibiot ics 
Ltd, (HAL) discovered hamycin in 1961, antiatnoebin {fin 
anti-helffiintic jmt ib io t i c ) p^ nd aureofungun ( an a n t i -
fungal s n t i b i o t l c ) in 1965. 
IDPL developed the technology for vitamin B-, 
for the f i r s t time in the country In November, 19^i3.'i'hls 
was a major break-through. There ere th re r novel compounds 
which have been developed through IDPL's own H&D ac t iv i t y 
which are in advanced stages jf biolo i c s l evaluation,/ , 
non-steroid-sl r^nti-lnfla-astory compound of IDPL i s also 
under; oinr^ c l i n i c s ! t r i r rds . 
There i s a tea® of 503 highly qual i f ied s c i e n t i s t s , 
technologists and engineers in various d i sc ip l ines working 
in IDPL's H D establ isNnents , This team made r, r.ignificpnt 
contr ibut ion and improved the exis t ing technologies o r ig ina l ly 
tcken from the Husoians, The expenditure on &^1> n the IDPL 
i s more than 2.5 per cent of the i t s tot?»l s-^les tumove , 
Table 6.3 below shows expenditure on R&D incurred 
by the public sector dru« units in d i f ferent ye r s . 
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T A B L E - 6.3 
R&D Expenditure of Pub!ic Sector Drug Units 
(Rs. in lakhs ) 
3.NO. Name of the Company Annual Expenditure 
Year Amount 
1. Bengal Immunity Ltd. 1982-83 29.97 
(Calcutta ) 
2. Hindustan Antibiot ics Ltd. 
(Pune ) 1981-82 71.41 
3. Indian Drugs & Pharmaceuticals 
Ltd,(New Delhi) 1982-83 129,29 
4. Bengal Chemicals & 1982-83 4.4l 
Pharmaceuticals Ltd, 
(Calcutta ) 
5. Smith Stanistreet 
pharmaceuticals Ltd, 
" (Calcutta ) 1931-82 7.00 
6. Indian lirugs &. 
Pharmaceuticals 
Ltd, (Gurgaon ) 1901-82 45. 50 
Source : Drugs & Pharmaceuticals - Industry 
Highlights, CDRI, September, 1984 p-433-436. 
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The above Table shows that the annual 
ex:3i»nditure of Hindustan Antibiot ics on K & i) j^j^ .j^ -fr I<?QI-.B2 
• ??s Rs, 7^A^ Iqkhs, whereps I^PL (New i^ lh i ) Spent fe,129.29 
a c t i v i t i e s 
Lakhs on these durin the year 1982-83. Bengal Iniraunity, 
3Klth iJ tanistreet and Bengal Cheflilcslc, the three nat ional ised 
units^spent ^,2 ', )7 lakhG,..i, 7,00 lakhs and fc.4,4l l;.->khs 
on K& U a c t i v i t i e s durinj 1982-33,19-1-82 and 1">82-85 
respect ively . 
The amount of money spent on l^i^ a c t i v i t i e s by 
various public sec tor drug uni ts appear to be quite hi-^ h. , iiut 
when th i s I s cwnpared with the expenditure incurred by 
t h e i r counterparts in the Western wor ld , i t seems to be 
ins ign i f i ant , T i s aay be aue to the following reasons : 
i ) 'ihe processes developed by the nat ional lebora tor ies 
a re economically not feasible as th~ cost of production 
i s very high, 
i i ) A cofflis niCi^tion gap is found between the laboratory 
personnel -nd the drug technologists in many org n i sa t ions , 
i i i ) Most of the work carr ied out in the nat ional laborptor ies 
i s of an acadanic nature and hence i t h??^  l i t t l e p rac t i ca l 
relevance for Indian drug firms, 
iv) Bpisic chemicals and intermediate compounds are 
eas i ly avai lable to the government run l abo ra to r i e s . 
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The indus t r ia l sector , however,* f e e . ^re-rt d i f f i cu l ty 
in obtaining them due to .iC'^rcity of .oreign exchnn^e ant 
im:>ort r e s t r i c t i o n s . 
v) The t e h ica l data sup l i ed by the laboratorier> are 
Inco p l e t e , which creates operational d i f f i c u l t i e s for the 
firm which used to u t i l i s e the laboratory knox^how, 
Resea -ch & i>evelQnmen '^ Expenditure : 
The fi & D in drug industry i s o£ a pecul iar natu'^e. 
I t i s costly as well as tiaie consuming. Therefore, the dru ; 
conpanier, are not b i l l i n g to invest huge amounts of n ^ney 
in such p c t i v i t l e s . The small scale drug un i t s cannot 
afford huge expenditure on R & D, because of l imited 
resource^, The pu i l i c sector companies, on t ' ;e contr-^ry, 
are in a posi t ion to spend hu^.e f -nds on th i Item, fcr 
R & D a c t i v i t i e s bocf'ur.e they have cer ta in soci?^l object ives 
too to jus t i fy t h e i r exis tence. Foreign sector companies 
usually incur subs tant ia l expenditure on t h i s head to 
cap i t a l i s e the opportunit ies avai lable in the market. 
There nre mainly three kinds of R & D a c t i v i t i e s 
v iz j (1) formulation development , (2 ) procer><i technolor^'' for 
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production of bulk dr .gs and (3) discovery and develof.wient 
of new medical tubstances. The s iaple and ear ly . 
rewarding research a c t i v i t y i s foraulati-jn developiaejit.'Ihe 
l a s t i . e . discovery of new cheiatcal substonce, i s the 
hardest one. The foreign sec tor , therefore , prefers 
to undertake the R 3t iJ a c t iv i t i eu which are concerned with 
the foHBulation de'-elopinent. Table 6,4 g ive i annual 
expenditure incurred on H & D by p u b i c and pr ivate sec tor 
drug cotBp^nies from 1972-73 to 1982-83. 
T A B L E 6.4 
Research and Developme t Kxpenditare 
(Public & Private Sectors ) 
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{ .%, in crores ) 
Year R&D Exp, ^omulfi t loi ^^^^ i^xp. as 
onles Turnover % of ^alea 
Turnover 
1972-73 
1973-74 
1 74-75 
1975-76 
1976-77 
1977-78 
1973-79 
1.579-80 
1980-81 
1981-32 
19B2-.3 
5.86 
6.24 
7.29 
8.00 
10.50 
12.00 
14.75 
18,00 
2?,00 
29.30 
N.A. 
300 
380 
403 
560 
700 
900 
105^ 
115^ 
1200 
1465 
1545 
1.9 
1.6 
1.8 
1.4 
1.5 
1.3 
1.4 
1.5 
1.5 
2,0 
N.A. 
>iJURC£ : Ca i t r l j Cqicuttp, December 6,193? and The Econor^ic 
Titnefi, New Uelhi, April 7,r:J-4 p , l . 
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Table 6.4 shows the trends in R & D expenditure 
in the 1970*s and the *arly 1980*s , It can be seen from 
this - Table 6,4 that R &D expenditure in the early 70's 
was higher compared with than in the late 70*s^ It was 
1.9 p.c, , 1,6 p.c, and 1,8 p.c, of sales turnover in 1972-73 
1973-74 and 1974-75 respectively. But immediately after the 
commencement of the Fifth Five Year Plan i.e., from 1975 onwards 
the expenditure on R&D shows a declining trend which continued 
till 1980-81, when it was Just 1,5 per cent of the sales 
turnover. 
In 1982, the percentage share of R & i^  on sales 
turnover of formulations showed an expenditure of Rs,29,3 
crores, which was 2 per cent of the sales turnover. The 1»reak 
up of R & D expenditure for 1981-82 is given in Table 6.5 
below :-
240 
^ A B L E ^,g 
Break -up of R8t D Expenditure in 1981-82 
Aaount No. of 
Companies 
R & D Expenditure 
Rs. 1 Crore and above 9 
ife, 50 Lakhs-Rs,1 crore 6 
fe. 25 Lakhs«Rs.50 Lakhs 12 
Rs. Below 25 laks 46 
16.93 
4.45 
4,43 
3.49 
TOTAL 73 29.30 
Source t The Economic Times, New Delhi, April 7,1984,p,1 
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The above Table shows that there were only 9 
companies in the entire drug industry which were spending 
more than Rs,1 crore for 8,& D, There were six ccMipanies which 
spen between 50 lakhs and te, 1 crores and twelve of their 
spent between Rs, 25 lakhs to Rs, 50 lakhs during this period, 
and 46 companies spent less than te,25 lakhs on R & 1>, The 
trends in expenditure on R&D indicate lack of attention on the 
part of drug units towards R & D , which is essential for the 
development of the phannaceutlcal industry. 
The expenditure pattern of 52 drug producing 
companies in respect of R & D ^ advertising and sales promotion 
is given in Table 6,6 below , This Table indicates that these 
companies do not bother much about R & D activities, whereas 
their expenditure on the promotion activities was very high. 
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T A B L E - 6.6 
Expenditure Incurred on ii & D and Advertising and Sales Promotion 
by 52 Companies 
( Percentage of Turnover ) 
Item of Expenditure on 1975-76 1976-77 1977-70 
1, R*D Activities 
2, Marketing Costs 
(a) Selling Commission 
(b) Advertising 
3, How many times more (2t1) 
0,3 
1.8 
2.0 
12 
0.3 
1.7 
2.0 
11 
0.4 
1.6 
2.0 
10 
Source : Capital, Calcutta, December, 1982 and The R,B.I« 
Bulletin, May,1980. 
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It can be seen from the above Table that 52 companies 
were spending 10 to 20 times more on sales promotion activities 
to capture a major share of the market than on the R&D activities. 
From Tables 6,4, 6,5 and 6,6 It is evident that generally a 
small amount is spent on R&D activities by the different sectors 
of the industry. Public Sector drug units have made a notable 
contribution towards R & D but their performance In this direction 
is not upto the desired level, since the processes developed by 
this sector are economically not feasible due to high cost of 
production and most of the work carried on concerning R&D is of 
academic nature and has little practical significance. Also there 
is lack of communication between the research centres and the drug 
technologists. Though the drug MNC^ incur a sizable amount on R&D 
In their home countries, but It Is commonly found that they 
make no worth-while efforts to strengthen the R&D programme 
through their affiliates in the host countries. The case of 
Indian private sector is quite different. This sector does not 
undertake any comprehensive R&D activities, mainly due to lack 
of financial resources and non-avaliability of qualified 
personnel. 
Reasons for the Poor Growth Rate in RStP Expenditure : 
Reasons for the slow growth of R & D activity In 
pharmaceutical industry are many. As mentioned earlier, the 
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cost of R & D is very high. According to on« estimate 
about $ 100 million are needed for developing a nevr drug^it requires 
about 12 years as the period of gestation. Heavy expenditure 
on R & D discourages drug units from going fast in this 
direction. Moreover, under the rules, patent protection is 
allowed only for 7 years and the drug so intn>duced is free 
from any price control Intervention for only 5 years, This 
short time looks unjustified considering the efforts and 
expenditure involved in the matter. This is acting as a 
deterrent to the growth oi R & D act ivi ty in drug industry, 
The other factor that has hindered tlit growth 
of R & D act ivi ty in the drug industry, is the fact that the 
prof i tabi l i ty of som pharmaceutical units has declined over 
the past few years and that these units are not able to recover 
even a part of the R&D expenses. That is why only a few large 
companies are er^eged in R & D ac t iv i t ies for discovering new 
drugs, ' 
There exists another problem. With abolition of 
brand nanes for single ingredient drugs, no prospective producers 
would l ike to introduce new drugs without getting i t patented. 
This act BS a disincentive for R & D in drag industry. There are 
many exsmples.of this , The case of cimetidine 'an ant i-ulcer 
drug*, which Steith kllne and French sought t4 introtiuce in India 
three years ago, is worth mentioning in this context. Although, 
the company wanted to manufacture the drug from the bssic stage 
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and to market it with its international brand name *Tagamet* 
the government insisted on marketing it with the generic 
name, The company had to give up its plan for the manufacture 
of this drug in the country as its parent U,3, Company did not 
allow it to market it with the generic name. This drug is being 
imported by India for formulation purposes. 
An indepth study of the working of drug companies, 
reveals that in the sphere of priorities, a substantial portion 
of the R &i D expenditure is incurred on superficial improvement 
of existing products with a view to enhancing their marketability. 
An examination of the H & D priorities in the private sector 
reveals that maximum weightage is given to packaging research 
compared with product or process research and least emphasis is 
given to basic research. Such practices are indulged In due to 
narrow outlook which is against the spirit of the social 
responsibilities of the finns. 
There are other factors responsible for the poor growth 
of R & D in the drug industry. Generally R & D activity in the 
industry is pursued more vigorously by the multinatior^ These 
MNCs have their firm bases in the countries of their origin. 
They spend a negligible portion of R & D money on tropical 
diseases. Most of the research in the field of discovery of new 
drugs for tropical diseases, was carried out in early 20th century 
when the people of Western countries were confronted with such 
infectious diseases both at home and in the colonies abooad. 
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The reasons for this neglect Is obvious,The low purchasing 
power of more than on billion poor people in the developing 
countries renders the profit profile of such efforts 
unattractive. The American Walter Reed Army Research Institute 
has been taking keen a interest in controlling malaria because 
of Vieta Nam war, and to safeguard the health of Aaerican 
q 
military personnel,^ 
The last factor limiting R & D in drug industry is 
the high rate of obsolescence of drugs. The tools and equipment 
used for producing new drugs become outdated within a short time, 
leading to high risk and uncertainties. Medium and small scale 
units do not have sufficient funds to meet the losses arising 
out of uncertain and quick changing environment. 
There are other reasons . which may be tensed non-
economic for the slow growth of developnent activit|r in drug 
industty . A research fellow at the Indian Institute of Public 
Administration, New Delhi has observed that foreign companies 
which have their firm bases in the developed countries seek to 
perpttuste the technological dependency of the host countries. 
These companies do not encourage much R & D expenditure to 
be incurred by t e Indian subsidiaries. Citing an example, he 
says that the Sandoz Group spent nearly 9 per cent of its 
worldwide sales turnover on H & D, whereas its Indian subsidiary 
spent only 1,4 per cent of its turnover on this head in 
1975.''° 
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The Government has indicated that 27 out of the 
43 foreign drug companies In the country have been spending 
merely one per cent or less of their total turnover on R & D 
and only 4 companies spend more than 3 per cent on this activity 
though thete Is little evidence to show that this level of 
R & D activity Is adequate to meet the needs of the Indian drug 
11 Industry ' '« 
Areas of Research & DeveloTPment > 
A working Committee has been formed to look Into 
the details of the working of different segments of *he drug 
Industry, The Committee has carried out an exhaustive analysis 
concerning the expansion and development of tfcis industry in 
a phased manner. It acts on behalf of the National Drugs and 
Pharmaceuticals Development Council, and one of its sub-group 
has made a number of feasible proposals regarding the production, 
pricing mechanism and technology development of the industry. 
Besides , the Committee has also proposed certain guidelines 
concerning the R & D in the drug Industry, The Committee has 
identified areas of R & D for different sectors of the 
iwiustry. 
These proposals are likely to be accepted and implemented 
with . their inclusion in the new drug policy of the 
Government of India, 
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Besides, it has been suggested by the sub-group 
of the committee that developmental research for improv^nent 
of indigenous technology is the primary responsibility of 
every bulk drug manufacturing unit in the country. The small 
scale unitsd.e, whose annual turnover is less than fe.50 
lakhs ) have also undertaken the production of bulk drugs 
but they do not have appropriate technical knowhow and other 
research facilities. These units are being attached to the 
national laboratories to procure process technology frcra 
them. 
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The Working Committee also recommended that larjge private 
unitsCi.e, those with annual sales turnover of above ris,5 crores) 
should have full-fledged development laboratories, the efforts 
of which should be directed towards the development of 
existing processes as well as of new processes. According 
the 
to it,yindustrial units with turnover of more than Hs,25 crores 
per year should undertake research work in areas of product 
development, and should also work for identifying market 
potential for new products. The Committee further recommended 
that large companies in this industry should undertake basic 
research for the discovery of new chemical entities^ and that 
their research is ought to be directed towards relevant areas 
of national health e.g, tropical diseases, fertility control 
and new and spphisticated delivery systems etc, and that 
researches in these areas should be conducted indigenously. 
The Government ought to give a serious consideration to 
the recommendations of the comnittee while framin^ ^ its new 
drug policy. Specific incentives may be offered to units 
undertaking research in relevant areas. 
Distribution Policyt 
Distribution involves various activities necessary for 
transferring goods from the producer to the ultimate consumer. 
It includes physical handling of goods such as their movement 
and storage as well as legal, promotional, and financial 
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activities involved in the transfer of ovmership* 
12 Kotler ^  says that physical distribution involves 
planning and implementing the physical flows of materials 
and their final transfer from points of origin to points 
of use or consumption to meet the needs of customers at 
a pn)fit, According to him, the main elements of the 
physical distribution mix are transportation, warehousing, 
inventory, carrying, receiving, shipping, packaging, 
administration and order pnjcessing. 
Managements are now increasingly concerned about 
the cost of physical distribution which varies from the 
industry to another and frt>m one situation to another. 
Substantial savings can be effected in physical distribution 
1"5 
which has been described by Parker '' as the lost frontier 
14 for cost economies" Drucker , calls it as "the economy's 
dark continent". 
The basic objective of a distribution system is 
to transfer the final product from the place of manufacture 
to that of consumption, providing best possible services 
to the consumers. Specific decisions concerning various 
aspects of distribution such as the type of distribution 
network to be adopted, the required market coverage in physical 
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tenns, the cost of transportation, commissions and credit 
terms for various intermediaties constitute the overall 
distribution policy of a company. All these components 
of the distribution policy have to be combined to ensure 
that the product is available to the ultimate customer at 
a reasonable price. 
Government Regulations Regarding Distribution t 
In the distritMjtion of drugs, additional features 
which need to be kept in mind are the conditions and 
specifications laid down by the ordinances of the Goverranent , 
The Drugs and Ckssmetics Act, 19^0, makes it obligatory 
for all the midalemen to possess licences for carrying out 
their distribution activities. These licences are Issued 
only to those drug distributors that have adequate physical 
facilities in terms of area, storage, space, ventilation 
end light arrangements. The Act also requires that there 
must be at least one qualified pharmacist at each retail 
outlet and every drug .retailer should have at least one 
refrigerator to maintain the specific potency of the drugs. 
Similarly, WCQs define certain norms for the pricing of the 
drugs that have also to be adhered to* 
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The Drug Prices Control Order-.1979 requires 
tha t no drug marwfacturer or d i s t r i b u t o r or importer can 
s e l l drug formulations to an intermediary a t a pr ice 
exceeding the manufactureffe pr ice shown in the pr ice l i s t 
asgpproved by the Central Government plus loca l taxes 
payable, i f any, or a t a pr ice exceeding the r e t a i l p r ice 
of t ha t formulation shown in the pr ice l i s t . 
Every manufacturer of a formulation which i s 
meant for sale i s required to inscribe in indel ib le p r i n t 
mark on the lable of the container of the formulation the 
words " r e t a i l pr ice not to exceed followed by " local taxes 
extra*. No dealer i s allowed to s e l l loose quanti ty of any 
formulation drawn from a bo t t l e pack of such formulation 
a t a pr ice which exceeds the prorata pr ice of the formulation 
15 plus five percent thereof. 
The Urugs and Cosmetics Act, 1946(23 of 19^0 ) 
does rtot allow any dealer to refuse to s e l l «* a drug held by 
him to a customer wanting to purchase such a drug, 
16 
Manufacturers pr ice i s t c be calculated by 
deducting 20?6 and 15 ^ in the cases of e th ica l and non-ethical 
drugs respectively from the r e t a i l p r i c e , exclusive of 
duty and adding there to the excise duty and loca l taxes 
payable, i f any, separately | 
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( i ) Not l e s s than 12% of the r e t a i l pr ice for the 
r e t a i l e r and not lens than 8% for a l l other intermedlatJies, 
in the case of e th ica l drugs, ( i i ) Iht lesa than 10^ of 
the r e t a i l pr ice iffor the r^i :ai ler and not l e ss than 3% for 
a l l other interraedlaries , in the case of non-ethicJil drugs. 
Apart from t h i s , every dealer i s required to 
maintain the cash memo orcred l t memo book, accounts and 
records of purchase or sa le of drugs in such a maimer as to 
show the se l l ing pr ice and loca l taxes separately and has also 
to make avai lable the said records of business for Inspection 
to such off icer as are authori ied by the Central Government 
in t h i s behalf. 
Furthermore, any off icer authorised by the 
Government, with a view to securing compliance with the orders 
of the Government or to sa t i s fy himself that the orders of 
the Government are being compiled with, can en ter and 
search any place, seize any drug, along with the conta iners , 
packages or coverings in which the drug I s found. Thereafter 
the authorised off icer can teke a l l measurers necessary for 
the producing the drug containers, packages and coverings so 
seized by him before a Judicia l magisterate in the court of 
law. The authorised of f icer can also se ize the cash memo and 
c red i t memo books, accounts and records of purchase and 
sale of drugs which appear suspicious t o him. 
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iiistribution Channels ; 
On the basis of interviews with executive of 
public sector drug companies it has been found that 
there are mainly two types of distribution networks. This 
classification is not based on the natui^ and categories 
o<f different drugs, but on different types of customers. 
Public sector drug companies divide their drug markets in 
two segments, segment-A and segment-B, 
Segment-A consists of common customers who purchase drugs on 
prescriptions given by the doctors. Such purchases are 
materialised through chemists and dealers of drugs. 
The two types of distribution networks are shown in Fig,6 1 
below 
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Segment -A type of customers get the 
medicines through channel-1 shown in Fig.^.l which show* 
how a drug reaches the pat ients , A drug firm produces 
drugs on the basis of the demand asiiessed by i t s cormnercial 
and production departments and passta the drugs to i t s 
branches or depots located a t different centres throughout 
the country. The tranches pass the drugs on tb wholesalers 
or the stockists at column«I p r i ce , ' ° The stockists or - — 
wholesalers l»ve a l i s t of re ta i le rs to whom drugs are sent 
a t column-II prices. The re ta i l e r or the chemist, on the 
basis of the prescription given by the doctor, se l l s the 
ethical drugs to the pat ients . He is also enti t led to se l l 
over the counter drugs without the prescriJ»tions of the 
doctors, 
Segment-B customers purchase the drugs directly 
from the branches /depots of the public sector drug companies 
on inst i tut ional sales basis , Segment-B consists of the 
following types of customers ; 
1- Government bodies l ike the Central Government Ins t i tu t ions , 
l ike the Railways ^ the E,i>,I, , and State Government Inst i tut ions, 
2- Itospitals and Nurshing Homes, 
3- Industrial Units^ 
4- Educational Insti tutions, end 
5- Share Holders and Eknployees of the Company, at wholesale 
pr ices . 
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Channel-2 shown in Fig, 6,2 shows this type of distribu-
tion network, 
Fig, 6.2 : Channel -2 
Factory 
or 
Plant 
\ / 
\ Branch / 
—A ot / ^ " ^ \ Depot / ^ 
This is used for the purpose of institutional 
selling. But in this type of sale a tough competition 
is faced, because of the sales on a mass scale. Mostly, 
in this case, tenders are invited by the institutions and 
ultiinAtely orders are placed with those submitting the 
lowest priced tenders, ^ ch sales were introduced first 
by the public sector enterpriees. The facilfcy of credit sales 
is mostly given in this type of network. Most of such 
sales are effected on credit terms and the bills take time 
in realisation. 
Main Considerationa: 
There are a number of considerations that 
Influence the decision for the selection of the appropriate 
distribution channel .They are as follows J-
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1) Selling Directly to Hospitals; 
Sales to hospitals constitute an important 
consideration for most of the pharmaceutical houses. Hospital 
purchases are made mostly on the basis of sealed quotations. 
The manufacturers of drugs, therefore, have a tendency to 
quote the prices directly to the hospitals. In this way, the 
profit margin that is available to the company is normally 
competitive. Sometimes, a manufacturer prefers to route his 
sales to the hospitals through a sole selling agent. This 
saves him fipoiii the botheration of collecting payments from 
the institutions that are run by the government, 
2) Selling Directly to Doctors s 
Selling directly to doctors, offers many advantages:. 
1, It helps in introducing new products to the doctors; 
2, It ensures continued brand loyalty for existing as well 
as future products? 3. It ensures a certain fixed volume 
of sales, A product purchased by the doctors is bound to be 
utilized. 
Because of the above advantages, a company may 
offer discounts in the prices of the drugs quoted to the 
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doctors. The difference In price level might fee compensated 
with the savings aiade on the margins given to the 
intermediaries. 
Though pharmaceutical products are ultimately 
consumed by the patients, Ixit the real consumer from the 
marketing point of view is the doctor. He is the decision 
maker about the efficacious use of drugs. The patient gets 
his medicine fronsthe fiospitals, doctors or from retailers 
and chemists on a prescription. He has no direct say 4n the 
matter of the medicines he buys. But 3the may exercise his 
influence by expreomg his reactions to the doctor relating 
to various drugs, A drug which is not favoured by a large nun 
ber of the patients is not likely to be prescribed by the 
doctor, 
3- Combined Chaainel of Distribution! 
Phannaceutical products are sold by the 
manufacturers directly to the hospitals, registered doctors 
or to licensed dealers. The following channels or combinatior 
of them are generally adopted to distribute the drugs in 
market. 
Fig- 6.3 Combined Distribution Channel : 
Manufacturer 
• M/ : 
Wholesaler 
Hi-
Doctors 
Retailers /Doctors 
NI1> 
Pat ients 
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A denaanci and supply matching chart i s given 
below, which shows the di f ferent channels through which 
a drug s a t i s f i e s the ul t imate customer's needs. 
Demand And Supply Matching Channelsi 
Fig.6.41 
People 
J,- Indicates Demanct 
Sickness 
f Indicates Supply Side 
Hospitals 
7K 
Health Need 
Doctors 
Tf-
Dlstr lbutors 
Drug Msiiiufacturer I 
reventive Measures 
People 
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Fig, 6,4 shows the pi^cedure through which the demand for 
drugs, emerges and the pa t ien t approaches the doctors for 
drugs. On the other side the drug manufacturer produces 
drugs and supplies them to chemists and drug dealers and 
simultaneouly approaches the doctor for being prescr ibed. 
In t h i s way the demarwi from the consumer's side and suppl ies 
from the manufactu^rers side are matbhed a t the 
point of the doctors , OTC drugs are those which are d i r ec t l y 
advertised to the consumers who purchase i t without the 
prescr ip t ion of any doctor. 
Dealers* Selection; 
Certain conditions have to be fu l f i l l ed by the deal-
ers to obtain the dealership of drugs, Registerat ion i s necess-
ary to obtain drugs a t dea l e r ' s r a t e s . I t i s granted on four 
bases . F i r s t , the f inancial conciltion of the t r ade r i s taken 
in to consideration, which i s t i e n»st important fac tor . The 
f inancia l conditions of the s tock i s t , who want to be an 
agent of a public sector drug en te rp r i ses , should be sound 
enough to survive in the d i f f i cu l t per iods . Secondly, the 
reputat ion of the t rader i s assessed, Cijite na tura l ly t h i s 
has a d i r ec t bearing on the success or fa i lu re of a business. 
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Thirdly, i t i s checked whether or not a p a r t i c u l a r area 
i s a po ten t ia l market for the product. Fourthly, the 
exis t ing turnover of the dealer has to be known and in 
addit ion to the exis t ing business, the expected annual 
sales of the dis tr ibut^im are estimated before granting 
him a c e r t i f i c a t e of dealership of the company.Facts 
regardintt a l l the above are inves t ig- ted and dealership 
i s granted to him i f they show an overa l l favourable p ic ture 
of the appl icant . 
Credit Policy! 
Credit policy* of a public sec tor drug companies 
i s concerned with the c red i t t ransact ions of the company 
with I t s customers , Credit sa le i s offejred to customers 
to have a be t t e r turnover, in p a r t i c u l a r to those tha t 
make bulk purchases l i ke t t e i n s t i t u t i o n s , Disoissions with 
the senior executives in public sec tor drug en terpr i ses have 
revealed tha t the average col lec t ion period re f lec t* both the 
credi t policy and col lect ion effor t of a company,There are 
alwayr- some inherent delays in credi t col lect ion which create 
the problem of the ad;Justment of f inal accounts of the company, 
Interviews with the executives have fur ther 
disclosed tha t companies generally f a i l to r e a l i s e the 
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credlx within the prescribed limits for certain reasons, and 
that the average collection period found in the companies 
sampled differs on the basis of their product lines and 
efforts of collection. Companies which have substantial turn-
over from consumer product lines seem to be strict in their 
credit policies as their avera;;e collection period is between 
55 to 30 days. As against this, companies which have industrial 
product lines seem reluctant to pressurise their customers 
lor recoveries. Their average collection period falls between 
60 and 70 days. Certain companies have average collection 
period of more than 75days, This is «only because major part 
of their sales consist of exports, and oveneas transactions 
take longer period to materialise. 
Distribution Costs : 
Distribution costs include total expenditure 
incurred on transportation, commissions payable to distribu-
tors and administrative overheads on branches , Trensport&tion 
cost includes packing and forwarding charges. Commission 
payable to distributors include all the expenses incurred 
by the authorised distributor of the company and all other 
outstandin expenses met with during the course of service. 
Branch expenses include the salary of the staff at branch 
offices, discounts and rebates offered by them vX\ and all 
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during the years 1931-82 , 1982-83 , 1983-84 , 1984-85 and 
1985-86 was 3.2, 3.5 , 4.3,3.9 and 4,3 per cent respectively. 
The break-up of the distribution cost is not available 
because itemwise records is not maintained by these companies. 
Only the total cost of distribution is recorded in books 
of accounts of the companies sampled for this study. 
Summary t 
Promotion is a key element in marketing 
strategy of a business concern. It is the process of 
establishing a communication system to develop the 
corporate and product image among the middlemen, the 
customers and the common people fits aim is to cormunicate 
the knowledge about the con^ jany, its objectives, activities, 
products, prices and policies. In marketing terms it aims 
at conveying to consumers the three elements of the 
marketing mix, Prc»iotion in drug industry comprises 
activities such as visits of medical representatives, 
mailing of literatures directly to doctors, advertising 
in medical journals, arranging medical film shows and 
presenting gifts and noveljty Items »to doctors, 
A break-up of promotional expenditure in Indian 
drug Industry given in Table 6,1 shows huge amounts of 
money being spent on this item by drug MI companies in 
India , Studies carried out earlier show that increased 
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by 
expenditure i s being incurred/ the companies under the 
head of publicity and advertising. 
Research and Development activity in the 
drug industry is of parama*nt., importance, Public sector 
drug entejT)rises have made notable contribution towards 
research and development activity. But when this is 
Compared with the development activity of their counterparts 
in the Western countries, its contribution appears insigni-
ficant, 
A committee known as Working Committee w-s formed 
to go into the details of the working of different segments 
of the drug Industry, The Committee, after sn indepth 
analysis of the programmes for expansion and development 
undertaken in this industiy, has identified areas of R&D 
which need to be given due attention. 
The basic objective of a distribution system is 
to transfer the final product from the place of manufacture 
to that of consumption. Decisions which are concerned with 
matters such as the type of distribution network to be 
adopted, the intended market coverage, the cost of trans-
PDrtation, commissions and credit terras for various 
middlemen, constitute the overall distribution policy of a 
company. 
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On the basis of interviews conducted *ith the 
executives of public sector drug companies it can be 
said that there are mainly two types of distribution netv.orks, 
» 
throuGh which a public sector drug enterprise passes its 
products to the patients. These two have been categoricsfd 
as Channel- 1 and Channel-2 , Credit policy of the public 
sector companies is concerned with the credit transr.ctions 
of the company with their customers. This system is mostly 
applicable to bulk sales like institutional selling.. The 
cost of distribution includes thtel expenditure incurred 
on transportation, commissions payable to the distributors, 
administrative overheads and expenses on the branch offices of 
companies. Transportation cost includes packing end forwarding 
charges. Commissions payable to distrilnators may include the 
expensGss incurred on distributors , and branch expenses 
include salaries of the staff and all other expenses incurred 
by them for mointainin the goodwill of their company, 
A recent study has revealed that the distribution 
cost of the drug companies, other than those in the public 
sector, ranges between 9#5 per cent and 16 per cent of the 
sales turnover, Neverthless, distribution ccost in public 
sector drug enterprises has been lower than that in other 
sectors of the economy, because of institutional sales by the 
former. 
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C H A P T £ R - 7 
P R I C I N G P O L I C I E S 
Introduction^! 
In the area of marketing, effectiveness of 
decision making procecs is most crucial because such decisions 
usually reflect trends and conditions prevailing in the market. 
Pricing decisions, being one of the important aspects of narketing 
msnagement, are vital for a business because they determine 
to a great extent the turnover and profitability of a concern. 
They are also crucial since customer satisfaction is greatly 
influenced by the pricing decisions of a ccwjpany, 
Livesey says j • It is a truism that profitability ts affected 
core directly by pricing decisions than by decisions relating 
to any other marketing variable. It follows from this that the 
pricing plan should be an integrr^ part of the marketing plan 
and hence ultimately the corporate plan," 
Oxenfeldt Opines, "^he corporate pricing 
fijnction within a decision making structure is a very complex 
process. Many components must be integrated and mana.^ ed as a 
unit of the firm is quickly to cppitaliae on its pricing opportu-
nities",^ 
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The above citations shoxv the importance of the 
pricing decisions for a firm, compared with the decisions 
rela ing to other marketing variables, in capitalising 
the opportunities available in a competitive market. 
Pricing strategy: 
Pricing strategy refers to practical application of 
pricir^ i^j decisions. Pricing policies are the general rules 
set by the management of e concern to achieve greater share 
of the market, taking into consideration the cost structure 
of a product, its market demand, price of the available substi-
tues, and the state of economic environment, whereas pricing 
strategy involves translating these rules into practice, 
Qindiff and Still opine, "Pricing strategy is adepta-
tion of pricing policies individualised tellorings of pricing 
decisions to fit particular competitive situations encountered 
by specific products, "^  
Kotler says^"pricing strategy is the. task of defining 
in initial p"ice range and planned price movement through 
time th.-jt the company will use to achieve its marketing objectives 
4 in the target market," 
Oxenfeldt, however, points out^ It is a well known fact 
that pricing decisions should be tskeu in conjunction with 
the decisions on other elements of marketing? mix. This 
implies that a company's pricing discretion may thereby be 
constrained,-' 
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The existence of internal constraints on pricing 
decisions has been highlighted by Oxenfeldt in his analysis 
of the choices facing U,S, producers in the early phase* 
of market's development, 
Joel Dean avers, "A coiipany is established in view 
of some objectives. In some cases these corporate objectives 
can be translated directly into pricing objectives which has 
a link with the short-run or long-run profit maximisation. 
In the long-run profi t maximisation objective, a firm should 
set e i ther a high in i t i a l price which i t would subsequently 
lower in the face of increasing competition, or a low i n i t i a l 
price in order to deter potential competitors and establish 
a high market share "^, He makes a dist inction between a *skimming* 
and s 'penetration* price policy while disussing the pricing of 
pioneer products. 
I t follows from the above that pricing strategy is 
adapted to determine the price of a product which sui ts the 
capacity of the average customer. Pricing decisions should 
be taken in conjunction with the decision on other elements 
of the marketing mix. This i s a complex process and a number of 
constraints are faced by the decision makers when a pricing 
policy is translated into actual practice to achieve the 
objectives of the company. 
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Pricing of Drugs In India: 
Prices day an important role in the regulation 
of different aspects of economic activity. The government, 
the management, and the society are involved in decision 
making regarding prices. In 1962 government controlled 
the prices of drugs as an emergency measure, A controversy 
arose on this issue which has not been settled so far. 
But the government took a firm decision on this issue. It 
issued a Drug Prices Control Order in 1970, This order v/as 
a me.-'sure to keep prices of drugs within reasonable limits. 
The m.anuf!?ctirrers of drugs ane dissatisfied with the 
existing pricing mechanism, Tb'is, the pricing of drug in 
India has become, crucial and It requires a continuous monitoring; 
and reviev, of the policies both on the part of the government 
as well as the manacements. 
As far as the customers are concerned, they are 
dissatisfied due to the fact that they Cire being sandwitched 
between the govemmtnt and the doug aauMtxi manufacturers. The 
manufacturers aim at earning maximum profits, but the government 
intervenes end regulates the prices in the intei*est of the 
society. Since the introduction of Urug Price control Oixier 
1970 companies have been pressurising the government to raise 
the drug prices. They also wont a reduction in the costs of 
canalised raw materials and other overheads to allow them to 
7 
increase their profit margins,' 
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Pricing is often a critical factor in the successful 
operation of 'rug companies. Although the basic pricing 
ingredients are the same for oil the fims (cost^  com-etition' 
legal pressures, demand, profits and customer behaviour)^ 
the ootiraua. six of the-^ e factors varies according to the 
nrture of a product, sensitivness of the market and corporate 
objectives of the drug industry. Thus, the job of a marketing 
management is to evolve a pricing str tegy that could meet 
the needs of ch:)nging, times , In con^onnity with the recommendatioi 
ions of the Hathi Committer, the ^ o^verranent of India formulated 
a New Drug policy in 1978,In order to pX^e effect to pricing 
provisions of this new policy, the Government issued the Drugs 
Price Control Order on 31st March, 1979 (DPCa-1979) replacing 
the earlier Drugs Control Order-.i970,As envisaged under the 
New Drugs Policy, the order brinjs under control three 
Categories of formulations aescribed as category I, II and III 
formulations. The DPCCLI979 provides for ceiling m^ rlc-up on 
ex-factory cost of production of c^ 'tegoiy I at 4o per cent, of 
category II formulations &t 55 per cent and of category III 
formul tions at 100 per cent. In respect of the leader prices, 
based on prices fixed by the concerns that are efficient 
and prosrerous, The.:>e were to be accepted by other manufacturers, 
even in small scale sector , as the ceiling prices of those 
formul'^ 'tions. Prices which were lower than the leader prices, 
and which were -frozen under the provisions of the New Drugs 
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Policy, were ellowed to go up to the leader price level 
through an amendment in the DPCO-1979. So prices can now 
go up to the leader price level only of those formulations 
which have the same compositions and ©re pecked in the same 
manner as those of the notified leader prices. 
Small scale units with an annual turnover not exceedings 
fe. 5 million continue to be exempt from the requirements of 
obtaining Goverraaent's approval for the prices of their formu-
lations except for iteas with fixed leader prices, which are 
the ceiling sale prices for these units also. 
Under the aboise-mentioned ordinance, all the bulk 
drugs which were used in the production of the price controlled 
formulations have been brought under price control. In this 
respect, DPCO-1979 is an improvement upon DPCO-1970, under which 
firm could fix prices of bulk drugs which have not been catego-
rised as essential under that order r-nd were obliged to seek 
Government approval only when they sought to increase these 
prices. 
Drug Price Control Orders-1970 and 1979 I An Assessment 
The Drug Price Control Order-1970(bpC0-197Q) empowered 
the government to exercise price control over the drugs, bosed 
on certain rules and fonnulas. It divided the bulk drugs into 
278 
two main heads viz,»essential drugs" and •others'. For essentlsl 
bulk drugs, prices were fixed and for other drugs the prices 
were allowed upto the levels prevailing inanediately before the 
promulgation of the order. Prices for formulations were based on 
two norms j 1, Ex-Factory cost : This was the sum of the raw 
matericls cost, conversion charges, packing materials cost 
and packing charges. Conversion and packing charges were subject 
to certain prescribed norms, 
2« Mark-up i This was the price marked upon the packets of a 
medicine, 
- According to the f i r s t ru l e for the pr ices of formulations, 
a l l formulation were allowed a ffirrk-up of 75 per cent on the 
t o t a l ex-factory cost without any p ro f i t c e i l i ng , 
- In accordance with the second r u l e , formulations based on 
eesent ia l drugs were allowed 75 per cent gnd while others 
could have a mark-up not exceeding 150 per cent with a prof i tob-
i l i t y t e i l i n g of 15 per cent pre- tax p rof i t on sa les turnover. 
The l^rug Price Control Order-1979, was promulgated in 
the month of Apri l , 1979» replacing the e a r l i e r order i , e , 
DPOO-1970* This order d i f fers to some extent not only from the 
e a r l i e r order but also from the approach of the Hathi Committee, 
I t i s based on the Idea tha t d i s to r t ions in the drug industry 
are not due t o r i g id pr ice control alone but t ha t the cost 
s t ruc tu re i s a lso responsible for causing d i s to r t i ons in 
o 
pharmaceutical industry. The Indian drag industry, like 
some other Industries, suffers from a high cost structure which 
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is attributable to several reasons. In some Cases the 
technology is unsuitable and obsolete. In others the 
scale of output is too small to be economically viable. 
Some of the essential materials which are used in the 
production of drugs and pharmaceuticals are available at 
twice or thrice the prices prevailing abroad. High rates 
of duties, including the heavy custom duty, on the it«ms 
which are not intended to the produced within the country 
in the immediate future also have contributed to the high 
cost structure. 
According to, this order, the selling prices of the 
bulk drugs and formulations are to be fixed in the following way 
Bulk Drugs : The order divides the bulk drugs Into three 
categories ; Viz. I, II and other category. The manufacturers, 
according to it, are ~llowed to enjoy a I'eturn on post-tax 
worth upto 14 per cent on the bulk drugs used in the production 
of Category 1 and II formulations while in the others the 
ceiling is upto only 12 per cent on the post tax value. Bulk 
drugs which have been evolved with the R & D efforts in India 
and are not being produced elsewhere are not to be brought 
under the price control upto 5 years. 
Formulations : 
Pricing of the formulations, according to DPCO-1979, 
are based on the two ccsnponents- ex-factory cost and mark-up. 
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Ex-factory cost, such as raw meterial cost, conversion cost, 
cost of packing materials and pecking charges, has to be assessed 
acoordini^  to certain prescribed nonas, 'Hhe martt-up is not 
to exceed 4o % for category I formulations, 55 per cent in 
case of Category II foraiulations and upto 10096 in respect of 
category III formulations. The rest are decontrolled drugs. 
Leader Pricet 
This is a limit imposed on all manufacturers in the 
drug industry. This price is fixed by the government on the 
basis of the costs incurred, in the production of formulations 
in categories, I,II and III, by an efficient and economically 
prosperous company. This is the ceiling for ell the manufsc-
turers producing the same formulations, including those in the 
small scale sector. 
Profitability Ceiling i 
Another restriction laid down by DPCO-1979 for the 
manufacturers of drugs is that they should not exceed the 
prescribed limits of profitability laid down for them. The 
profit cilling varies between 8 and 13 per cent for the 
formulations for different categories. As a result, the 
pre-tax profit on formulation acrlvity or responding units 
gradually declined from 8*8 per cent in 1978 to 7*29 per 
cent in the year 1979 and further to 4,25 per cent in the 
ye?r 1980, 
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Impact of DruK Price Ck3ntrol Orders -1970 and 1979 l 
The impact of the Drug price Control order I970 was 
analysed by the Hathi Committee, In its report, the Committee 
concluded that the rst.-^.o of pre-tax profits to the sales 
turnover had declined, since they were put under statutory control 
from 15.#7 per cent in 1969-70 to 8,53 per cent in 1972-73. 
So, the return on investment was not commensurate with the 
size of the operations. This trend impelled some manufacturers 
either to diversify or to discard the production of some 
important drugs. 
The DPCO-1979 could not be implemented till the end 
of the year,1980. Revised prices for different categories of 
formulations began to be fixed in 1981-82, Though the order 
was passed in 1979^ it took nearly a year and ha]f to put 
into practice. During this period many signific nt changes 
have been noted which may be stated as under t 
The Government has announced leader prices for many 
product based on the performance and cost structure of 
effecient producers. Though the leader prices have been enforced 
officially, they do not seem to be rational. The cost struc-
ture of different firms is not necessarily the same. It 
varies, depending upon several factors, such as the intensity 
of labour problem, power cuts, cost of inputs, level of 
technology etc, A proper mix of these factors wculd determine 
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the coat performance of d i f ferent f i r a s . The claini t h ? t 
not i f ied pr ices of row m-rterials and prescribed norms 
for conversion and packing charges could lead to a uniform 
cost s t ruc ture i s not tenable in the l i gh t of the pbove. 
I t i s evident from the survey conducted by Narayana < tha t 
the sales of formulations belonging to the categories with 
a r ig id pr ice control decreased during the years 1978,1979 
and 1980, while those of the decontrolled category increased 
during the same period. The value of sales in the f i r s t two 
ca tegor ies , under the D?C0«1979» declined from %,1.384 lakhs 
to &,1,376 lakhs gnd from ife. 5,159 lakhs to %• 5,041 lakh 
respect ively between 1978 and 1980. This w?s mainly due t o 
of 
diminution in sales drugs in category I and I I formulations. 
The sa le v - l u e ^ f the category I I I and decontrolled formulations, 
however, increased. In the cnse of category I I I formulations, 
the increase was of the order of 26 percents while ths Sole 
Value 0* decontrolled formulstions increased by 53 percent 
during the above period. 
The ex-factoi-y cost , which includes the raw«.naterial 
cos t , conversion cost , cost of packin£ mater ia l and packing 
charges, rose by 30,3 per cent between 1976 and 1930, from 
fis. 171,09 crores in 1978, to Rs. 223,01 crores in 1980. 
On the whole, i t Bay be said tha t the p r o f i t a b i l i t y 
trends in the companies producir^ drugs i s not s a t i s f ac to ry . 
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As a result the production of drugs, particularly of bulk 
drugs, has decreased. A detailed analysis of the profitability 
trends of bulk drugs and formulations is given belowi 
The audit reports of 10 bulk drug manufacturing units 
were analysed by NCAER £n 1980, The totalj costs of the 
manufacture of the drugs produced by the companies are 
represented in the Table given bftlow t 
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T A B L E »7«1 
Cost and P ro f i t ab i l i t y of Bulk Drugs, 1930 
Items Amount 
Raw Materials 
Staff Expenses 
U t i l i t i e s 
Works overheads 
Repairs & Maintenance 
Royalty 
R & D 
Depreciation 
Other overheaas 
Other Expenses 
TOTAL 
Less a) Credits from sa le 
b) Other c redi t s 
c) Captive consumptio 
d) Balance of opening 
e) Sales r e a l i s a t i o n 
of 
(fe, in crores 
23.6628 
2. 2193 
3.8290 
3.5549 
2.3435 
0.0979 
1.3115 
1.3402 
2,8613 
1.4553 
42.67§7 
by-products 
Net cost 
n 
& closing stock 
?8,5172 
) Shares 
0.0696 
0.7026 
41.9035 
28,3900 
1.5562 
8,5710 
( in%) 
55.5 
5.2 
9.0 
8.3 
5.5 
0,2 
3.1 
3.1 
6.7 
3.4 
100.00 
Loss 3,3863 
Source : Economic Times, K.Delhi Survey by NCAER, Sat ,Supp, 
13 Aug. 1983. 
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The above Table shows that the cost of raw materials 
accounted for 55.5 per cent of the total manufacturing cost. 
The second major item of expenditure was the cost of utilities 
which accounted for 9 per cent of the aggregate cost. Taking 
the money received from the sale of by-products, into account 
t.ie net cost of bulk drugs amounted to Rs.t 41,90 crores. The 
captive consumption appropriated 68 per cent of the manufact.ring 
cost. These 10 companies recovered another 20 per cent of the 
net cost by sales realisation. As a result, the loss suffered 
by these companies on bulk drugs came to approximately 8s,3.39 
f rjres. 
As far as individual companies are concerned, only 
3 out of 10 could make profits and the remaining 7 companies 
suffered losses. It is reported that the manufacturing costs 
of individual bulk drugs are much higher in India in 
comparison with the cost of imported bulk drugs. The m in 
factors responsible for this arej the high cost of drug 
intermediates, uneconomic plsnt-sizes, use of obsolete 
technolo/y and lo-js/ labour productivity. 
It can, therefore, be said that the rofit performance 
of companies deslinij; in the production of bulk drugs is not 
Satisfactory which may be due to the rigid price control 
exercised by the Government, Table 7.2 shows the break even 
m rk up for different categories of drug formulations. 
T A B L E 7.2 
Break-Even Mark-up 
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Item 1978 1979 1980 
1.Ex-factory cost 17,109 19,639 22,301 
(RS. in lekhs ) 
2,Expenses out of 
mprk-up 10,834 12,570 13,940 
(Hs,in lakhs) 
3 . Break Even 63.3 64.0 62.5 
Mark-up 
(In %) 
SOURCE : Financial Express, N.Delhi, Nov, 15,1983. p .5 
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The expenses met out of the mark-up were f!s, 10,83^ 
lakhs or 63.6 per cent of the ex-factory cost In 1978,which 
rose to Rs. 12,570 lakhs or 64,0 per cent jh 1979» but declined 
t o 62,5 per cent in 1980, The Government, through i t s DPC0-.1979, 
has permitted itO% mark-up for category I , 55% mark-up for 
category I I and 100?6 for category I I I formulations to meft 
the post manufacturing expenses while the actual expenditure 
incurred by the companies in th i s regard, i s generally more 
than the allowed mark-up. 
For an in-depth ana lys i s , the companies are being 
divided into two broad classes (1) on the bas is of the s p l e s -
turn-over and (2) and on the basis of contribution to 
production made in categories I , I I , I I I formulations and 
those in the decontrolled category, 
1) The brerk-even mark-up of the companies with sa les turn-
over of &, 30 crores per annum was 61% in 1980 as compared with 
79.6 ^ for those in the range of Rs,6 xaare. crores to Ife. 10 crores 
and 73.S^* i o r those in the sa les turnover of l e s s than fe,6 
crores . Therefore, the p r o f i t a b i l i t y of large companies i s 
higher th&n •. tha t of the fcmaller ones, 
2) I t i s implieu tha t due to comprrtively lower mark-up for 
categories J and I I (i ,e,40% for category I and 55?& for 
category. I I) , they con be marketed with minimal promotional 
ef for t , The report of NCAS^  survey shows t h s t the break-even 
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mark-Up of the companies producing greater qur.ntities of the 
category I and II formulations, did not significrntly differ 
from those which were more keen on the procuction of III and 
decontrolled category formulations. However, the profit 
performance of the producers of the first two categories w s 
better compared to with th^  t of the latter. 
Pricing Principles in Public Sector Brug Companiest 
This is a controversial issue. Opinions vary on this 
10 
issue for example, Ranji Sahai giving his views on the , 
ideal pricing policy for public sector , soys that pricing 
policy for ublic sector should be such that aS a whole it 
plays a vital role in accelerating economic development, tht 
this policy may vary from product to product, from industry 
to industry and from one situation to another, and that the 
decision, whether public sector should make profit or not, 
is to be taken by the parliament, 
11 Murti puts forward a different views on the 
pricing principles. He asserts that profit maximisation is the 
guiding principle in the general theory of pricing. But , he 
says, this may lead to the exploitation of consumers, which is 
to be avoided by the otate, and hence the 'Marginal Cost Pricing' 
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Theory end 'Ko Profit Wo Loss* theory have been put £or^--rd. 
According to him the chief defect of this theory is that it 
does not cover total costs, Murti argues th&t the pricing 
policy should be such thpt it promotes the growth of the 
national surplus, theoeby accelerating the rate of economic 
growth. So he advocates the abendonment of the principle of 
*No Profit No, Loss* as the supreme criterion for the pricing 
of the products of public enterprises. 
It has alSD been sug£ested that for evolving n 
appropriate pricing policy, particularly for public enterprises 
which are opex'ating in monopoly or semi-monopoly market 
conditions, it is necessary to take explicit note of (l)market 
structures of the products (2) the nature of product mix and 
(3) the customer composition. Identification of several other 
aspects is required and they should be kept in mind while 
formulating the pricing policy. These are the essential 
requirements for the formulrtion of a pricing policy, *'• 
13 Agrawal points out that management of public sector 
undertakings have, by and large, adopted a cost -oriented 
pricing policy but they also believe that competition and demand 
factors should be given proper weightage. He says that break-even 
technique is used by these undertaking sparingly, end competitive 
parity' and *what the traffic could bear'techniques are 
also being fallowed by them though the norms of pricing prescribed 
by the government are given top priority. 
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The pr ic ing p r inc ip les t ha t are formulated for 
public sector drug industry should be such tha t on the one 
hand they are beneficial to the manufacturers and on the 
other they are within the purchasing power of the consumers, 
'Maximisation of Profi ts o r 'No Prof i t No Loss' o r 'Marginal 
Cost Pricing • or ' Surpluses to the Nation ' theor ies should not 
be applicable to t h i s industry. Pricing in the drug industry 
i s a complex problem, since i t depends upon aay^factors which 
affect the demand and supply of items produced by the phamace-
14 
u t i c a l industry. 
I t i s due to the apathy of those who are a t the 
helm of a f f a i r s of public sector drug companies t h a t a 
r a t i ona l pr icing policy for dnjgs and phannaceuticels has 
not been evolved. The pr ic ing policy has therefore , bectxse a 
t a rge t of c r i t i c i sm, Tlat and again various companies belonging 
to t h i s sector of the economy have c r i t i c i s e d what they 
consider uncalled for measures in tfcis respec t . The matter 
needs immediate and pr<Mspt a t t en t ion of a l l those who ere conceraed 
with the determination of a s tab le pricing policy in respect 
of drugs and pharmaceuticals. 
The prevai l ing pr ices of bulk drugs and formulations 
are governed by the Drug |i Prices Control Order«1979•National 
Drugs and Pharmaceutical Development Coiincil (NDPDC) baa been 
entrusted with the respons ib i l i ty of seeing t h a t the pr ic ing 
orders of the government are complied with. Crit icism of the 
pr ic ing of bulk drugs and fonaulations has impelled the 
NDPDC to review the p r i o s s . This task has been entrusted to 
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to a working group - for formulating a suitable 
pricing policy which is acceptable to different interests 
connected with the industry. 
Prices of 24 tailk drugs were revised and those 
of 8 bulk drugs were fixed for the first time in February, 
1984, Besides, prices of about 9,000 formulations and 
leader prices of about 700 fonaulations belonging to categories 
I,II and III had been either fixed or revised by the end of 
February 1984, 
Determinants of Pricing Policy i 
Pricing is one of the crucial Jobs of Managementg 
Charging a price for a specific drug does not appear to be 
a dlffioilt task but series problons may arise due to the 
lack of knowledge of competitive situations^ legal procedures 
and behavioural factors involved in it. There are & host 
of faetors«.econ(»aic, legal and behavioural which should be 
taken into consideration while formulating a rational 
pricing policy for public sector drug enterprises. These 
factors aBt discussed belows 
Competitive Sltuatloni Joel Dean'^has identified three main 
kinds of competitive situations that face a particular 
product, f. «^ may arise where the product has % 
2.92 
(1) i^ l^a sting dlstlnctlvtnessj 
(il) P«nshabl« distinctiveness and 
(111) little distinctiveness. 
Distinctiveness * means the degree to which a 
product can be sold above or below the competltirs * prices 
without disrupting these prices or their sales, A product's 
distinctiveness varies with the stage of product life-cycle. 
During the growth stage of the product aarket, demand tends 
to Increase, concerns earn abnormal profits In this stage 
because of absence of close subsliaites and of competitors. 
This situation is nearer to monopoly bpt how long this 
situation will prevail in the market depends upon the nature 
of the product. For Instance, malaria used to be controlled 
by Chloroqulne but it could not have a'lasting distinctiveness.* 
Its producers started losing the market share when other 
antl<4ialaria drugs belonging to sulpha group such at Ketakelfln, 
Malaxin etc. entered the market as close substitutes and 
with least side effects. Thus the lasting dlstinctlveniBS 
competitive situation of a product favour those producers 
who are efficient in innovations. This situation may be 
tackled effectively by those companies which lay great emphasis 
on R & D activities, 
A product which loses its 'lasting distinctiveness' 
descends to the category of'perishable distinctiveness'. 
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In such as situation proaotlonal pressures of dlff«r«nt 
coBipanies pull the market shares In their direction* 
Intensity of coapetition leads to the situation of 
monopolistic ccKBpetitlon and the product reaches the 
Baturity stage of Its life cycle. In this situation prices 
for the product stay stagnant with very little flexibility. 
Other factors, therefore, becoae active such as product 
differentiation, quality cnntrol either through Isprovenents 
for gaining a favourable public opinion or by reduction in 
the quality specifications to increase the sargin spread 
between cost and price. 
The 'perishable distinctiveness* situation Is 
unethical as it affects the consuaers adversely,'Little 
distinctiveness* is that condition of a product where it 
enters the declining stage of product life cycle. There 
reaialns no incentive for increasing its production except 
to meet the residual deeand of the drug aaiicet. To protect 
the Interests of the consuaers the govemaent took certain 
steps such as the abolition of brand names, strict watch 
over the quality of drugs and fixation of reasonable prices. 
To achieve these objectives a Drug Policy was evolved in 
the year 1978, and later a new Drug Policy was formulated 
by the Government in December, 1986 which alms to correct 
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th» iabalancefi created by earlier policleg. 
Legal Procedures t 
Price deterainatlon of both bulk dnigs and 
foraulations is baaed on certain guidelines. The Central 
Govenaent fixes the maximum sale price of an essential 
bulk drug which is an unprocess«d pharmaceutical dhesical 
and is processed into formulatiozis. Every importer of bulk 
drug is required to report to the Central Goverrmient within 
4o days of its import,its landed cost and its selling 
price. Thereafter he is not allowed to increase its selling 
price without the prior approval of the Central Government. 
Similarly, every firm which starts manufacturing a new bulk 
drug has to inform the Govenwent about this within 14 
days of commencement of its production. 
The Central Government has the power to direct 
any manufacturer to sell the bulk drugs to formulators for 
the preparation of a consumable drugs at fixed prices. 
The retail price of a foraulation has to bt calculated in 
16 
accordance with the following formulai 
(1+MU) + ED 
RP« { m • C C + P C ) x 
100 
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WhereI 
RP • stands for retail price 
MC - stands for material cost (including the coat of 
drugs and pharmaceutical aids used ) 
CC . stanAs for the conversion cost worked out in 
accordance with nonas spe«ified by the Govern-
ment from time to time, 
PC • stands for packaging cost 
MU * stands for mark-up 
£D - stands for excise duty* 
The retail price of the indigenously prepared 
formulations is determined according to this formula. But 
in the case of an importer of a formulation, MU+CC+PC 
can not be more than the landed cost of the formulation. 
There are certain manufacturers who neither import formul-
ation, aor do thty prepare them indigenously but simply 
purchases the drugs in bulk and Ji'epack them for sale. In 
such a case the actual cost incurred upto the repacking woultt 
be the sei:if^ price subject to nuch profit ceiling as may 
be arrived at on the basis of the fonnula given above. 
As far as MU (mark-up ) is concerned, it is the 
price printed on the container and on the different packs 
of medicines. It includes the distribution cost, outward 
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freight^ promotional expenses, aenufacturerb Mai^in and 
trade conmisslon and Is not to exceed 40,55 and 100 per 
cent for fornulations specified in categories I, II and 
III of the third schedule respectively. Further, there 
is a concept of leader price which is fixed by the Central 
Qovemaent, The manufacturers cannot sell any drug at a 
price exceeding the leader price of that formulation. 
Every manufacturer of categories I, II and 
III formulations intended for sale has to furnish to the 
dealers a price list containing the manufacturer's price 
at which fonaulation is to be sold to the retailers, 
including excise duty and retail price at which the 
formulation is to be mertEeted to the customers. This list 
has to be furnished to the dealers in the following manneri 
(i) In preparing the list every manufacturer has to calculate 
the retail price of a formulation mailceted by him , in 
accordance with the rules laid down in this reppect. They 
are further required to sulKoit the list to the Central 
Goverament alongwith the details of the cilculationa, 
ii) The price list, accompanied by details of the calcu-
lations has to be submitted to the central Government within 
one week of its transmission to the dealers, 
iii) While introducing a new formulation in the martiet, the 
manufacturer has to intimate the Central Government about 
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the nature ot the product, whether it is to be imported 
or prepared indigenously and expected time of the arrival 
of product in the market. This intimation ought to reach 
the Central Government within two oontha from that date 
on which he has furnished the price list to the dealer. 
The Central Government has the power to fix 
manufacturer's prices, retail prices and trade coamission 
for certain formulations. If on the scrutiny of the price 
list and details of calculations furnished to it, the Otntral 
Government is of the opinion that the retail prices of the 
formulations have not been fixed in accordance with the 
rules laid down, it m:y refix the retail price of such a 
formulation and communicate this to the manufacturer who 
is required to revise the price list forthwith and send 
the - revised prices to the retail dealers. 
The retail price of a formulation, once fixed 
and enforced in accordance with the provisions of this 
order, cannot be revised before the expiry of one year 
except with the prior approval of the Government, 
A firs marketing a number of formulations may 
submit to the Central Government, for approval, a scheme 
of prices covering all its formulations. It has to price 
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Its drugs In such a way that iti overall profit befor« 
taxation doas not exccad 15?^  of Its aaXea tumovar. For 
this purpose tha price list alongwith other details has to 
be aubolttad to the Govaamient, If approved, It will becona 
a valid price list for the fomulatlon* aarlcetad by the flra. 
No manufacturer or Importer Is allowed to sell 
any formulation to an IntexTaedlary at a price exceeding 
the mamifacturer*s price shown In the price list plus local 
taxes, If any. 
The producers of drugs face certain legal constra-
ints regarding their pricing decisions. They hardly get the 
required quantities of raw materials because of the canalised 
system of supply through the 3TC and II1*L, which also involves 
increased costs. The Hathi Coomlttee has pointed out the factors 
r»aponslble for unjust prices of drugs to the consumer*. It has 
stated that the drug Industry, like many other Industries, 
sttflera from a high cost structure which Is attributable to 
several reasons. In some cases the technology la Improper while 
in others the scale of output is too small to be economically 
viable. Some of the essential materials which $go into the 
production of drugs and pharmaceuticals are available at high 
prices. High rates of duties, including heavy custom duties 
on certain Items also, contributes to the high coat ataucture. 
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According to a survey, th« ex-factory cost of fonnulations 
which included material cost, conversion charges, packing 
materials cost and packing charges, increased from Us, 171.09 
crores in 1978 to 8s. 223.01 crores ln1980,^^ 
The policy of resale price oalntenanct adopted 
by GDvemment brings down the profi ts of aanufactarers. I t 
permits prof i tabi l i ty ceiling on pre»tax return on sales 
turnover of formulations between 6^ and 13?6 .According to 
the survey report of NCAER the pre-tax profi ts on fonaulation* 
declined fro» 8,8% in 1978 to 7,29 % in 1979 and went down 
further to 4,25?^ in 1980. Table 7,3 presents data concerning 
the sales value of categories I , IX,III and decontrolled 
fomulations for the years 1978, 1979 and 1980, 
JOO 
T A B L E 7.3 
Sales Value a t Manufacturers Retail Price 
( lis. In lakhs ) 
DPCO Category 1978 1979 1980 
Aaount Share Aaoimt Share ilnount Share 
I 1384 k,5% 1477 ^*2% 1376 3.6% 
I I 5156 16.7% 5169 14.8% 504l 13.2% 
III 2(yr2D 67.1% 23756 67.8% 26134 68.6% 
Decontrolled 2630 11.7% 4613 13.2% 5547 14.6% 
TOTAL 30893 100% 35015 100% 38097 100% 
Source j The Economic T l a e s , 13 August, 1983f p * I I I . 
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The data In above Table shows that the total share 
of controlled formulations of categories I,II and III 
declined fron 88.3% in 1978 to 85,4% in 1980. The sales value 
of category III and decontrolled foraulatlons increased by 
19 
1,5% and 2,9% respectively during the sane period, ' 
In the light of the above factors the fomulation of 
pricing strategy becooes a difficult task to offer a viable 
solution to the problem,The drug industry is on the one hand 
termed as a *ltfe line • one and on the other, it does not en;Joy 
the desired autonomy in formulating its own pricing policies. 
Behavioural Factors t 
Behaviour of the mtddlaaen towards the manufacturers 
and consumers may have a considerable impact on the success of 
a policy. Middlemen are very keen on their margin of profit. 
Traders generally promote a drug for which they are given a high 
margin. They may even substitute the drugs of companies which 
benefit them more in terms of trade commissions with those 
drMgs of other companies. Doctors also prefer to prescribe, 
drugsfor which they receive free samples. 
In Government hospitals, bulk purchases of medicines 
and made directly from the manufacturers. Hospital authorities 
Bay be more oriented to their personal inter-sts rather than 
the interests of the patients. The present system allows them 
to deal with manufacturers of l«w quality products who tffer 
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lowtr prices \tfith an attractive package of personal incentives. 
In this process, manufacturers producing quality products fail 
to get ccmtracts from government hospitals because of the 
absence of these incentives. Should they Ignore the requirement* 
of pricing strategy to ettract that segaent of market end 
indulge in such malpractices? It is difficult to answer this 
question in *yes» or 'no* ,It requires a careful analysis of 
all the factors which have an important bearing on pricing 
strategy so as to determine a desired plan of action. The task 
for fixing the prices of drugs is a difficult one, The cost of 
raw- material Is Increasing day:^y day* Packing charges are foBo-
wing the same treiKi, Moreover, traders and retailers are 
keen to earn higher profit margins,The maiiset is highly 
competitive. Consumers are more conicious of their rights than 
ever before. In such a situation, efficient manageo«at alone 
can produce the desired results. Undoubtedly, the ^o}> of formula^ 
tlcm and implementation of an optimal pricing strategy is 
a challenging one. Lack of imagination and innovative skills, 
and lack of insight into the problem may produce an adverse 
impact on business. 
The pricing decision in the public sector drug 
industry is greatly influenced by the above mentioned factors 
viz| competitive situctions, legal procedures and behavioural 
factors. Transnational drug companies, in some cases, offer a 
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taugh competition in tcnss of pricing to the public sector 
drug companies but this competitive situation should have 
no bearing on the their business , since the public sector 
has the advantage of sectoral reservations due to which, 
in a number of cases, other sectors Cannot conp^ tfe with> it. 
In practice behavioural factors too, do not have much bearing 
on the pricing decisions of the public sector, as the public 
sector drug conpanies are interested in institutional sales 
where individual customer's and retailer's behaviour has little 
relevance. The public sector drug units have assured sales to 
government hospitals, defence establi«h»tnt« and cater to the 
railways aedical needs and those of other government agencies 
where these units are given preference over other as a result 
of their bilateral contracts with these agencies. 
Legal procedures have an important bearing on the 
pricing decisions of the public sector drug craapanies due to 
political interference and corporate legal status of these 
firms. Each aspect of pricing decisions of the public sector 
drug units is regulated by legal provisions and the decisions 
concerning the prices can in no case M against legal guidelines. 
Also, pricing decisions in the public sector drug 
units are taken in keeping with the social objectives of helping 
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the weaker, under prevlledged and unorganised sections of 
the society. Thus its pricing decisions aim primarily at 
making the products and technological assistance available 
to the small scale producers of the industry at highly competi-
tive prices. In such cases *ttaximisation of profits' gets 
secondary Importance, In other words, maxJUaisation of sales rather 
than maximisation of profits constitutes the pricing philosphy 
of the public sector drug companies. 
Summary t 
In the area of marketing, an effective decision 
making process is most crucial because decisions are mostly 
the reflection of the trends and conditions of the market. 
Pricing decision, being one of the important aspects of 
marketing decisions is, therefore, very significant. Prices 
play an important social role in the regulation of all the 
aspects of eccoiofflic activities, i,e, production, sale, distrib-
ution and consumption. Prices of drugs, controlled as an 
emergency measure in 1962, still remain a controversial issue. 
Customers are dissatisfied because they are being Bandwitched 
between the government aiKi the drug mamifacturers. Pricing 
strategy pursued by drug manufacturers aims at earning more 
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and more profits but the government intervenes and regulates 
the prices In the interest of the society. Thus fomulatlcai of 
a pricing policy for the drug industry in general and for the 
public sector in particular has become diff icul t task. 
In the l ight of the rectnamendstions nadc by the 
Hathi Ccomittce, the Ck>v«rnfflent formulated a drug policy in 
the year 1978, In order to give effect to the provisions 
regarding pricing, the Ctoveraaent has promulagted the Drug 
Price Control Order-1979 which.replaces the Drug Price Control 
Order-1970, The Drug Price Control Orderwi979 was brought into 
force in April,1979. The theme of th i s order varies to a 
greater extent from that of the iJrug Price Control Order 1970, 
in accordance with the approach of the Hathi Conmittee, 
Pricing principles followed by the public sector 
hand 
drug industry are most controversial. On the one. drug prices 
have to be beneficial to the drug Manufacturers and on the other 
they have to be within the purchasing powar of the consumers. 
No single principle such as *Maxifflisation of Profit* or *No 
Profit No Loss* or ^Marginal Cost Pricing * and 'Surpluses to the 
Nation* can be ap?li«d to a l l public sector undertakings. I t i s 
a coBplex problem the solution to it^ieh depends upon a number 
of factors which affect the trends in demand ai^ supply of the 
goods produced by the pharmaceutical industry. 
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Strtttgic pricing is one of the crucial ;3ob« of 
a menageajent, S«rious problems may arise du« to the lack 
of knowledge of conpetltive situations, legal procedures and 
behavioural factors involved in it. It requires a careful 
analysis of all the factors which have an important bearing on 
pricing strategy. Pricing decisions in the public sector drug 
units are linked with the social objective of helping weaker 
sections of the society. In such a situation, the maximisation 
of profit gets secondf^ry importance. In other words maximisation 
of sales rather than maximisation of profits should be the 
dominant objective of the pricing philosphy of pilblic sector 
drug companies. 
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C H A P T E R - ^ 
i N A L Y S J S OF F I N D I N G S 
In tht present study use has been made of both secondary 
as %fell as primary data. The secondary data was collected from 
various, sources such as Anmial Reports of the companies, 
the various publications of the organisation of Pharmaceutical 
Producers of India, The Indian Drug Manufacturers Association, 
the Reserve Bank of India, and the Ministry of Petroleum, 
Chemicals and Fer t i l i zers , 
For collecting data for th i s project, the present researcher 
visited the Library of the Department of Company Affairs, 
Government of India and also the Libraries of the Ministry of 
Petroleum, Chemicals and Fer t i l i ze rs , the Ministry of Finance 
and the Ministry of Labour, The data for th is study was 
collected from various Journals and dai l ies also. 
For gathering information from primary sources a 
well designed questionnaire was sent to the senior executives 
of public sector drug enterprises. Also, data was collected 
with the help of interviews and discussions were held with 
senior marketing managers and officials of selected public 
sector companies, Airing the v i s i t s , wherever possible, 
cassette tapes were used to record discussions with the 
officials of the companies. 
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The reasons for conducting the Interviews with the 
marketing managers in public sector drug units, were mainly twoj 
First, since the information sought through questionnaire 
could not fully be supplied by the respondents because of 
considerations of secrecy and It could only be obtained 
through personal discussions. Secondly, the accuracy of the 
infonnatlon supolied through the questionnaire could be 
verified and further Information could be sought which could 
not be obtained by the questionnaire* Thus discussions which 
were scheduled to end within ten to fifteen mlraites usually 
took at least half an hour. In some cases it spread over 
4n hour and a half to finish. This indicates that the 
executives showed a keen interest In discussing the Issues 
involved In this wmX study. Indeed, the answers given by them 
helped a good deal in clarifying the attitudes and policies 
of companies towards the important aspects of the aariteting 
strategies* 
An analysis of the data, obtained with tte help of 
questionnaires and interviews with the senior executives 
of selected public sector drug enterprises is given below. 
Instead of disclosing the individual identity of the 
companies, ccmpany codes have been used for reasons of 
keeping the information confidential. 
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liable 8,1 shows the growth achieved by the public sector 
drug units in terms of annual sales turnover front 1981-82 to 
1985-86 which together contribute a major portion of the 
to t a l bulk drug production and export of drugs from the 
country. The turnover of company A stood at Rs» 99*6 , h* 105.6, 
Rs, 108.8 and Rs, 120,9 crores during the years 1981-82 ,1982-83, 
1983-84 and 1984-85 respectively. This represent an increase 
of 5.7 % , 2,9 % and 10.0 ^ over the years 1982-83, 1983-84 and 198^ 
;-• soPCt:velv 
85/ , only in the year 1985-86 there was a decrease of 0,3 per 
cent in the annual sales turnover of company A, 
The sales turnover of company B , was Rs, 27.8843 ,Rs,36,2936 
Rs, 31,8950 , Rs, 41,3534 and Rs, 42,7391 crores respectively 
during the years 1981-82, 1982-83, 1983-84, 1984-85 and 1985-86, 
The percentage incrtast was 23,17 , 22,87 , 3,24 during 1982-83, 19fi 
respectively 
1984-85 and 1985-86 over the years Just preceedlng. Only in 
the year 1983-84 i t . suffered a 13,79 per cent decrease in i t s 
sales turnover. The turnover of the company C was Rs,7,6640, 
Rs. 9,1445 and Rs, 12,0577 crores during 1983-84 , 1984.85 and 
1985 -86 , which was an increase of 16,199tond 24,l6%respectively 
over the proceeding years while that of company D was te,7.92, 
Rs, 8,99 f te. 9.17, fe, 9,08 and RS, 9.34 crores respectively 
durin 1981-82 , 1982-83, 1983-84, 1984-85 and 1985-86, A 
regular increasing trewi was maintained by this unit which 
showed a sales growth of 11,90 per cent , 0,99 per cent ,0,98 
per cent and 1,82 % respectively over the proceeding years . 
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T A B L E »e>2 
Main Product Groups of the Companies 
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S.No, Bulk Orugs 
1, A n t i b i o t i c s 
2 , AntAcids 
3 . An t i -hyper t ens ives 
4 , Analgssics & An t ipy rec t i c s 
5 . Sedat ives & T r a n q u l l l i s « r c 
6 , Antl-»Convulsants 
?• Sulphonamides & 
A« t i«Bec te r i a l s 
8 . A n t i - T . a , 
9 . Antl-amoeblc? 
10. Vitoifiins 
1 1 , Anti-.Mf»larials / 
F i l a r i a l s 
12 . Antl-Fungals 
13 . OtherSulphr Drup'^. 
14, MisJjDther i tems 
'i'OxAL OF YES 
£,„o„.,.i, 
4 
Yea 
r»o 
Yes 
Ves 
Yes 
Yes 
Yes 
Yes 
rio 
Yes 
Yes 
Yes 
Yes 
Yes 
12 
,.p.„a,T»,y„ 
B 
Yes 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
Ho 
Yes 
Ih 
Yen 
5 
Co d e 
C 
Yes 
Yes 
Yes 
Yes 
Yes 
Yss 
Yes 
Yes 
Yes 
No 
No 
No 
t-lo 
Yes 
10 
D 
Yes 
No 
Yes 
Yes 
Yes 
)D 
No 
Yes 
No 
Yes 
Ko 
Yes 
Yes 
Yes 
9 
Source I Compiled on the basis of information obtained with 
the help of questionnaire and interviews conducted 
with senior executives. 
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Table 8,2 shows th© main product groups undertaken by 
the companies* Company A produces drugs belonglijg 
to 12 therapeutic groups and in each product group a 
number of foroulations are produced by it »The number 
of product groups shows the product lines Bird the 
number of fonaiulations in eachnproduct liiM» shows Its 
length. The companies B, C and D produce 5»10 and 9 
product groups respectively. Though the number of product 
groups is only 5 in the case of the B, the ctMipany 
has a number of foroulations in the antibiotic group. 
It produces Pencillin, Streptomycin, Rifaapicin, 
AnpiciUin etc, all of which are in the antibiotic 
group. This shows that the policy of the conpany is to 
specialise in a particular product line. This table 
also shows that conpany 4 has a much broader product 
group base compared to companies B, C and D, This 
may be on account of its larger size and resources. 
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The comparative Importance of each product l i . 
In terms of i t s contribution to the t o t a l turnover of 
the d i f ferent companies i s shown in Table 8,3. In the 
case of company A two product groups, anti-h3rpertensives 
and analges ics , showed an increasing t rend. In the year 
1983-84 the contribution of anti-hypertensive drugs to the 
net sa les was 3.6 per cent which increased to 5 per cent and 
6,8 per cent respect ively during 1984-85 and 1985-86, 
whereas the share of the an t i b io t i c s and sulphas groups declined 
from 11,9 per cent . and 12 per cents in 1983-84 to 
9 per cent and 10.9 per cent in 1985-86 respectively,The 
management could not specify the reasons responsible for these 
t rends . However, discussions with the executives indicated 
tha t the ccmpany had divers i f ied i t s production in some 
cases from the l ess p rof i t ab le areas to comparatively higher 
prof i tab le product groups. 
Contrary to t h i s the company C increased i t s 
production of an t i b io t i c s as well as suphas as well as 
i t s contribution to the t o t a l annual sales of the company. 
The share of the an t i b io t i c s group was 12 per cent , 13 per cent 
15 per cent during 1983-84, 1984-85 and 1985-86 respect ively 
while tha t of sulphas was 18 per cent^20 per cent , and 19 
per cent respect ively during the same years . The company 
followed the same trend in analgesics where i t contr ibution 
was 8 per cent, 10 per cent, 12 per cent during the same 
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years respectively. In case of antl-hypertenslves the 
contribution remained 2 per cent throughout the period. 
The management of company C felt that market 
trends in the drug industry are determined by the disease 
pattern of the country, the ability of the constaners to 
buy drugs and the government requirements for meeting 
certain obligations, especially in the areas of anti* 
leprotic drugs, anti-malarials, anti-T.B, drugs etc. 
Companies B and D did not furnish any information regarding 
the contribution of each product line to their total sales 
turnover, hence they have been excluded from this table. 
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T A B L E« 8>4 
Factors Determinlm Product /Market Divers i f icat ion 
S.NO. F A C T O R S 
1» Contribution of each product towards the fixed cost 
2, Disease pa t t e rn prevail ing in the country, 
3 , The nature of demand for the product in the market 
4 , Avai labi l i ty of resources such as j men, machines, o a t e r i a l s 
and money 
5, De«ire t o have a grea ter market share of a product 
6, Government regulat ions on the production and on marketing, 
7, Health needs of the people 
Source I Compiled on the basis of interviews conducted with 
the executives and information obtained with the help of 
the questionnaire duly filled in by the executives. 
T A B L E «8.5 
Distribution Network 
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S.NO. Company Code No. of Medical 
Representatives 
No, of Pistrlbut*© 
o r s / S t o c k l s t s / 
Regional Sales 
Offices 
1. 
• 
2 . 
3 . 
4 . 
Company A 
Company B 
Company C 
Company D 
400 
121k 
N.A. 
43 
16 
N.A. 
12 D 
7? S 
RSO 
Source : Compiled on the basis of Interviews and information 
given in the Annual Reports. 
KSO 0. Hegional Sales Office: 
D « Distributors 
S « Stockists 
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Distribution network is one of the major constituents 
of a COTspany*.^  distribution policy. Company A has a wide 
spread distribution network which consists of 16 
regions located at different state headquarters headed 
by Regional Martceting Managers, Each region has been further 
sub dividfd into zones. The whole distrlbtition wirtc is 
channelised through a team of Medical Representatives, 
Company A has a team of 400 trained and skilled Medical 
Representatives spread over throughout the^  country. 
Company B did not mention the nimber of its regions 
but the number of Medicsl Representatives employed by the 
company was 124, The company C, which operates in the whole 
of Uttar Pradesh hns 12 Distributors , while the total number 
of Medical Representatives employed by it is not mentioned. 
Company D has adopted a distribution network consisting of 
75 stockists in its region and 43 medical representatives. 
These companies follow similar pattern* of distribution. 
They mostly sell their bulk drugs and formulations on the 
basis of institutional selling where direct supply is made 
on the basis of seeled tenders while their open market 
sale is routed through authorised stockists and distributors. 
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I A B L E - a.6 
• • — — I i i i i i i i i - » -«8—» 
Distribution Expenditure 
(fet i>?l?rHt?5) 
Company A 
itctual % of 
Sales 
turnover 
Company B CoiHpariy C Company D 
Actual % of Actual i^ot Actual % of 
Sales Sales Sales 
turnover turn* turnover 
over 
i«561-82 
1982-83 
1933-84 
1984.85 
1985-86 
372,32 
471.11 
470.77 
516.71 
497.10 
3.74 
4.46 
4,33 
4.27 
4.13 
97.6 
106.83 
79.94 
111.65 
141.04 
3.5 
3.0 
2.5 
2.7 
3.3 
N.A. 
N.A. 
25.29 
33.83 
42.20 
N.A. 
N.A. 
3.3 
3.7 
3.5 
1.78 
2.57 
3.69 
4.81 
2.83 
0.22 
0.29 
0.41 
0.52 
0.30 
on 
Source { Cooplled/,, . the basis of Infonnatlon obtained with the 
help of questionnaire filled ib by the executives and from 
Annual Reports of the conpanjtes. 
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Distr ibut ion expenditure given in Table 8.6 
above included packing and forwarding charges, commission 
payable to d i s t r ibu to r s and s tock is t s and the expenses 
incurred by the branch offices of the company. The 
d i s t r i bu t ion expenditure incurred by company A was fe»319«77. 
372,32,&. 471.11, Rs. 470,77 , fis, 516.71 and Si. 467.10 lakhs 
respect ive ly , representing 3.74 %^ 4.46 %p 4.33 %, 4,27 96 and 
4.13 ?» of the t o t a l sales turnover of the company during the 
years 1981-82 , 1982-83 ,1983-84 , 1984-85 and 1985-86 r e s -
pectivf-ly. The average d i s t r ibu t ion expenditure of the *total 
annual sa les turnover of company A was 4.19 per cent for the 
said five years . The d i s t r ibu t ion expenditure of company 
B was 9.76, 108,88,99*94, 111,65 and l4 l ,04 lakhs respect ively 
representing an average of 3^ during the same period. The 
d i s t r i bu t ion expenditure of company C for the period 
1983-84 to 1985-86 , was &. 25.29 , fe. 33.83 and Rs,42.20 lakhs 
respect ive ly . The average d i s t r ibu t ion expei^i ture incurred 
by the company was 3.5 per cent of i t s t o t a l annual turnover, 
A comparison between the company A and caapany C reveals 
t h a t there i s a difference of 0.69 -per cent in the average 
d i s t r ibu t ion expenditure of the two companies , The 
company D showed a d i s t r ibu t ion expenditure of &. 1.78, 
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Rs. 2.57, fe, 3v69 , Rs, ^.81 and ^, 2,83 lakhs 
during 1981-82, 1982-83 , 1983-3^ , 1984-85 and 1965-86 
respectively, A distribution expenditure of 3 to 5 per 
cent of the annual s^les turnover is Juatilitd, When a 
comparisbn between public sector drug companies and those 
in the other sector* is made it is found that there is a 
great difference between them in terms of their average 
distribution expenditure, l>nLg multinationals spend 
between 10 to 16 per cent of their turnover on distribution, 
Thi3 wide difference may be mainly due to two factors. First, 
the public sector units generally produce bulk drue.s and go 
for institutional selling system which minimises the cost 
of distribution. Secondly, public sector companies in roost of 
the Cases, route their sales through their own branches 
and depots which results in lower distribution expenditure 
than hiring agencies for the purpose of distribution. 
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T A B L E »8.7 
Promotional Expenditure 
(as. in lakhs ) 
Company A Company B Company C Company i> 
Actual % of Actual % of Actual % of Actual % ©f 
sales Sales sa les 
turnover turnover turnovei 
salesi 
turnover 
1981.82 15.08 0,15 
1982-83 19.60 0,19 
1983-84 13,45 0,12 
1984-35 16,50 0.14 
1985-86 6,92 0,06 
195.16 7.0 
206.85 5.7 
213.73 6.7 
264.64 6.4 
200.88 4 .7 
N.A. N,A, 19,00 2,4 
N.A, N,A, 23.37 2.6 
78.94 10.3 24,52 2.7 
91.45 10.0 22,93 2.5 
116.96 9.7 21.48 2.3 
Source : Compiled on the bas i s of data obtained with the 
help of quescionnalre duly f i l l ed in by the 
executives.Kt 
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Companies mostly adopt two types of promotional 
methods ; namely, direct method and indirect methods. 
Again there are different kinds of direci; methods tool 
The promotional tools used for the ethical drugs and 
non-ethical drugs are quite different. Ethical drugs are 
proii50ted through the medical representatives aided by free 
samples and product literature. The companies covered in 
our sample use both the techniques, namely, |irofflOtion 
through the medical representatives as well as distribution 
of free samples and product literature among the physicians. 
In the Case of non-ethical protlucts, mass media communication 
systems including radio, 'i,V, and magazines are used for 
the purpose, None of the companies under study mentioned the 
techniques used by them for the promotion of over the country 
(ore ) drugs. 
Jndirect px^ omotion methods include organisation of 
seminars, distribution of medical literature other than 
product literature and comrauni^ y development programmes. No 
informj^ tion regarding the use of indirect promotional methods 
was made available to the presept researcher by the companies 
under study. Table S,7 shows the promotional expenditure of 
the companies. 
329 
The table gives the annual expenditure on promotional 
activities of the public sector drug companies. The total 
promotional expenditure companising salaries for field 
staff, their travelling and conveyance expenses, cost of 
literature and samples and expenses on media advertising 
was not revealed by the executives during interviews with 
them. The only item of expenditure revealed by company, 
A through the questionaire was that of publicity, which was 
Rs.15.08 lakhs, fis. 19.60 lakhs, te ,13.45 lakhs, Rs, 16.50 
lakhs and te, 6.92 lakhs dxxrlni 1931-82 , 1982-83, 1983-84, 
1984-85 and 1985-86 respectively, which represented 0,15 % 
0.19i^  , 0,12?6 , 0,14% and Op6% respectively of its sales 
turnover during the period. Company B spent out its promo-
tional expenditure Rs, 195.16 lakhs, 206.85 lakhs, te,213.73 lakha 
fis.264,64 lakhs and Bs.200,88 lakhs registering 7 ^, 5.7^ , 
6.7^^6,4 )4 and 4,7% ^rui that of company D fe, 19,0 lakhs, 
Rs.23.37 lakhs , fe. 2#,52 lakhs, Rs, 22.93 lakhs and Hs.21.48 
lakhs registering on an average of 2.5^ respectively of its 
sales turnover during 1931-82, 1982-83, 1983-84, 1984-85 
and 1985-86, Company C mentioned that about 10?^  of the 
total turnover of company is spent on its promotional 
activities which works out to fe.78,94 lakhs, te,91.45 lakhs 
and Rs, 116.96 lakhs during 1983-84, 1984-85 and 1985-86 
respectively. 
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The difference between the expenditure on proraotion* 
incurred by company A and C may be on account of the fact 
thPt the former has disclosed the figures only of expenditure 
on publicity. Its expenditure on the promotion of non^ ethlcal 
products, which ere advertised through mass media, costs 
very little between 0,06 per cent and 0,19 per cent of the 
coBipany *s total annual sales turnover. In the case of ccmipany 
C, all the main aspects of promotional coopeign such as 
salairles of field staff, cost of free samples , medical 
literature and advertising and publicity etc j xwt are metout 
of the promotional budget, which approximately costs 10 per 
cent of the total annual sales turnover of the company. 
Another reason for the difference in the promotional 
budget between the two coopenies may be that the company 
A mostly deals in bulk drugs where promotional cost is 
minimum, while the company C deals both in bulk drugs and 
in forwulations, and prt)motion of foiTDulations needs greater 
expenditure than that of balk drugs. 
T A B L E « 8.8 
Branding Policy of the Company 
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S.NO, Ck>mpany Code Statements 
1, Company -A 
2, Company -B 
No comments 
As regards institutional 
.^ ales- Generic Names ; 
For Market Sales-Brand Names 
3, Company- C 
4, Company - ^ 
The concept of having a brand or 
selling the product under generic 
name is to be seen in the background 
of the drug. Life saving, drugs as 
far as possible, should be 
encouraged to be sold undergeneric 
name only. 
No Comments 
oource : Compiled on the basis of data obtained with the 
help of the questionnaire and interviews conducted 
with the excutives. 
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T A B L E -. 8.9 
Attitudes towards Brand iiame abolition policy of the 
government. 
S.NO, Response Category No, Per cent 
1. 
2. 
3. 
^. 
EFFECTIVE 
SATISFACTORY 
UNSATISFACTORY 
NO RESPONSE 
<•• 
«> 
1 
3 
-
-
25 
75 
TOTAL 4 100 
Source : Compiled on the basis of the interviews and 
information obtained with the help of the 
questionnaire. 
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The Goverranent has abolished the use of brand names 
for certain drugs and wants the sale of drugs to be 
under their generic names. This is because, the Govern-. 
ment is of the view that the use of brand names is 
unethical since it allows companies which are efficient 
in marketing arrangements to charge higher prices for 
their branded drugs in a manner that suits the consumers. 
From the point of view of the company, a drug marketed 
under its brand name, as compared with one in its generic 
name, helps the consumer in differentiating it frosi similar 
drugs produced by the competitors. Opinion regarding 
this was Bolicited from public sector executives. The 
company - B was the only concern which responded to the 
question in this regard. In its opinion, the Government 
policy was unsatisfactory. The other three companies A,C 
and D did imt offer any comment in this regard. They deem 
it as a matter of interference in the affairs of the 
Government, 
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T A B L E » aia 
Major Consideratiomin the Determination of Drug Prices 
S.Not Company code Main Considerations 
1, Compaiy -A 
2, Company -B 
3, Company -C 
4, Company -D 
Fixed Through DPCO 
Raw material cost, distribution 
and promotion cost as well as 
mark*up. 
Raw material cost, distribution 
and promotion costs as well as 
mark-up. 
Fixed- through DPCO 
Source j Compiled on the basis of interviews conducted with the 
senior executives. 
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The companies A and D mentianed that 
ptlces for their drugs are fixed through Drug Prices 
Control OrdersC DPCO) since they are bound to follow 
strictly the provisions of Drug Price Control Orders 
However, the remaining companies i,e, B and C said that 
in the fixation of drug prices, the costs of raw 
materials, distribution and promotion are taken into 
account and appropriate oarks-up may also be allowed. In 
our sample 50 % of the executives are of the opinion that 
price fixation should be done keeping in oind to the 
cost of raw materials, distribution and promotidn wherees 
the remaining 50% of the executives felt the drug prices 
be fixed according to DPCO norms. 
T A B L E >8.11 
Impact of WCOs on Company»s P r o f i t a b i l i t y 
S.NO. Response Category No. Percent 
2 
1 
1 
50 
25 
25 
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1, ADVERSE 
2, POSITIVE 
3, NO RESPONSE 
TOTAL 4 100 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmtmmmmmmmmmmmm^ 
Source i Compiled on the basis of the infonnatlon obtained 
questionnaire duly 
with help of/filled in by the executives. 
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The Drug Prices Control Order (IFCO) -1970 
categorised drugs into two c l a s ses - e s sen t i a l and 
non«essential-with maric-up of 75 per cent and 150 per 
cent respect ively . Later new pr ic ing proposals under 
DPCO- 1979 were introduced. This order envisaged four 
categories instead of two, with marks-up a t St 40 per cent 
and 55 per cent respect ively for drugs of categories 
I & 11^ a t 100 per cent for drugs under category I I I 
and free mark-up for dmigs under category IV, The 
executives were asked whether the exis t ing pr ic ing 
mechanism has affected the p r o f i t a b i l i t y of the ©rug 
companies in India, Opinions on i t vary on t h i s i s sue . 
Fifty per cent of the executives argue tha t the impact 
of DPCOs on the p r o f i t a b i l i t y of drug un i t s i s adverse 
while ene of the executives mentions tha t i t s ro le i s 
pos i t ive and the remaining one did not offer any comment 
in t h i s regard. 
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T A BL E > 9 t 1 ? 
Research & Developwient Expenditure 
(RS, In lakhs ) 
Company*A Company-B Company -C 
Actual % of Actual % of Actual 
Sales Sales 
Turnover Turnover 
?^ /^ ales 
Turnover 
1981-82 
1982-83 
1983-84 
1984-85 
1985-86 
127.48 
129,29 
272.00 
447.33 
457.90 
1.28 
1.22 
2.5 
3.7 
3.8 
55.76 
68.96 
57.41 
82.70 
98.30 
2.0 
1.9 
1.8 
2.0 
2,3 
N.A. 
N.A. 
6 
8 
11 
N.A. 
N.A. 
0.78 
0.78 
0.91 
Source : Compiled on the basis of Infonnation obtained 
from Annual imports and with the help of the 
questionnaire filled in by the executives. 
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R&D ac t iv i t y i s the backbone for the sound developnent of the 
drug industry. Drug companies in technolog|:cally advanced 
countries usually spend about 10 per cent of t h e i r ennual 
sales turnover on development a c t i v i t y . Table 8.12 shows the 
t rends of annual expenditure of the Indian public sec tor drun 
companies on H & D a c t i v i t i e s , Ck«npany C spent meagre amounts 
of te. 6,8 and 11 lakhs on R& D a c t i v i t i e s respect ively during 
1983-84, 1934-85 and 1985-86 which represent 0.78 ^, 0 . 7 6 / 
and 0,91 ^ of the turnover respectively during these years . 
Company B spent on R & D as,55.76, fe. 68.96, Rs. 57»41, 
{te,82,70 and fe.98.30 lakhs respect ively during 1981-82,1982-83, 
1983-84, 1964-^985 and 1935-86 by which represents on an 
average xint an expenditure of about 2,0 per cent during t h i s 
period. Company A spent reasonable amount of money on R & D 
a c t i v i t i e s . I t s annual expenditure on R&D wr-s Rs, 127»48 lakhs , 
fe.129.29 lakhs, fe, 272,0 lakhs, K 447,33 lakhs and fe.457.90 
lakhs respect ively durin?: 1981-82, 1982-33, 1983-84, 1984-85 
and 1985-86 which represents on an average, an expenditure 
of about 2,5 per cent during thia per iod. But when t h i s trend i s 
compared with trends In R & D prevai l ing in the advanced 
countries th i a expenditure i s s i t l l very low and neeAs to be 
Increased subs t an t i a l ly . One of the study has pointed out 
tl-iat snal lness of big enterpr ises i s causing R & D gap 
in India, This gap needs to be narrowed down to achieve 
s igni f icant gains for the Indian economy in general and drug 
Industry in p a r t i c u l a r . 
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Introducing a new basic drug needs heavy expenditure 
amd takes a longer time. Drug manufacturers were asked 
about their efforts towards the development of new drugs 
In this regard two of the four companies said*ye»* they 
have made efforts for the development of new drugs while one 
said'no' and the remaining one did not respond. Company A 
introduced Vitamin B6 through i t s own H & D ac t iv i t i es 
during 1983, and three of i t s novel compounds are in thei r 
advanced stage of biological test ing, while company B developed 
two drugs from the basic stuge viz , HAMYCIN anti-fungal 
for human use and AUROFUNGIN antifungal for agricultural 
uses. Company D did not furnish any infonaation because i t s 
R&D act iv i t ies are confined to rraHteting research only and 
development ac t iv i t ies are undertaken a t i t s parent 
headquarter. The case of company C is quite different. I t 
could not develop any basic drug although intensive R &D 
ac t iv i t i es were confined to the di^elopnent of new 
formulations. 
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T A B L E «8.14 
Factors Limiting Full Capacity Utilisation 
S^NO, F A C T O R S 
1. 
2, 
9. 
4 . 
5. 
6. 
7. 
Power cuts 
Labour Unrest 
Govennment Taxes 
Excise I^ties 
Non-avAilability of raw materials 
Low Mark-up 
Lack of Funds 
Source j ComiAled on the basis of the information obtnined 
with the help of questionnaire duly filled in and 
interviews with the executives. 
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Table 8,14 identifies the oain factors 
which hinder full capacity u t i l i sa t ion in the drug 
ccxapanles. The main problems are power cuts, labour 
unrest and non-availability of rsw-materlals. The other 
less sef^re problems faced by the drug units were, low, 
mark-up, govenirnent regulations end inadequate funds. 
The need of the time is to remove these constraints for 
attaining increased and uninterrupted production and 
for attaining full capacity u t i l i sa t ion . 
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T A B L E - 8>15 
Licensing Policy of the Government as <ui Obstacle to Growth 
S.NO, Response category No» Per cent 
1. YES 
2. NO 
3. NO RESPONSE 
1 
1 
2 
25 
25 
50 
TOTAL 4 100 
Source :Compiled on the basis of interviews conducted with 
the executives. 
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A drug unit cannot be established without 
obtaining prior governmental approval. The authority 
to pjnovide licences to the manufacturers vests In the 
hands of the Director General of Technical Development* 
Manufacturers of drugs feel dissatisfied with the 
prevailing state of affairs. At times, producers who 
have applied for a licence for the production^essential 
drugs, do not get it even they have the necessary 
expertise and finances to establish a unit. 
Information concerning goverranent*s licencing 
policy acting as a barrier to growth was gathered through 
a question. Opinions expressed by the public sector 
executives differed on this issue. While only one of the 
executives said 'yes*, the other one said 'no* , The 
reajaining two companies executives did not answer this 
question. They merely said that it is a matter of g 
Governraent policy, and they do not want to interfere with 
the poliqrdecisions of the Governeent, 
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T A B L E «8,16 
Attitudes Towards the Pricing Policy of the Government 
S.NO. 
1 . 
2 . 
3. 
Fiisponse Category 
YES 
No 
NO RESPONSE 
No. 
1 
1 
2 
Per cent 
25 
25 
50 
TOTAL 4 100 
Sdurce J Compiled on the basis of the interviews conducted 
with the senior executives. 
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In India the drug prices and pro|i.t Margins of 
manufacturers are subject to ceilings imposed by the 
goverrment. No drug manufacturer can fix up the price over 
the limits specified and the profit cannot be earned beyond 
the overall ceiling of 15 per cent. The executives were 
asked whether the price and profits ceilings imposed by the 
goverrment were unfair and unjustified , Whilt one 
said *yes* the other one said •no* and reg'irded it as a 
rational approach of the Goverraaent, The ramaining companies 
did not answer this question , 
The executive who said 'yes ' to this question sugg-
ested that the pricing restriction Imposed by Government 
should be amended rather than totally withdrawn. He felt it 
necessary otherwise poor masses will have to face the 
brunt of it. 
Summary i 
The findings of this chapter are based on the 
imiteiwation gathered from the primary sources. For this 
a well designed questionnaire was sent to the senior 
executives of public sector drug enterprises. Also, data 
was collected with the help of the interviews and 
discussions held with the senior marketing managers of 
public sector drug ccwipanies. The analysis of the 
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data reveals some interesting facts, 
of 
The data obtained fi-wn four the public sector 
drug units , which together contribute a macJor portion of 
the to ta l bulk drug production and export of drugs from 
the country, shows that the growth achieved in tenas of 
annual sales turnover of the company from 1981-82 to 1985-86 
was inipr«islve except a few set backs suffwrred by companies 
A & B in the years 1983-84 and 1985-86, 
The companies A,B,C and D produce mainly 12,5t10 
and 9 product groups respectively. In case of company A, 
contribution of ant ibiot ics , antihypertensives, analgesics 
and sulphas groups to the to ta l sales turnover of the 
companies has been96,8 6*3 and 10,9 per cents respectively 
during the year 1985-86, Likewise the contribution of 
ant ibiot ics , antacids, analgesics, sedatives, an t i -
convulsants, sulphas, anti-tuberculttsis and anti-amoeblcs 
to the total sales turnover of the company C has been 13i3 » 
2,12, 1,2,19,23 and 8 per cents respectively during the 
year 1985-86, 
%>ecific decisions relating to aspects such as 
distribution network and distribution expenditure 
constitute the overall distribution policy of the companies. 
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Siullarly, decisions concerting the *ethods of promotion 
and promotional expenditures, constitute the promotional 
policy of the companies. Distribution expenditure which 
included packing charges, commission payable to distributors 
end the branch expenses, of the companies A,B,C and D 
has been 4,13, 3, 3.5 and 0,3 per cents of the salesturnover 
of the companies respectively during the year 1985-86. 
Promotional expenditure which included salaries of medical 
representatives, cost ofsaaples and free literatures,of 
the companies A,EI,Cand D has been 0,06, 4,7 , 10 and 
2,5 per cents respectively, of the salesturnover of the 
companies durinr the same year. 
The attitudes of the executives of public sector 
drug companies towards the brand r'^-^e abolition policy of 
the Goverraaent and impact of DPe.Cfe on the profitability 
of drug companies, vary significantly, 
tesearch and Development activity is one of the 
neglected areas in the Indieii drag'industry, Although 
Public Sector drug enterprises are engaged in conducting 
basic researches in thi'' area, But the data gathered in this 
companies 
regard shows that generally the/invest a m&Bll amount on 
R&D , The smalli^ss of big enterprises causing R&D gap 
in India , 
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Bower cuts, labour unrest,noivavsilabill ty of 
raw materials and lack of funds are the raa^or factors limiting 
full capacity u t i l i sa t ion in drug companies. Opinions on tlie 
issue whetl^r licensing policy i s a aajor obstacle to growth vary. 
Similarly^ Managerial at t i tudes towards- the pricing policy of 
the Govermaent differ. Public enterprises have been sufferrlng 
mainly due to lack of advance planning, i rrat ional pol icies , 
lack of autonomy and accountability and poor marketing arrangements, 
I Hard measures need to be taken by the government for revamping 
the public sector drug units in the country. 
C H A P T E R ^ g 
mmmmmmmmmmtHmmmmmmmmmmmmm'aHmmmmmmm 
S 0 ^ M A R X 
A N D 
C O N C L U S I O N S 
3o3 
C H A P T £ R * 9 
^ M M M A R Y ANB C 0 N C L ]j[ S I 0 N S 
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Over the l a s t thr«e decades, the jniblic sector has 
emerged as a major factor ID the country's economic growth, 
A v i t a l role has been assigned to th is sector In the 
economic l i fe -cCthe country. Hence I t is necessary that 
this sector is efficient and aiakfs i t s du« contribution 
towards the economic progress of the oation. Besides, the 
Indian drugs and pharmaceuticals industry holds a place of 
pride in the national econoiay of the country in terns of 
prtjduction, investaient, generation of eraployment and i t s 
contribution in meeting the health needs of the people. 
The drug industry of the country may be divided into four 
sectors viz . , the public sector, the Indian private sector, 
the foreign sector and the small scale sector. The impor-
tance of public sector drug units l i e s in the fact that 
th is sector has been specially established to produce drugs 
a t reasonable prices, to cater to medical f a c i l i t i e s in the 
rural as well as urban areas, to achieve self- sufficiency in 
drug production and to earn foreign exchange for the country 
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from exportable su rp lus . 
In the pi-esent study coajbinatioti of several nethods of 
data col lec t ion were used for col lect ing information r e l a t ing 
to the marketing po l ic ies of the public sector drug companies 
and the areas of t h e i r external enviromsent in which they opera te . 
The data about the company po l i c i e s was collected with the help 
of a well-designed quest ionnaire , personal interviews conducted 
with company executives, and hy looking into the luinual 
Reports of the companies. The drug p o l i c i e s of the government 
have been studied with the help of various policy documents 
issued from time to time, drug associat ions bu l l e t ins and other 
Journals and d a i l i e s published, 
Hie focus of t h i s study i s on the marketing s t a r t e g i e s 
of arugs and pharmaceutical companies in the public sec tor as 
ref lec ted in the functional po l i c i e s pursued in the areas of 
production, d i s t r l lx i t ion , promotion, pr ic ing & RM), The purpose of 
the present study i s to invest igate the merketing p rac t i ces of 
publ ic sector drug enterpr ises in the context of the prevai l ing 
socio-economic enviroranent. 
A company, whether public or p r i v a t e , functions In an 
environment which i s determined by economic,pol i t ical , l ega l , 
soc ia l and cu l tura l f ac to r s . These extraneous factors over which 
the ciMDpany management has no d i r e c t control offer opportuni t ies 
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BS well as threats and prescribe guidelines within which 
a company must survive and grow, The objectives and policies 
of a company must be formulated In the context of these 
factors. At each stage of of planning and strategy formulation 
these external factors exercise a great influence on the 
-aecisions taken by the management, 
Togather information on the prevailing economic 
environment of public sector drug canpanies the technique of 
administration of questionnaire and conducting Interviews 
has been adopted by the present researcher. Some executives 
pointed out that market level factors ( i . e . economic factors , ) 
such as demand and competition, have not had any significant 
impact on the operations of their companies for two reasons. 
F i r s t , the size of the market Is large enough to absorb the 
existing production and 4x>ut seventy per cent of the market 
consisting mostly of rural and agricultural areas, r ^ a l n s 
untapped. Second, government licensing system has obviated 
the possibi l i ty of much competition In the naiicet by ensuring 
that there are not too many manufacturers competing for the 
production of the same drugs. 
Most of the managers in public sector drug units feel 
that external factors which have a significant affect on the 
356 
operations of the companies are primarily legal or 
political In nature and are deterained by the policy of 
the govenment towards public sector drug companies 
in particular and pharmaceutical industry in general, 
A review of the work done in the field of pharmaceutical 
industry, in India shows that, with the exception of a 
few studies that have been carried out, very little work has 
been done in the area of marketing strategy of public 
sector drug enterprises in India, Studies by Mehra (1975) » 
Sengupta (1976), Lall and Streeten (1977), Johri (1983), 
Satwlnder Singh (1985) and Khan and Ahmad (1987) 
have mainly looked into the policies, practices ani 
strategies of Indian private sector or multinational dmg 
companies. In none of the above-mentioned studies, the 
marketing strategy of public sector drug industry has been 
looked into. Thus, in this context the present itudy 
assumes a special significance. 
Public enterprises play a crucial role in the economic 
development of the country. At the commencement of the 
first plan, the total investment in this sector was merely 
Rs, 29 crorts , which Increased to approximately, Rs, 43,000 
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crores at the end of the sixth plan. The importance of public 
sector enterprises cannot be overemphasised in view of the 
fact that this sector occupies "commanding hights " of the 
Indian economy covering a wide spectrum of industrial and 
economic activity in the country. Public sector also covers 
dnigs and pharmaceutical industry of the country. 
The drug industry in the public sector comprises of five 
units. The first two units, namely, IDPL and HAL were 
established by Central Government, The other three units, 
namely, BCPL, SSPL and BIL were initially private concerns 
but later they were taken over by the Central Coveriment, 
To examine the marketing policies and practices of 
public sector units, the companies that have been selected 
in this study include the Indian Drugs and Pharmaceuticals 
Ltd. ,( IDPL ) , the Hindustan Antibiotics Ltd (HAL), and 
three sick units viz, Bengal Chemicals end Pharmaceuticals 
Ltd. (BCPL ), Bengal Immunity Ltd. ( B I L ) and Smith 
Stanistreet Pharmaceuticals Ltd. ( SSPL) along with their 
subsidiaries located in different states. These companies 
accounted for more than 36 per cent of the total investment 
of the Industry in 1974-75, which came down to 33 per cent 
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In 1977-78. %«y have b«eii accordad • Itaderahip role in the 
production of nost essential bulk druga in the country. 
These companies are located in different parts of the country 
and have aade efforts to reduce regional loibalances created 
in the country. According to our survey regarding narketing 
practices of public sector drug uni ts , the following facts 
emerge | 
Production Pgltgjff t 
Production policies of the public sector drug companies are 
aainly guided by the econoajic considerations including the forces 
of denand end supply, excepting the l i f e saving drugs, for which 
production policies are decided keeping in view the social 
reasoning so that the masses do not face brunt of i t . They are 
also linked with the rtquireaents ux^er the mt lonal health 
programme of the country, especially in the areas of ant i - leprot ic 
drugs, antl-malarials, «iiti-T»3, di\igs e tc . Thus the production 
policies of public sector units prinarlly aim a t naking available 
the drugs to aistomers a t competitive pr ices . The •axloisation 
of profi ts gets secondary Jjaportance, In other words fflaxinisation 
of sales rather than naxlaisation of profi ts constitutes 
the production philosophy of these public sector drug 
enterprises. 
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In c«s« of l«8s««ssential drugs and oth«r kind of 
oedicines, production policies hav« a link with the customers 
net disposable income. They are d«temined keeping in view the 
prof i tabi l i ty and development cr i ter ion. When sales s t a r t 
declining, prices r ise and scarcity of raw- aa ter ia l s is f e l t 
the product elittlnation is resorted. Market diversification is 
also resorted to on geographical and customer basis . 
Promotion and Distribution Strategy t 
Ifethods of promotion awi the pattern of promotional 
expenditure incurred, constitute the overall promotion policy 
of a company. Promotion policy persued by public sector drug 
industry largely depends on the categories of i t s products. 
Ethical drugs are directly promoted through thei r medical 
representatives (MR) with the help of free samples and p3'x>duct 
l i t e r a tu re . In the case of non-ethical drugs or over the counter 
drugs (OTC) mass-media communicition syr.t^i is adopted for 
promotion. Indirect methods of promotion include organisation 
of seminars, community d«veloi»ent programmes and fr te 
distr ibution of medical l i te ra ture other than l i t e ra ture 
on part icular products. 
The promotional expenditure of different public sector 
drug companies varies greatly. It ranged between 0,14 and 10,0 
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p«r ctnt during 1984-85. It is determined keeping In view 
m number of economic BJIA non-econcKDlc conslderatitRS. Th9 
distribution network adopted, the cost of transportation! 
e 
warehousing and storage and ccMamitslon offered to mlddlmen 
constitute the overall distribution strategy of the public 
sector drug coiipanles. Most of these units produce bulk drugs 
which are directly supplied to the Indentors, and hence no 
internediarle3 are required. But in some oases, formulations 
are supplied through a mimber of middlemen. Distribution cost 
between different firms also differs to a great extmt. It 
varies from 0.52 per cent to 4,27 per cent during 1984-85. 
Price Planning i 
The public sector drug enterprises by and large have 
adopted cost-oriented pricing policy. Management also gives 
due consideration to the competition and demand factors while 
detemlning the prices of the drugs. Because, the price 
decisions determine the allocation of consumption expenditure 
on the demaiKi side and the allocation of the factor Inputs on 
the supply side. In other words, pricing policy highly bases 
on the Interaction of demand and supply which Is 8ub;}ect to 
change owing to changes in Income level, testes , fashions, and 
availability of complements and substitutes. 
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Executives of the public sector drug units also 
make use of the break-even technique sparingly, 'Competitive 
parfcy' and 'what the traffic could bear 'techniques are also 
being followed. Despite these techniques, the norms prescribed 
by the government through various Drug Price Control Orders 
are given top priority. Thus the pricing policy of the 
Government Companies is characterised by social reasoning and 
the Government has been trying to ensure that the prices of 
these drugs are not beyond the means of the common man. 
Research & Development Activity; 
R & D activity is of crucial significance for the 
development of the pharmaceutical industry. And the development 
of the drug industry is linked to the health of the people. 
Due to certain reasons companies generally do not invest 
more money in this direction. R&D is not only time and money 
consuming but also gestation period is long and the profit 
performance of this industry is dismal. To this end, the 
public sector drug units have performed better by setting 
up extensive R & D facilities and developing backward 
linkages in technology generation. The progress in these 
two fields have been significant. As technology adopters 
and generators these units have immense structural importance 
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and their role In producing essential bulk drugs is 
coomeiidable* The public sector produced 39 drugs from the 
basic stages concentrating mainly on developing beokvard 
linkages, and 6 drugs from the intermediate stages during 
1985. 
A cosamittee appointed by the Gk>vemment has gone into 
the problem of R & D, It has specified certain areas where 
different seeiirs are required to step up their research 
activities. It is hoped that the suggestions put forward by 
by the committee to step up R & D activity, if enforced 
strictly, will go a long way on putting the pharmaceutical 
industry on sound footing. 
General Conclusions i 
On the basis of the above discussion concerning the 
marketing policies pursued by the public sector drug enterprises, 
the following conclusions can be drawn. 
The present study found that the public sector drug units 
have suffered a set back in drug production in the past and 
targets set In this respect have not been achieved , While 
the mangement of the public sector drug units ascribe this 
shortfall to non-availability of raw-materials, the employees 
363 
allege that this is largely due to nismanagiMBeiit. 
The employees of IDPL pointed out that while the 
production in the analgesic plant of the company 
has been stopped due to supposed non-availability of 
raw«material, the productions of units in private sector*, 
mostly owned by the officials of IDPL or their relat ives 
has been going on smoothly, ibployees have further 
alleged that the formula and technology for most of the 
drugs produced in these private establislments are taken 
from the research laboratories of the IDPL. 
The second reason for the set-back i s the rigid price 
control measures adopted , The public sector units are 
required to produce these drugs «ven when they are suffering 
losses, iBower cuts and industrial disharmony are other 
factors which have a bearing on production of public sector 
drug uni ts . 
On the basis of the findings of the present study, 
i t may be concluded that the prcMBotion as well as distribution 
pol ic ies , adopted by the public sector drug companies, are 
ill-conceived and have not yielded the desirable resu l t s . 
This is because no specific plans for catering to rural 
requiroients have been executed so far by these companies. 
There i s an acute shortage of essential drugs, part icularly 
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In rural areas. The rural market which constitutes about 70 per 
cent of the total drug market is still untapped and the people 
inhabiting villages are being deprived of modem medicines, 
Ma;3ority of the companies have been affected by the controls 
on prices of drugs. The profit on sales of many companies have 
declined. To overcome this almost all the companies have tried to 
reduce their advertising expenditure as percentage of sales. Some 
companies have also tried to reduce the distribution expendi. 
ture by lowering the commissions for various intermediaries in 
the distribution network. Other companies which had diversified 
their operations by entering non drug product liwts have tried 
to overcome the impact of price ODntrols by increasing the 
proportion of non-^rug product sales. Both in terms of profit 
and growth the diversified companies had better r«cord as compared 
to some of the noiwdiversified coo^anies. 
The position regarding R&D in the drug industry shows that 
despite the efforts of public sector units, the industry has failed 
to make any significant break through in dtug research (excepting 
Hamycln by HAL and Vitamin Bg by IDPL ), owing to lack of 
co-ordination in their various research departments and because 
of the academic nature of the research undertaken by researchers. 
The failure in H&D is reflected in the meagre spending of 
about two percent of their sales income for research purposes. 
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Th« findings of the present study indicate that th« R&D 
exp«ndltur« of public sector drug coapanits is •xtr«m«tly low. 
It ranges between 0»78 per cent and 2.5 per cent of turnover 
and i t can not be favourably compared with ttoir counterparts 
in technologically advanced countries which generally speiKi more 
than 10 per cent on this head. Thus, i t can be concluded that 
public sector drug companies are not research oriented. The 
R&O which is supposed to be one of the basic needs of the 
industry, largely remains a neglected area. 
Specific Conclusions i 
On tlM basis of the information collected In our survey, 
the following specific conclusions are drawn, 
i ) Imbalance in supply and demand as a result of product diversifi^ 
cation under-taken by drug menufacturera in the country, 
II) As a result of diversification, essential life.savlng 
drugs are in short supply and consequently overpriced, 
III) VaTB run the risk of being adtaiinlstered spurious and 
sub«8tandard drugs with serious consequences, 
iv) No specific plans for catering to rural requlrenents have 
been Implemented , 
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v) The txisting pricing policy has nade manufaclairing of--
essential life saving drugs unattractive due to low returns* 
vi) Diversion of investments to non-essential dsugs and 
formulations because of high returns, 
vil) Proliferation of spurious and sub-standard drugs due to 
ineffective enforcement of quality control by enforcing 
authorities, 
viii) Special status accorded to Small Scale Units of the industry 
has paved way to unethical practices by unscruplous enter-
preneurs, 
ix) As a result of (vii) and (viii) , competition within the 
industry has become unhealthy with opportunists capitalising 
on the situation, 
x) Due to licensing restrictions and sectoral res©, rvations, 
drug companies life-saving drugs, 
xi) Low rate of investment in the area of Hcsearch & Developaent, 
xii) In some cases, medicines banned in other countries are sold 
over the counter (OTC) in India. 
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Th« Issuts are clear but there is a lack of clarity 
on the part of both the Government and the nanagement of these 
companies In dealing with them* Hence official intervention 
to see that the industry grows by assuring the supply of better 
and rational medicines for the people must begin from this 
end. So long as the industry operates in multiple sectors it 
must also ensure that the nojnns for the product mix are 
observed, quality control standards toned up and more efficient 
system of drug administration than the existing one is evolved. 
Suggestions i 
Any suggestions for future growth of the ladian public 
sector drug industry should begin with the realisation that 
the solution of problems such as, smooth supply of life saving 
drugs, the price policy, careful regularisation of marketing 
practices, decreasing import dependence, R&D activities and 
assuring a reasonaHe rate of growth to the industry in 
compariF!on to the growth of other private sector undertakings, 
depends only on the effective implementation of a set of 
pragmatic policies towards the whole gamut of issues, 
1, The issues such as giving leadership role to the public 
sector and sectoral reservation are no doubt, a delicate one, 
but ill-conceived production policies on the part of the 
management of public sector drug enterprises isave resulted in 
acariclty of essential drugs in the market. It is, therefore. 
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3» I t i s alno suggested t h a t the span of pr ice control should 
be smaller. The Drug ordinance of 1979 covers oiore than 80 per 
cent of drug formulations which are being martteted within the 
country. The tsaiuifacturers of drugs find i t d i f f i c u l t to ach|.«ve 
the bresK-evan po in t . Consequently, investanent in t h i s indu8||ry 
has dried up,I f t h i s s t a t e of a f f a i r s continues, i t would be 
d i f f i c u l t for the industry to achieve the na t ional goal , i . e . 
heal th for a l l by 2000 AD, 
In December 1986, the Government announced a new drug 
policy which can to some •xtent, iBitigato the i l l - e f f e c t s of r ig id 
control over th i s industry. As a i n s u l t of t h i s new pol icy , 
p r i ces of drug fonaulations are l i ke ly to go up by 12 to 25 per 
cent . But tlie number of drugs brought uadsr tiie purview of pr ice 
cofitrol i s s t i l l jriuctustiiis a t tho d i sc re t ion of the newly 
const i tuted Netionai iirug, Authority, 
4 , Keeping in view of the rura l supply of modern medicine a t 
reasonable pr ices and ensuring the qual i ty of the drugs i t i s 
suggested tha t on the pat tern of Food Corporation of India , s 
centr.^I procurement and purchasing agency of druga should be 
se t ap to take c^re of the isarketljjsg problems of publ ic sector 
drug €nt*3rprises end ensure regular d i s t r i bu t ion of drugs. At the 
same tiiue, i t should ensure the qual i ty of drugs a t the procurement 
l e v e l . No doubt vflth the es tabl ishaent of such an organisat ion there 
may be some economy in terras of aiddlemejfli coat and Bnd i t may 
also regulate warehousing problems and strearaliae smooth d i s t r i b u -
t ion system. But since d i f ferent en terpr i ses wi l l be dealing with 
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with different types of bulk drugs and formulation 
and will be concerned with different types of markets, 
the feasibility and economy of their operations will 
remain a big question nark. One uniform policy for 
different types of drugs can rarely help In achiivlng 
the oaJiceting objectives. Thus marketing problems of 
various public sector drug enterprises will have to be 
solved with reference to individual drug formulation and 
patient group, J^ch will depend apon the marketing orientation 
of individual units and extent of involventnt in marketing 
operations. The Integrated control through effective maxlcetlng 
strategy would vary but the guiding principle to be kept in 
mind would be Identical i,e| drugs should be prepared and sold 
on the basis of the study of the doctors attitudes, 
patients habits and disease incidence of the country and in 
doing so their ultimate objective should be to develop 
distribution and communication mix which will facilitate purchase 
by patients and satisfaction of doctors. Then proper feedback 
should be ensured to ascertain market satisfaction and if 
necessary to take corrective measures, 
5. As far quality of the drugs is concerned that is also 
directly linked with good manufacturing practices. Factors 
such as environment controls, building design, equipments, 
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p«no»Ael policy, availability of raw mattrlals , production 
control proctdure, packaging and labelling, considerably 
contribute to the good manufacturing practices. Without 
IfflpltRaentlng good manufacturing practices, which depends on 
the R&D activities also, it is difficult to Introduce quillty 
drugs In the market. 
An analysis of the findings of the present study 
Indicates that the public sector drug enterprises are not as 
research oriented as they tend to Ignore R & D which is the 
back- bone of this Industry. It is therefore suggested 
that these units should be motivated to make a significant 
InvestmentCi, e, about 8 to 10 96 of their turnover ) in R&D, 
so that they are able to compete effectively with their 
coMBterparts in econonlcally advanced countries. 
Consequently, it can be inferred that the crux of the 
problem which is confronted by the imblic sector drug industry 
in evolving an effective marketing strategy lies in increased 
production and pro(kictivity, so that uninterrupted market 
supplies could match the market demand for drugs. In this 
regard, the responsibilities of the Government and various 
agencies may be clearly identified in the following «ny t 
a) Responsibility of the Government I 
1) To ensure that ob^Jective information on drugs Is available 
to health care professionals | 
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11) To provide to the public good informatlom oa the country's 
policy with respect to pharmaceutical»| 
111)T© ensure that the regulatory authorit ies have adequate meaiis, 
to control the use of pharmaceuticals { 
iv) •"•o prx>mote the use of generic namesj 
v) To s tr ive for the lowest possible costs of pharaaceuticals and 
adequate quality standards ; 
v i ) To use competitive tenders for purchasing | 
vll)To decide on reimbursenent leve ls | 
vlll)To decide who should prescribe ) 
Ix) To enact legislat ion for ethical noras for advertising 
and promotion of phanaaceuticals { and 
x) To improve prescribing px^actices, 
b) ResDonsibllitv of the Pharmaceutical Industry t 
1) To pnividt coBiplete and desired information on the drugs 
available tn the marketj 
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11) To adhere to Good MaaufacturlHg Practices (GWRi) 
Hi) To comply with ethical norms for njanufacturiiig, advertising 
and promotion• end 
iv) Further to develop new drugs through intensive R&D for 
tropical diseases and for diseases of less developed 
countries, 
c) Responsibility of the Mass Media^ 
1) To report favourably on these conpanies which comply with the 
ethical norms on promotion and advertising, and give those 
firms good publicityj and 
ii) To report unfavourably on those companies which do not 
adhere to the promotional code, and to give them bed 
publicity, 
d) Responsibility of Prescribers > 
1) To implement good and rational pjf^scribing practices ; &nd 
ii)To t e l l the truth and only the truth about the dnigs to the 
pat ients , 
t ) Responsibility of Consumer Representatives t 
i ) To propagate the information of drugs that i s relevant to 
the publicI 
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li) To monitor with vigilance the full compliance with 
norms on advertsing aad promotion j and 
iii) To support essential drug programmes ; and 
iv) Telling the rational drug use, 
A clear-cut identification of the responsibilities of the 
govemiment and various other groups, it is hoped, will go a 
long way in revamping the marketing systems of public sector 
undertakings. However, the marketing problems of public enterprises 
will have to be solved with reference to the nature and objectives 
of these enterprises, their individual product and consumer group. 
The need of the time is that the management of public enterprises 
should become marketing oriented as well as result oriented. 
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A P P E N D I X , 3 
On 
"Marketing St ra tegies of Druga & Phameceutical 
Industry in Public Sector" 
Below you wi l l find a l i s t of questions concerning 
the marketing s t ra tegy of Public Sector drug uni ts* The 
questions are divided into three p a r t s , Part I , I I and I I I . 
To answer the quest ionnaire , please give the desired infor-
mation along the given space, 
P A R T - I 
1. 
2 . 
3 . 
4 . 
5 . 
Name of the ctrnpai^r 
Qesignation of the person 
who f i l l e d in the 
questionnaire : 
Address of the firm i 
No, of employees 
Annual Sales turnover 
From 1981 to 1985 Year 
1981 
1982 
1983 
1984 
1985 
Turnover 
Ms* 
te. 
te. 
Rs. 
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6. Main product Groups 
7. Signature of the 
person who filled in the 
questionnalred 
P A R T -II 
1, What are the various product-groups of your company? 
2, What was the share of each product group in the to ta l 
annual turnover of your coropany since 1981 7 
Product Qrpups Ptrcentage s^are in 
1981 1982 1983 1984 1985 
3, Please indicate the reasons for certain l ines of 
product gaining a higher share in the total turnover 
of your company since 1981? 
4 , Could you please explain in brief the policy of your 
company towards product diversification? 
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9.What Is the branding policy of your conpany? 
10, What do you think of the brand name abol i t ion policy of 
the Goverrment ? Please put a t i ck a t the desired answer, 
a) Effective ««_--.__----«--««-«_«_----. 
b) Sat isfactory «-«-««-------«.->------->_--^ 
c) Unsatisfactory .««---..-«------.---_-«>------«. 
11. In your opinion, what should be the main consideration in 
fixing up the pr ices of various drags produced by your 
company ? 
12, What has been the impact of various drug pr ices control 
orders on your company's profi tafci l i ty? 
13, Please indicate the R&D expenditure of your company 
during the l a s t five years . 
Year R&D Expenditure 
1881 i^ 
1982 te. 
1983 fe," 
1984 as.' 
1985 Rs." 14, lias your company developed any new basic drug through R & D efforts. If yes, please specify. 
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P A R T •. I l l 
Below you wi l l find sorae problems t h a t may be encountered by 
the drug companies in implementing t h e i r marketing s t ra tegy . 
Please answer them by put t ing a t ick ( V) along the space 
which you consider t o be most appropriate , 
1. Do you think following are the most iraportsnt fac tors 
l imi t ing fu l l capacity u t i l i z a t i o n in your organisat ion? 
1) Power cut 
ii) Labour unrest 
iii) Govt. Taxes 
Excise 
iv) Availability of 
raw materials 
2, Do you think that the licencising policy of Government for 
drugs production is a major obstacle to growth for drug 
producers ? 
Yes 
Yes 
Zts 
Yes 
.ease 
' • • - — 
specify 
No« 
No 
No 
No 
Yes No 
5, Do you think that the price and profit ceilings 
imposed by the Govenwaent are unfair and unjustified ? 
Yes No 
4. Should it be withdrawn or amended 
Withdrawn Amended 
5, What is the capacity utilization percentage In your 
company for the last five years ? 
Year Capacity utilization 
1961 „ 
1982 
1983 
198# 
384 
COMMENTS AND SUGGESTIONS ( If any) 
Thank you very much for your help ami cooperation. 
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A P P E ; H D I X » 4 
The salient features of the New Drug Policy 
1, A national Drug & Phannaceutical Authority 
will be cvea'tod. This authority will be an apex body 
which will have representation from all the concerned 
agencies Including those from the industry. This 
authority would function as an advisory body on matters 
of development of pharmaceutical industjry. Among other 
things, it would go into the question of rationalisation 
ot existing formulation in the ajarket including the 
l«nning of formulations of harmful nature, and better 
control over introduction of new drugs. The authority 
will have a permanent secretariat. It is expected that 
the authority would be set up within a period of 3 months. 
2, Quality Controls 
It is proposed to give statutory effect to the 
good mamifacturing practices and also to introduce a 
certifications system under which recognised institutions 
with proven e^ qperiise and testii^ facilities would certify 
the adoption by formulators of good manufacturing practices 
and the quality of formulations manufactured. 
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3, Pricing t 
In order to Increase production which will lead 
to ultimate lowering of prices of drugs, it is proposed 
to reduce the existing span of price control over drugs 
and pharmaceuticals. However a very strong monitoring 
system will be evolved. As against the existing three 
categories of dnigs and pharmaceuticals hereafter there 
will be two categories. The first category there will be 
two categories, The first category will cansist of drugs 
necessary for the National health programme and the 
second category that of other essential drugs. Formulations 
of the first category would have a MAPE ( Maxlraum Allowable 
Post Manufacturing Expenses ) of 755^  and those of the second 
category that of 100-^ , 
A high level expert committee would draw up a list 
of drugs to be included in the second category , However, 
the existing Drug Price Control Order ( OPCX) ) will continue 
to be in force till a new one has been announced after 
the finalisation of drugs in these two categories. 
The Government would retain the right to brin.i 
within the ambit of control any drug In the decontrolled 
category whenever considered necessary. Prices of drugs 
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